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Alzheimer’s Disease (AD) is a neurodegenerative disease characterized clinically 
by progressive cognitive decline and frequently present with behavioral and 
neuropsychiatric symptoms.  The major neuropathological hallmarks of AD are senile 
plaques, neurofibrillary tangles and neuronal loss. In particular, losses of glutamatergic, 
cholinergic and serotonergic neurons, as well as concomitant neurochemical alterations in 
specific brain regions, may underlie the clinical features of AD (Francis et al. 1993; 
Minger et al. 2000; Wilcock et al. 1982).   
The N-methyl-D-aspartate (NMDA) receptors are thought to be critically involved 
in learning and memory.  In AD, hypoactivity of NMDA receptors has been speculated to 
contribute towards the neurodegenerative process (Olney et al. 1997).  Others have 
demonstrated a loss of coupling of postsynaptic cholinergic muscarinic M1 receptors 
from their G-proteins in AD neocortex (Flynn et al. 1991) as well as deficits of 
downstream signaling molecules such as protein kinase C (PKC) (Cole et al. 1988) in AD 
neocortex. There is also evidence from in vitro studies that potentiation of NMDA 
receptor function is regulated by agonists of G-protein-coupled receptors, including those 
for muscarinic receptors, in a pathway dependent on PKC and Src kinase (Ali and Salter 
2001; Lu et al. 1998). Taken together, these results suggest that the disruption of M1-
mediated signaling as well as associated NMDA receptor hypofunction may underlie the 
cognitive symptoms in AD.   
Although there is some evidence that serotonergic deficits are correlated with 
cognitive decline, changes in serotonergic neurochemistry is thought to underlie many of 
the neuropsychiatric symptoms of AD, which are often more stressful for the caregivers 
 ix
to cope compared with the cognitive decline (Chen et al. 1996).  These observations are 
in line with many pre-clinical and clinical studies establishing the essential roles of 
serotonergic neurotransmission in mood and emotional states, especially in the 
hippocampus and neocortex (Barnes and Sharp 1999; Lanctot et al. 2001; Meneses 1999).  
Currently, the effect of functional polymorphisms of serotonin (5-HT) receptors, such as 
those of the gene promoter region of the serotonin (5-HT) transporter on receptor levels 
or behaviors is unknown. Therefore, my research aim to measure the M1 receptors, 
NMDA receptors, and 5-HT transporters in the postmortem frontal and temporal cortices 
of two cohorts of well-characterized AD patients as well as controls.  Neurochemical 
findings are then correlated with the rate of cognitive decline as well as behavioral 
changes to test the hypothesis that neurochemical alternations may underlie both 
cognitive decline and behavioral changes in AD.  Moreover, the status of M1/G-protein 
coupling in AD is measured and correlated with cognitive decline as well as with 
measurements of choline acetyltransferase (ChAT), protein kinase C (PKC) and Src 
kinase activities to investigate the possible interactions between M1 receptor mediated 
signaling and NMDA receptor status.  Besides, the effects of two functional gene 
polymorphisms (i.e. ApoE ε4 allele and LL genotype of the promoter region of 5-HTT) 
on the cholinergic and serotonergic systems, respectively, are examined.  
  This project will add to our understanding of the neurochemical basis of 
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1.1  INTRODUCTION 
In 1907, Dr Alois Alzheimer described the first case of dementia which now bears 
his name (Alzheimer 1907).  In his report, he described the clinical symptoms of a 
middle-aged woman who had developed memory deficits and progressive loss of 
cognitive abilities.  The patient also showed behavioral symptoms such as hiding objects 
in her apartment and believing that people intended to kill her. At her death, Dr 
Alzheimer did an autopsy on her brain and discovered amyloid plaques and 
neurofibrillary tangles in the neocortex and hippocampus.  After this case was reported, 
the term Alzheimer’s disease (AD) was given to this type of presenile dementia.     
Now, the neuropathology of AD (amyloid plaques, neurofibrillary tangles [NFTs] 
and selective loss of neurons, will be discussed later in Chapter 1) is recognized in 
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senile, or late onset, dementia, of which one of the most prominent features is progressive 
loss of cognitive functions. Besides cognitive impairment, AD patients frequently exhibit 
behavioral and psychological symptoms of dementia (BPSD, IPA 1996).  BPSD include 
both psychotic symptoms (e.g. hallucinations and paranoid/delusional ideation) as well as 
non-psychotic symptoms (e.g. aggression and wandering, affective disturbances, and 
anxieties/phobias, Cummings et al. 1994).  BPSD occur frequently in AD and BPSD such 
as aggression and psychosis, which have negative impact on both the patients and the 
caregivers, are causing tremendous distress to the caregivers and these symptoms often 
lead to institutionalization of the patients (Gilley et al. 1991).  
1.1.1  Clinical Course of Alzheimer’s Disease  
As the clinical heterogeneity of AD complicates differentiation from disorders 
other than AD with similar phenotypes (e.g., other progressive dementias), AD diagnosis 
has remained somewhat difficult. Nevertheless, the standardization of the clinical 
diagnosis of probable AD by the National Institute of Neurological and Communicable 
Disease and Stroke / Alzheimer's Disease and Related Disorders Association 
(NINCDS/ADRDA) criteria (McKhann et al. 1984) has improved diagnostic accuracy 
and allowed meaningful comparison of results of therapeutic trails and other clinical 
investigations.   
According to the fourth edition of the Diagnostic and Statistical Manual of Mental 
Disorders of the American Psychiatric Association (1994), the definition of dementia is 
“the development of multiple cognitive deficits that include memory impairment and at 
least one of the following: aphasia, apraxia, agnosia, or a disturbance in executive 
functioning”.  Dementia represents a decline from a higher level of cognitive function 
2 
such that a demented patient conducts accustomed activities less well because of 
cognitive loss.  Dementia is typically progressive, although the pattern of decline (for 
example, rate of cognitive decline and the extent of loss of different cognitive domains) 
may not be uniform.  Although the pattern of cognitive decline may differ among 
patients, there are recognizable stages of cognitive dysfunction during the course of AD 
which may be roughly divided into mild, moderate, and severe stages.   
 The stages of AD as described below were summarized from Morris 1999 (Morris 
1999). The initial symptoms are insidious and may not warrant medical attention for 
several years.  The main feature in earliest AD is mild memory loss, manifested by 
repetition of questions or statements, misplacement of items, and failure to recall 
conversations.  There is also imperfect recall of recent events or names of new 
acquaintances.  In contrast, long term memory such as personal demographical 
information and other highly learned materials are minimally affected.  Language 
disturbances include word-finding difficulty and hesitancy of speech.  The mildly 
demented patient is usually capable of performing self-care (e.g., dressing and toileting) 
independently.  Other personality changes such as passivity and disinterest may become 
evident, such as when the patient is more withdrawn from social settings, although they 
rarely have psychiatric disturbances.   
 As the patient progresses to the moderate stage, typically 4-7 years after disease 
onset, he or she becomes increasingly dependent on others.  New information is rapidly 
forgotten and, though established memory may be recalled frequently, obvious 
inaccuracies are noted; for example, long-deceased persons may be discussed as if they 
still were living.  Judgment and problem solving skills are impaired and driving and other 
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complex activities are relinquished by this stage.  Language skills also deteriorate further 
with poor comprehension of spoken and written language.  Some patients may displace 
disruptive behaviors such as agitation, restlessness, aggressive verbal and/or physical 
behavior, delusions, and hallucinations.  Supervision of self-care is usually required at 
this stage as the patient neglect bathing and grooming as well as demonstrating poor table 
manners. 
 The severe stage is characterized by nearly complete dependence on caregivers 
for even basic functions. Only memory fragments remain, and accurate identification of 
relationships and names is lost. Comprehension is limited to the simplest spoken 
language and verbal output is limited to short phrases and repetition of words.  Although 
troublesome behaviors may still be evident, eventually they disappear along with all 
semblance of the patient’s personality. Complications such as extrapyramidal 
dysfunction, tonic-clonic seizures, falls, and incontinence are present.  In the terminal 
stage, the patient is bedridden and uncomprehending, dysphagia and weight loss are 
common, and death is usually attributed to complications associated with chronic 
debilitation, such as pneumonia, urosepsis, and aspiration.  
 
1.2  COST TO SOCIETY 
AD is a progressive neurodegenerative disorder with a mean duration of around a 
decade between onset of clinical symptoms and death.  With the advances in medicine, 
the proportion of elderly people in the population has been increasing steadily since the 
last few decades.  AD, which affects an estimated 15 million people worldwide, is one of 
the most common causes of dementia in elderly people. The prevalence of dementia / 
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cognitive impairment in elderly Singaporean Chinese is estimated at between 5-8% (Lim 
et al. 2003), similar to rates in Europe (Berr et al. 2005) and the USA (GAO 2006). As 
mentioned, many AD patients also exhibit BPSD such as aggression and psychosis, 
which have negative impact on both the patients and the caregivers, and often lead to 
institutionalization of the patients. Therefore, the burden of the disease has become a 
tremendous problem to both caregivers and national economics. Studies in the USA  have 
shown that the direct costs for the care of patients in 1991 were calculated at US $20.6 
billion and the total cost was calculated to be $76.3 billion and that a large proportion of 
the cost come from late stage disease when patients are placed in nursing homes (Ernst 
and Hay 1994). The expense of nursing home care was estimated at $47,000 per patient 
per year (Rice et al. 1993); hence, treatments that result in delay of institutionalization by 
even one year could represent billions of dollars in healthcare savings.  The first step in 
finding treatment for AD is to acquire better understanding of the etiology and 
pathophysiological mechanisms underlying cognitive dysfunction and neuropsychiatric 
behaviors in AD.   
 
1.3  NEUROPATHOLOGICAL FEATURES IN AD 
As mentioned before, amyloid plaques, NFTs and loss of various 
neurotransmitter-producing neurons are the prominent neuropathological features of AD.  
These features may underlie both cognitive and behavioral clinical features of the disease 
(Cummings et al. 1996; Cummings, 2000; Cummings and Kaufer 1996; Naslund et al. 
2000; Tekin et al. 2001; Zweig et al. 1988). Descriptions of the neuropathological 
features of AD have been summarized by Terry et al. (1999).   
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1.3.1  Amyloid Plaques 
Amyloid plaques (Figure 1.1) are one of the major neuropathological hallmarks 
of AD, and are considered by many to play a critical pathogenetic role in the disease. 
Amyloid plaques are formed by extracellular accumulation of insoluble fragments of β-
amyloid (Aβ) peptides which are 40 to 42 amino acids in length which in turn are derived 
from the proteolytic processing of a much larger amyloid precursor protein (APP) (see 
Chapter 2 for the proteolytic processing of APP in detail).  Amyloid plaques are grouped 
into three types:  diffuse, neuritic, and burned out plaques.  Diffuse plaques are mostly 
amorphous amyloid peptides without abnormal neurites.  Neuritic plaques contain dense 
bundles of amyloid fibrils forming a filamentous amyloid core and are surrounded by 
dystrophic neurites which are mainly composed of paired helical filaments, laminated 
bodies, synaptic vesicles, mitochondria, and dense lysosomes suggesting that neurites are 
the debris of degenerated neurons.  Burned out plaques consist of dense amyloid with 
reactive astrocytes without neurites.  In addition to the amyloid fibrils and the abnormal 
neurites, amyloid plaques are surrounded by reactive microglia.  Activated microglia 
have been implicated in amyloidogenesis.  Perhaps activated microglia may be involved 
in the formation of filamentous amyloid which is derived from APP (Terry et al. 1964).   
APP comprises a heterogeneous group of polypeptides that arise both from 
alternative exon splicing and from complex posttranslational processing, including N- 
and O-glycosylation, phosphorylation and sulfation, resulting in three major APP species 
with 770, 751, and 695 residues.  The major difference between APP751/770 and APP695 is 
that the former contains a 56-amino acid region homologous to the Kunitz family of 
serine protease inhibitors (KPI).  Furthermore, APP770 has an additional 17-residue signal 
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peptide at the NH2 terminus. Of the three APP species, the APP695 is neuron-specific, 
while the APP751/770 forms are highly expressed in non-neuron cells, even though low 
levels are also found in neurons.  At present, the physiological roles of APP are not clear 
and still under intense investigation.  Studies using knockout mice which lack either APP, 
APLP1, or APLP2 have shown that the animals are viable with only minor neurological 
deficits (von Koch et al. 1997).  Nevertheless, when two of the three proteins, either APP 
and APLP2, or APLP1 and APLP2 are deleted in knockout mice, resulting in premature 
death without histological abnormalities in any of the organs including brain.  On the 
other hand, mutant mice with deletions at all three genes loci showed early lethality as 
well as high incidence of cortical dysplasia (Heber et al. 2000). Taken together, these 
data suggest that APP and related molecules play crucial roles in neurogenesis, but there 
is a certain degree of functional redundancy (von Koch et al. 1997). Further studies are 
needed to elucidate the role that APP and its derivatives after proteolytic processing (e.g. 




















Figure 1.1  Neuropathology of Alzheimer’s disease.  Neurofibrillary tangles (red arrow 
















1.3.2  Neurofibrillary Tangles (NFTs) 
 Unlike amyloid plaques, although NFTs (Figure 1.1) are critical lesions in AD, 
they are not specific to the disorder per se.  NFTs have been found in a number of other 
neurological diseases such as postencephalitic Parkinson’s disease and dementia 
pugilistica.  Nevertheless, NFTs are quantitatively much higher in AD than normal aged 
brain.  In AD brain, NFTs are commonly found in entorhinal, neocortex and 
hippocampus.  NFTs consist of hyperphosphorylated microtubule-associated τ proteins 
which is usually required for microtubule assembly in axons (see Chapter 2 for the 
process of NFTs formation in neuronal cells).  There are six isoforms of τ proteins which 
are derived from alternative slicing of the same gene located on chromosome 17 (Goedert 
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et al. 1989; Lee et al. 1988).  The finding of extraneuronal tangles may imply that the 
tangles are particularly toxic to neurons and are an important cause of neuronal death in 
AD.  One mechanism could be that the formation of τ is accompanied by a gradual loss 
of microtubules which are normally stabilized by τ, resulting in disorganization and 
disintegration of neuronal cytoskeleton, as well as cell death (Buee et al. 2000).   
1.3.3  Selective Loss of Neurons  
In AD, a number of neurotransmitter systems are severely affected, including 
losses of cholinergic and serotonergic neurons, and associated neurochemical deficits. 
These will be described in detail in Chapter 2 (cholinergic) and Chapter 4 
(serotonergic). Established preclinical and animal studies have shown the importance of 
cholinergic and serotonergic transmission in both memory and behavioral processes. 
Therefore, it is likely that neurochemical perturbations are a basis of clinical features in 
AD. Using postmortem brain tissues from two cohorts of longitudinally assessed AD 
patients, this thesis focuses on the correlations between cholinergic and serotonergic 
changes and the cognitive decline and BPSD to further elucidate the neurochemical and 
genetic bases of these clinical features in AD, as well as uncover additional associations 
between neurochemical changes and other molecules known to be involved in AD 
pathogenesis (e.g., ApoE, protein kinase C, Src kinase). Specifically, the aims of my 
thesis and the chapter which address them are: 
1. To examine the effects of apolipoprotein APOE ε4 alleles on neurochemical 
alterations in a range of pre- and postsyanptic cholinergic markers in AD, 
including muscarinic M1 and M2 receptors, α4β2 nicotinic receptors*, M1/G-
                                                 
*Performed by our collaborators in the UK (see Appendix I)  
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protein coupling, choliner acetyltransferase (ChAT) and acetylcholinesterase 
(AChE)* activities (Chapter 6); 
2. To uncover possible correlations between muscarinic M1/G-protein 
uncoupling, cognitive decline (Chapter 7), protein kinase C and Src kinase 
activities, as well as glutamate N-methyl-D-aspartate (NMDA) receptors 
(Chapter 8); 
3. To examine the effects of serotonin transporter 5-HTTLPR polymorphism on 
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2.1   INTRODUCTION 
 AD is characterized by progressive loss of memory and cognitive decline, the 
presence of neuropsychiatric symptoms such as hallucination, aggression, and anxiety, as 
well as neuropathological features. The major neuropathological hallmarks of AD include 
amyloid plaques, neurofibrillary tangles and selective loss of neurons in discrete brain 
regions such as the neocortex and hippocampus. AD severely affects the cholinergic and 
serotonergic systems in the brain.  Cholinergic neurons primarily innervate the 
neocortical and hippocampal regions, which are crucial for learning and memory 
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processes.  In addition, cholinergic receptors such as muscarinic receptors are coupled to 
a number of G-protein subtypes and activate multiple signaling pathways which may 
further influence the process of learning and memory.  Thus, cholinergic neuronal 
dysfunction may form the basis of learning and memory deficits in AD (Bartus et al. 
1982).  Deficits in cholinergic neurotransmission are also linked to hyperphosphorylation 
of τ protein as well as amyloidogenic processing of β-amyloid (Aβ) peptides in the brain 
(Hellstrom-Lindahl 2000).  Taken together, the central cholinergic system plays an 
essential role in learning and memory processes and may be closely associated with AD 
neuropathology. In this chapter, the anatomy, function and neurochemistry of the central 
cholinergic systems are discussed, followed by a review of cholinergic neurochemistry in 
AD and its significance to clinical features of the disease. Knowledge gaps, which this 
thesis aims to address, are also discussed.      
       
2.2 THE CHOLINERGIC SYSTEM IN MAMMALIAN BRAIN  
2.2.1 Distribution of Cholinergic Neurons in the Brain  
In the mammalian brain, the basal forebrain and pontine cholinergic neurons 
provide the primary cholinergic innervations to much of the cerebral cortex and brain 
stem region (See Figure 2.1). The basal forebrain cholinergic regions consist of the 
medial septum (MS), the vertical and horizontal diagonal bands of Broca (VDBB and 
HDBB), and the nucleus basalis of Meynert (NBM). While the neurons situated in the 
MS innervate predominately to the hippocampal formation, the neurons located in the 
VDBB and HDBB project to the anterior cingulate cortex and olfactory bulb, 
respectively. Additionally, the NBM is the source of cholinergic projections to the 
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amygdala as well as throughout the neocortex. Much research data have pointed to 
cholinergic circuits in the hippocampus and neocortex as playing essential roles in 
mediating learning and memory processes. 
 
Figure 2.1  Cholinergic system in mammalian central nervous system. (Kandel et al.   
















2.2.2 Cholinergic Pathways in the Brain  
Cholinergic neurons are characterized by the expression of the enzyme choline 
acetyltransferase (ChAT), the enzyme that catalyzes the biosynthesis of acetylcholine 
(ACh). However the expression of acetyl- and butyrylcholinesterases (AChE / BChE), 
enzymes that catalyze the hydrolysis of ACh, is relatively less specific to cholinergic 
neurons (Darvesh et al. 2003; Mesulam et al. 1989; Mesulam and Geula 1988).  
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Biochemical studies which measure ChAT and AChE activities in human brain have 
demonstrated regional variations of enzyme activities, with the core limbic areas such as 
the amygdala and hippocampus having the highest ChAT and AChE activities while the 
visual cortex region has the lowest ChAT and AChE activities (Davies and Maloney  
1976; Perry et al. 1977; Rossor et al. 1982).  Both ChAT and AChE play important roles 
in the ACh metabolic pathway in the central nervous system.   
 ACh, synthesized in the terminals of cholinergic neurons, is one the major 
excitatory neurotransmitters in the brain. ACh can increase the intracellular membrane 
potential by reducing potassium ion conductance, leading to higher propensity to 
depolarization in cholinoceptive neurons. ChAT plays an essential role in ACh 
production in the brain by catalyzing the transfer of the acetyl group from acetyl 
coenzyme A to choline (See Figure 2.2).  Thus, the activity of ChAT is a neurochemical 
marker for cholinergic innervation and status of the cholinergic neurons.  Once ACh is 
produced, the neurotransmitter is packed into synaptic vesicles by vesicular ACh 
transporter (VAChT). After release into synaptic clefts, ACh is catabolized by 
acetylcholinesterase (AChE) resulting in the production of acetate and choline.  
Subsequently, choline is accumulated back into the presynaptic neurons via a high 
affinity Na+/choline transporters and is used again for ACh synthesis.  Therefore, AChE 
is important for determining the intensity and duration of cholinergic neurotransmission, 
and the enzyme regulates a number of cholinergic functions, including arousal, sensory 
















2.2.3 Cholinergic Receptors in Brain  
Cholinergic signaling is mediated by two main groups of  cholinergic receptors, 
the ion channel nicotinic receptors and the G-protein coupled muscarinic receptors.   
2.2.3.1  Nicotinic receptors 
Nicotinic receptors are ligand-gated heteropentameric ion channels. Nicotinic 
receptors primarily mediate conductance of Ca2+ ions. Currently five nicotinic receptor 
subunits have been identified, each of which exists in several subtypes (Steinbach and 
Ifune 1989).  In mammalian brain, the α and β subunits combine with different 
configurations to form at least three pharmacologically distinct nicotinic receptors 
(nAChR), namely, α4β2, α3β4, and α7 nAChR (Giacobini, 1990; Newhouse et al. 1997).  
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Nicotinic receptors are not distributed uniformly in the brain, with the highest densities 
found in the hippocampus, followed by deeper layers of neocortex (Cimino et al.  1992; 
Rubboli et al. 1994). 
2.2.3.2 Muscarinic receptors 
Muscarinic cholinergic receptors are coupled to G-proteins, especially those 
belonging to the Gs and Gq/11 families, thus modulating multiple intracellular signal 
transduction pathways including those mediated by adenylate cyclase and phospholipase 
C (PLC). At present, five different muscarinic receptors (m1 – m5), each of which is the 
product of a different gene, have been identified. The m1-m3 receptors correspond to the 
pharmacologically characterized M1-M3 subtypes: M1 and M3 have relatively higher 
affinity for the antagonist pirenzepine, and low affinity for AFDX-116 or AFDX-384, 
while the M2 subtype show the reverse affinities.  Muscarinic receptors are distributed 
widely but heterogenously in human brain, with the highest densities found within the 
striatum and hypothalamus, followed by the hippocampus and cerebral cortex, and the 
lowest densities in the cerebellum (Cortes et al. 1987; Lin et al. 1986).  In addition, 
higher densities of M1 receptors are found in most parts of limbic and paralimbic regions, 
whereas M2 receptors are commonly found in the primary sensory areas as well as parts 
of the primary motor cortex. The limbic and paralimbic localization of M1 and M3 
receptors suggest that these receptors may be critically involved in learning and memory 






         
2.3 CHOLINERGIC SYSTEM IN THE CNS AND AD 
2.3.1 Cholinergic Hypothesis 
In AD, brain regions that are associated with higher mental functions e.g. the 
hippocampal formation, entorhinal cortex and neocortex, are more prone to 
neurodegeneration. As mentioned above, these areas are widely innervated by ChAT -
containing neurons arising from the basal forebrain. It is well established that the basal 
forebrain cholinergic neurons are severely affected in AD (Whitehouse et al. 1982).  
Since such cholinergic neurons project widely to the hippocampus and cerebral cortex, 
they are thought to play important roles in learning and memory.  The loss of these 
neurons may be involved in cognitive impairment in AD. Indeed, the integration of 
animal pharmacology, biochemistry, and clinical research have led to the proposal of the 
cholinergic hypothesis of AD (Bartus et al. 1982), which attributed the cognitive 
symptoms associated with AD to the cholinergic deficits. A series of human and primate 
studies have suggested the involvement of the cholinergic system in cognition. Drachman 
and Leavitt (1974) demonstrated that low doses of the cholinergic antagonist, 
scopolamine, resulted in cognitive deficits that were similar to those seen in elderly 
volunteers.  Others have also shown that the pattern of cognitive deficits induced by 
cholinergic antagonism mimicked some of the cognitive deficits in AD patients (Bartus et 
al. 1985; Smith and Swash 1978). Furthermore, primate studies have shown that 
scopolamine induced cognitive deficits which closely matched the naturally occurring 
cognitive deficits in aged monkeys, while age-related memory losses in monkeys could 
be ameliorated by the anticholinesterase compound, physostigmine (Bartus 1979). Taken 
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together, findings from these studies suggest a direct relationship between central 
cholinergic receptors and cognitive function. The second line of evidence that gives 
support to the cholinergic hypothesis of AD is the finding of profound cholinergic 
deficits in AD. In addition to the loss of basal forebrain cholinergic neurons, 
neurochemical studies of AD have shown severe losses cholinergic neurons elsewhere in 
the cognitive brain, for example, loss of ChAT and AChE activities, reduction in ACh 
release and choline uptake, and loss of cholinergic (both nicotinic and muscarinic M2 and 
M4 receptors in the hippocampus and neocortex (Francis et al. 1985; Mash et al. 1985; 
Mulugeta et al. 2003; Perry et al. 1977; Perry et al. 1987; Sims et al. 1983; Wilcock et al. 
1982). Postsynaptic M1 receptor densities appear unchanged (Araujo et al. 1988; Mash et 
al. 1985).  However, later studies reported losses of M1 coupling to G-proteins, as well as 
associated deficits in phosphotidylinositide hydrolysis and protein kinase C (PKC) 
activities (Cole et al. 1988; Ferrari-DiLeo et al. 1995; Ferrari-DiLeo and Flynn 1993; 
Flynn et al. 1991).  
2.3.2  Cholinergic System Association with Cognitive and Non-cognitive  Features  
in AD 
 
An increasing number of studies have demonstrated that cholinergic system 
dysfunction is associated with cognitive as well as non-cognitive features in AD.  For 
example, the loss of ChAT activity is a reflection of the degeneration of cholinergic 
neurons in the CNS; thus, when ChAT activity reduction is correlated with dementia 
severity in AD (Perry et al. 1978; Wilcock et al. 1982), the loss of the CNS cholinergic 
neurons is associated with dementia severity (Wilcock et al. 1982). Moreover, Lai et al 
(2001) have demonstrated that the muscarinic M2 receptor densities in frontal and 
temporal cortex are upregulated in AD patients with delusion and hallucinations. The 
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muscarinic M1 receptor density, on the other hand, is unaltered in AD; thus, these results 
may provide an explanation why cholinergic replacement therapy results in improvement 
of BPSD including psychosis and suggest that M2 receptor may be a potential drug target 
for BPSD in AD.  Other cholinergic markers may not relate to neuropsychological 
behaviors as well as they relate to cognition. Procter et al (1992), for instance, have 
demonstrated that there is significant loss of ChAT activity in the cerebral cortex of AD 
patients both with and without aggressive symptoms. However, Minger et al (2000) have 
shown that the ratio of ChAT to dopaminergic D1 receptor correlates negatively to 
aggressive behavior in AD.  These results suggest that central cholinergic system may not 
be directly associated with BPSD but may regulate other systems which do. Table 2.1 
summarizes the known deficits of pre- and postsynaptic cholinergic markers and their 







Table 2.1  Cholinergic changes in AD and their clinical correlates. 
 Changes in AD Clinical correlates 
Cholinergic neurons 
& nerve terminals 
Postmortem ↓ acetylcholine producing 
neurons in the BFC system (Davies and 
Maloney 1976; Whitehouse et al. 1982). 
Postmortem Correlated with ↓ ChAT, 
thus indirectly with dementia severity 
(Wilcock et al. 1982). 
ACh Biopsy ↓ [14C]ACh synthesis in FC and 
TC (Francis et al. 1985; Sims et al. 1983). 
Biopsy ↓ [14C]ACh synthesis correlates 
with cognitive impairment (Francis et 
al. 1985). 
ChAT Postmortem ↓ widespread: cerebral 
cortex , HP and basal nucleus (Araujo et 
al. 1988; Bowen et al. 1982; Davies 1979; 
Rossor et al. 1984). 
 
Biopsy ↓ neocortex  (Sims et al. 1983). 
Postmortem ↓ ChAT correlated with 
dementia severity (Perry et al., 1978; 
Wilcock et al. 1982) but ↓ cerebral 
cortex in AD patients both with and 
without aggressive symptoms (Procter 
et al. 1992)1. 
AChE Postmortem ↓ ( Davies, 1979; Garcia-
Alloza et al. 2005; Perry et al. 1978). 
 
Biopsy ↓ neocortex (Sims et al. 1983). 
Postmortem AChE / serotonin ratios 
correlated with predeath cognitive 
scores (Garcia-Alloza et al. 2005). 
HACU Postmortem ↓ FC and HP; ↔ caudate-
putamen and cerebellum (Pascual et al. 
1991). 
Not reported. 
Muscarinic receptors   
M1
Postmortem ↔ FC and TC (Lai et al. 
2001);  ↔ cerebral cortex (Mash et al. 
1985);  ↔ cortical, subcortical regions, 
but modestly ↑ in HP and ST (Araujo et 
al. 1988); uncoupled from G-proteins 
(Flynn et al. 1991). 
Postmortem M1-G-protein uncoupling 
correlated with dementia severity  
(Tsang et al. 2006)2. 
M2 Postmortem ↓ in cerebral cortex (Mash et 
al. 1985); ↓ all cortical areas and HP, but 
↔ in subcortical areas (Araujo et al. 
1988). 
Postmortem Delusion and 
hallucinations correlated with ↑ in FC 
and TC (Lai et al. 2001)2. 
M3 Not reported. Not reported. 
M4 Postmortem ↓ in HP (Mulugeta et al. 
2003). 
Not reported. 
M5 Not reported. Not reported. 
Nicotinic receptors  
(nAChR) 
Postmortem ↓ cortical areas and HP, but 
not in subcortical regions (Araujo et al. 
1988)3. 
Postmortem  specific ↓ α4β2 populations 
in TC (Warpman and Nordberg 1995); ↓ 
α4, but ↔ α3 and α7-containing nAChR 





Table 2.1  (previous page)  Note: ↓ = decreased; ↑ = increased; ↔ = no change; ACh = acetylcholine; 
AChE = acetylcholinesterase; ChAT  = choline acetyltransferase; FC = frontal cortex; HACU = high 
affinity choline uptake; HP = hippocampus; ST = striatum; TC = temporal cortex  
1Results may suggest that 5-HT deficits is more closely related than acetylcholine to aggression 
  in  AD (Procter et al. 1992). 
2 Correlations with longitudinally assessed clinical data. 
3 Use of [3H]carbamylcholine which has limited specificity for nAChR subtypes. 
 
2.3.3 Cholinergic Neurotransmission, τ Phosphorylation and Aβ Processing  
The major pathological hallmarks of AD are extracellular deposit of neuritic 
plaques (NPs), intracellular formation of neurofibrillary tangles (NFTs), and selective 
loss of neurons (Braak and Braak 1997; Dickson 1997; Jellinger and Bancher 1997).  
Furthermore, as mentioned above, AD severely affects the cholinergic system. Previous 
studies have suggested that cholinergic system function, Aβ production, and formation of 
NFTs are closely related.         
Amyloid precursor protein (APP) processing follows two alternative pathways: 
the non-amyloidogenic and amyloidogenic pathways.  Most of APP is cleaved by α-
secretase within the Aβ domain (between positions 16 and 17), resulting in the release of 
a large, secretory N-terminal fragment - secreted APP (sAPPα) - into the extracellular 
space, and leaving the 83-amino-acid carboxyl-terminal (C83) fragment in the cell.  This 
pathway is also known as non-amyloidogenic pathway because α-secretase cleave within 
the Aβ domain, thus precluding its formation. Alternatively, the amyloidogenic pathway 
involves the sequential cleavages by β-site APP-Cleaving-Enzyme (BACE) and γ-
secretase at the N- and C-termini of the Aβ domain, respectively. After APP is cleaved 
by BACE, two peptides are generated: secreted sAPPβ and a 99-amino-acid C-terminal 
peptide.  The subsequent cleavage of the C99 peptide by the γ-secretase complex which 
consists of presenilin, nicastrin, Aph-1 and Pen-2 (Xia and Wolfe 2003) liberates either a 
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40- or 42-amino acid Aβ peptide into the extracellular space and an amyloid intracellular 
domain (AICD) inside the cell.  While the accumulation of insoluble Aβ40/42 peptides 
produce the neuritic plaques in the extracellular space, AICD may regulate expression of 
specific genes such as apoptotic genes (Leissring et al. 2002). Additionally, cleavage of 
C99/AICD by caspases generates a neurotoxic peptide (C31) (Lu et al. 2000, see Figure 
2.3).   
 















       
       
 
NFTs are deposits of insoluble filaments and amorphous material in the cell body 
of a neuron, and when similar deposits are found in axons and dendrites, they are termed 
neuropil threads (NTs).  Both NFTs and NTs are composed of paired helical filaments 
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(PHFs), which in turn consist mainly of τ protein.  τ protein belongs to a family of 
proteins known as microtubule-associated proteins (MAPs) which binds to and stabilizes 
microtububles (MTs).  τ protein is widely distributed throughout the central (CNS) and 
peripheral (PNS) nervous system, especially in the axons of nerve cells (Binder et al. 
1985). τ is a phosphoprotein containing both proline-directed serine/threonine 
phosphorylation sites and non-proline directed phosphate acceptor residues (Morishima-
Kawashima et al. 1995; Trojanowski and Lee 1994).  In vitro studies have shown that 
mitogen-activated protein kinase (MAPK) (Drewes et al. 1992; Greenberg and Kosik, 
1995), glycogen synthase kinase-3 (GSK3, Hanger et al. 1992; Mandelkow et al. 1992; 
Sperber et al. 1995), and cyclin-dependent kinase 5 (cdk5) (Baumann et al. 1993) 
phosphorylate τ at a number of the identified serine/threonine-proline residues.   
Phosphorylated τ proteins dissociate from MTs and accumulate in the perikarya.  They 
may then associate with other intracellular chaperones, for example, sulfated 
glycosaminoglycans (SGs), RNA, and/or DNA, forming NFTs in the cell body of a 
neuron, or NTs in axons or dendrites, and/or around the cores of amyloid plaques (see 
Figure 2.4).  The deposits of NFTs and NT have profound effects on neurons.  For 
example, the aggregates can block normal trafficking, resulting in cell death.  
Additionally, when τ proteins are hyperphosphorylated, they cannot bind to MTs which 
become depolymerized, resulting in disruption of the neuronal cytoskeleton and 
interference of axonal transport which may result in neuronal degeneration (Vincent et al. 






Figure 2.4  Neurofibrillary tangles (NFTs) formation. 
         (Picture credit: http://www.alzheimers.org/rmedia/graphicslowres.htm) 
 
Several lines of evidence suggest a close relationship among cholinergic system, Aβ, 
and NFTs. Perry et al. (1978) have reported that cholinergic depletion as measured by 
loss of ChAT activities correlated with senile plaque counts.  More recent in-vitro studies 
have demonstrated that even very low concentrations (at picomolar to nanomolar ranges) 
of Aβ can inhibit ACh synthesis in SN56 cells derived from mouse basal forebrain 
cholinergic neurons (Pedersen et al. 1996) and ACh release in rat hippocampal and 
cortical slices (Kar et al. 1996).  Moreover, Nitsch et al. (1992) have shown that in human 
kidney embryonic cells overexpressing muscarinic M1 and M3 receptors, activation of 
these receptors with carbachol, a non-selective agonist which activates both nicotinic and 
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muscarinic receptors, increased the release of soluble APP.  Similarly, reduction of the 
levels of phosphorylated τ in PC12 cells which were transfected with the gene for 
muscarinic M1 receptor was observed when the cells were treated with carbachol and 
AF102B (Sadot et al. 1996).  In addition, Arendt et al. (1999) have demonstrated a strong 
association between cholinergic deficits and the cortical distribution of 
hyperphosphorylated τ in AD. Taken together, although these correlative studies cannot 
confirm the cause-effect relationships between cholinergic dysfunction and plaque and 
tangle formation, they do suggest that the cholinergic system, APP and τ interact during 
the AD process.   
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3.1  INTRODUCTION 
As mentioned in Chapter 2, one of the most consistently affected transmitter 
systems in AD is the cholinergic system in regions such as cerebral cortex and 
hippocampus.  Findings of loss of cholinergic neurons in the basal forebrain have been 
supported by neurochemical findings of reductions in presynaptic cholinergic markers 
such as choline acetyltransferase (ChAT) activities.  Since cholinergic neurons project to 
widespread areas of the cerebral cortex and are thought to play essential roles in learning 
and memory, the loss of these neurons may lead to cognitive impairment in AD.  
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Furthermore, Lu et al (1999) demonstrated that G-protein coupled acetylcholine receptors 
may potentiate glutamatergic N-methyl-D-aspartate recceptor (NMDAR) via a protein 
kinase C (PKC) dependent signaling pathway.  Because NMDAR function, especially in 
mediating long term potentiation (LTP) is widely believed to be a mechanism in learning 
and memory, it is possible that cholinergic deficits may affect learning and memory 
processes via its effect on NMDAR. 
Acetylcholine receptors can be classified into nicotinic receptors and muscarinic 
receptors.  Muscarinic receptors belong to a group of seven-transmembrane spanning 
receptors which transduce their signals across membranes by interacting with GTP-
binding proteins (G-proteins).  Muscarinic receptors can be further divided into 5 
subtypes – M1 to M5.  While M1, M3 and M5 receptors are coupled to Gq/11, M2 and M4 
are coupled to the Gi/o proteins.  In brain, M2 receptors are predominantly presynaptic 
autoreceptors while M1 receptors are believed to be postsynaptic heteroreceptors.  Using 
radioligand binding approaches, Araujo et al. (1988) have demonstrated that in AD 
muscarinic M2 receptors are markedly reduced while M1 receptors are unaltered.  
However, Flynn and colleagues (1991) later showed that muscarinic M1 receptor is 
“uncoupled” to its G-proteins in AD. Other studies (Cole et al. 1988; Masliah et al. 1991) 
also found that PKC activities are significantly reduced in AD.  Taken together, the 
findings suggest that the downstream signaling of cholinergic system in AD is impaired.  
This chapter provides a brief overview of the pathways and molecules involved in         
G-protein-coupled receptors (GPCR)-mediated signaling which may be affected in AD.  
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3.2  G-PROTEINS 
3.2.1  G-protein Structure and Activation 
G-protein stands for guanine neucleotide dependent protein.  In general, G-protein 
serves as intermediaries between GPCR (e.g. muscarinic M1 and M3 receptors) and 
downstream effectors (e.g. phospholipase C [PLC]). When G-proteins of the type 
associated with muscarinic receptors are inactive, they exist as complexes made up of 
three subunits - α, β, and γ subunits – with guanosine diphosphate (GDP) binding to the 
α subunit. Once GPCR binds to an agonist, the coupled G-protein undergoes 
conformational changes and exchanges GDP for guanosine triphosphate (GTP). 
Subsequently, the  α subunit of the activated G-protein separates from the β and γ 
subunits and may activate downstream effectors. After the α subunit activates its target, 
the GTP is hydrolyzed to GDP by intrinsic GTPase activity, and the inactivated α subunit 
reunites with its β and γ subunits.   
3.2.2  A Common Gq/11 G-protein Signaling Pathway 
Figure 3.1 depicts a common signaling pathway for Gq/11-coupled receptors.  Briefly, 
agonists bind to GPCR and subsequently activate PLC via Gq.  The activated PLC 
cleaves phosphatidylinositol-4,5-bisphosphate (PIP2) and yields inositol-1,4,5-
triphosphate (IP3) and diacylglyceral (DAG). The released IP3 binds to specific IP3 
receptor in the endoplasmic reticulum and Ca2+ is liberated, causing its intracellular Ca2+ 
concentrations to rise. Ca2+ and DAG then activate protein kinase C (PKC) which in turn 
triggers multiple downstream signaling pathways. In addition, increased cytosolic Ca2+ 
levels cause Ca2+ membrane channel to open.   
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3.3  PROTEIN KINASE C (PKC) 
3.3.1  PKC Structure 
PKC is a proteolytically activated serine/threonine kinase (Nishizuka 1992). Since 
the discovery of PKC in 1977 (Takai et al. 1977), at least 12 PKC isoforms that are 
expressed by mammalian cells have been discovered.  PKC isoforms can be classified 
into 3 main groups based on their different requirements for activators such as Ca2+ and 
DAG (Casabona 1997):  calcium or conventional (cPKC) (α, βI, βII, γ), novel (nPKC) (δ, 
ε, η, θ), and atypical (aPKC) (ι/λ, ζ).  The groups differ in cofactors requirements, tissue 
distribution, intracellular localization and potential substrate specificity.  Two new 
isoforms of PKC (μ/PKD,ν) were added to the list later. Of all the mammalian PKC 
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isoforms, the γ, ε, θ, ι/λ PKC isoforms are specifically expressed in the CNS, whereas 
others are widely expressed in different cell types (see Table 3.1).  
Table 3.1  Mammalian protein kinase C isoenzymes. (Battaini et al. 2001)  
Type  Activators  Isoenzyme Distribution  
Conventional  Ca, PS, DAG  α  Widespread  
  βI  Widespread (low levels)  
  βII  Widespread  
  γ  Brain, Spinal cord  
Novel  PS, DAG  δ  Widespread  
  ε  Brain, Hematopoietic  
   tissues  
  η  Heart, Lung, Skin  
  θ  Hematopoietic tissues,  
   Brain, Skeletal muscle  
Atypical  PS, PI-3,4,5-P3  ζ  Widespread  
  ι/λ  Brain, Kidney, Lung  
Recently  DAG, PI-4,5-P2  μ/PKD  Lung, Epithelial cells  
described   ν  Widespread  
Ca = Calcium; PS = Phosphatidylserine; DAG = Diacylglycerol;  
PI-3,4,5-P3 = phosphatidylinositol-3,4,5-triphosphate, PI-4,5-P2 =  
phosphatidylinositol 4,5 diphosphate  
 
PKC is a single polypeptide with an NH2-terminal regulatory region and a C-terminal 
catalytic region. (See Figure 3.2)  In general, all PKC isoforms share similar but non- 
identical domain structures.   In the NH2-terminal of cPKCs, for example, the regulatory 
region contains two conserved sequences - C1 and C2  - that are important for regulation 
of enzymatic activity. On the other hand, the nPKCs and aPKCs possess a C2-like 
domain.  In both cPKCs and nPKCs, the C1 regions comprise a pseudosubstrate sequence 
and two cysteine-rich repeats that bind to DAG and phorbol esters (Ono et al. 1989), but 
there is only one cysteine-rich region in the aPKCs.  Additionally, the C2 region which is 
present only in cPKCs is responsible for Ca2+ sensitivity and is involved in the 
translocation to membranes after the levels of Ca2+ increase in the cell. Two additional 
conserved regions – C3 and C4 - are found in the C-terminal catalytic region.  The C3 
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domains are responsible for ATP binding while the C4 domains are important for protein 
substrate binding.  Taken together, possession of the various domains allow PKC 
isoforms to respond to a wide array of signals from hormonal, neuronal and growth factor 
stimuli. All PKC isoforms except the μ/PKD and ν also contain a pseudosubstrate 
sequence which interacts with the substrate-binding region, thus keeping the enzyme in 
an inactive state.  The mode of activation for μ/PKD and ν PKCs may be different from 
the other PKC isoforms since they lack the pseudosubstrate sequence; nevertheless, the 
activation of the conventional, novel, atypical as well as the μ/PKD and ν PKCs is 
regulated by phosphorylation-dependent pathways.  PKC is mostly located in the cytosol 
where it is in inactive state.  Upon external stimulation, PKC translocates to the plasma 
and/or nuclear membrane where it is bound by PKC anchoring proteins or RACKs 
(receptor for activated C-kinase) (MacDonald et al. 2001). Muscarinic receptors which 
couple to Gq/11 G-proteins (M1, M3 and M5), are known to activate PLC, leading to Ca2+ 
influx, intracellular release of Ca2+, IP3 and DAG, which in turn activates cPKC. In brief, 
3-phosphoinositide-dependent kinase-1 (PDK-1) which is activated by inositol 
phospholipids phosphorylates the newly synthesized PKC enzymes as membrane-bound 
enzymes in the catalytic region.  Subsequently, the phosphorylated PKC undergoes 
autophosphorylation and translocates to the cytosol.  Although the cytosolic PKC is 




























                       
3.3.2 PKC Functions 
PKC contributes to the function and maintenance of neurons in a number of ways, 
including the transduction of mitogenic signals of receptor tyrosine kinases (RTKs) as 
well as GPCRs (Gutkind, 1998; Luttrell et al. 1999). In neuronal cells, PKC is 
responsible for multiple neuronal signal transduction pathways by phosphorylating 
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specific substrates, resulting in increasing neuronal excitability in response to external 
inputs.  In particular, PKC is involved in the control of ion channel function, 
desensitization of receptors and enhancement of neurotransmitter release, suggesting that 
PKC may regulate synaptic plasticity which in turn plays an important role in learning 
and memory processes (Tanaka and Nishizuka 1994).  In addition, specific PKC isoforms 
may be involved in regulating apoptotic pathways. Although most PKC isoforms are 
antiapoptotic, some PKC isoforms such as PKCδ is pro-apoptotic in a number of cell 
types (Dempsey et al. 2000), including neurons (Maher 2001). Therefore, PKC may play 
a part in the pathogenesis of neurodegenerative diseases, including AD. 
 
3.4  NMDA RECEPTORS 
3.4.1  NMDA Receptor Structure and Subunits 
The N-methyl-D-aspartate (NMDA) receptor belongs to the ionotrophic glutamate 
receptor family, which also includes the α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid  (AMPA) receptor, and kainate (KA) receptors.  NMDA receptors 
(NMDAR) possess unique features such as voltage-dependent block by Mg2+, Ca2+ 
permeability, and slow deactivation kinetics (Cull-Candy et al. 2001). Since excitatory 
postsynaptic transmission is mediated by glutamate receptors, NMDAR is thought to play 
critical roles in synaptic plasticity events such as LTP which is a cellular mechanism in 
learning and memory in mammalian central nervous system.   
NMDAR is made up of NR1, NR2, and NR3 subunits.  The NR1 subunit can exist 
in 8 splice variants due to three independent sites of alternative splicing in the NR1 gene 
(Sugihara et al. 1992).  The NR2 subunit family comprises four members (NR2A to 
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NR2D) which are encoded by separate genes. The NR3 subunit family consists of two 
splice variants, NR3A and NR3B (Cull-Candy et al. 2001).  
Functional NMDARs exist as heterotetramers or heteropentamers which are 
assembled from any two obligatory NR1 splice variants interacting with two or three 
NR2 encoded subunits to form a functional NMDA receptor. While the NR2 subunits 
contain the glutamate-binding sites, NR1 subunits contain the glycine-binding sites which 
modulate the function of the receptor in the presence of glycine. Therefore, functional 
NMDARs contain at least 2 glycine-binding sites and 2 glutamate-binding sites on the 
ion channel complex, and both ligand binding sites have to be occupied for the channel to 
open.  Similar to NR2 subunits, NR3 subunits do not form functional NMDAR alone.  
However, NR3 subunits can bind with the NR1/NR2 complexes and depress NMDAR 
responses (Das et al. 1998).  Several studies have demonstrated that NMDAR channel 
properties are determined by NMDA subunit composition (Flint et al. 1997; Misra et al. 
2000; Monyer et al. 1992; Takahashi et al. 1996). NMDARs also contain allosteric 
recognition sites that can modulate their function.  These include the binding sites for 
polyamines (e.g. spermine and spermidine) and Mg2+. There are regional distribution 
differences in NMDAR subunit compositions.  In dorsal horn spinal neurons, NR1/NR2D 
and NR1/NR2B receptors are predominately located  extrasynaptically and NR1/NR2A 
receptors are found in the primary inputs to mature cells (Momiyama 2000).   
3.4.2  NMDA Receptor Functions 
NMDARs are thought to play critical roles in learning and memory because of 
two unique characteristics.  Firstly, NMDARs are highly permeable to Ca2+ and other 
cations; thus, activation of NMDARs is particularly effective in promoting Ca2+ entry.  
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Secondly, NMDAR channels are blocked by voltage-dependent Mg2+.  These properties 
of NMDARs are important for long-term potentiation (LTP) / long-term depression 
(LTD) which are thought to be the cellular substrate for learning and memory (Bliss and 
Collingridge 1993). Briefly, at normal membrane potentials, NMDAR channel is blocked 
by Mg2+.  However, if enough glutamate is released to activate the postsynaptic NMDAR 
channels after a conditioning train of stimuli, the voltage-dependent Mg2+ molecule is 
then removed from the NMDAR channels resulting in PKC activation by the influx of 
Ca2+.  Subsequently, the activated PKC phosphorylates AMPA receptors as well as other 
proteins that are involved in gene transcription in the postsynaptic cells.  Activation of 
gene transcription in the postsynaptic neuronal cells may be essential for remodeling of 
synaptic structures, which lead to synaptic plasticity. 
 
 
3.5 GPCR SIGNALING PATHWAY IN RELATION TO NEUROPATHO-
LOGICAL AND NEUROCHEMICAL ALTERNATIONS IN AD 
 
The major neuropathological hallmarks of AD include senile plaques, neurofibrillary 
tangles (NFTs) and selective loss of neurons.  The formation of senile plaques and NFTs 
has been discussed in detail in Chapter 1 and 2.  As mentioned in Chapter 2, there is a 
strong association between cholinergic deficits and the cortical distribution of 
hyperphosphorylated τ and Aβ in AD.  Furthermore, Qiu et al. (2003) has demonstrated 
that treatment with the cholinergic agonist carbachol increases sAPP release and reduces 
Aβ production in rat hippocampal slices and that M1, not M2 receptors, are responsible 
for the effects.  Similarly, activation of PLC-linked M1 and M3  receptors is found to 
enhance the non-amyloidogenic cleavage of APP as well as reduce the levels of 
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phosphorylated τ (Hellstrom-Lindahl 2000).  Although these correlative studies cannot 
confirm the cause-effect relationships between cholinergic dysfunction and Aβ and NFTs 
formation, findings from further studies (Cole et al. 1988; Kurumatani et al. 1998; 
Masliah et al. 1991; Smith et al. 1987) suggest that cholinergic system may affect the 
production Aβ and τ proteins via muscarinic M1 receptors / PLC / PKC signalling 
transduction pathway.  
Besides plaques and tangles, AD is also characterized by cortical atrophy and losses 
of glutamatergic and cholinergic neurons.  Throughout all layers of the neocortex as well 
as in the hippocampal formation, glutamatergic pyramidal neurons which form extensive 
synapses with basal forebrain cholinergic neurons are known to be severely degenerated 
AD (Francis et al. 1993). Because of its proximity with cholinergic neurons, degeneration 
and hypoactivity of glutamatergic pyramidal neurons which mediate the bulk of 
excitatory neurotransmission and synaptic plasticity in the brain may underlie the 
cognitive symptoms of AD (Francis 2003).  
A direct interaction between cholinergic and glutamatergic systems has been 
established by several studies in that both muscarinic and nicotinic receptors can activate 
glutamatergic pyramidal neurons, resulting in increasing glutamate release (Chessell et al.  
1993; Dijk et al. 1995). Other studies have demonstrated the potentiation of NMDAR 
currents by muscarinic agonists in a PKC  and Src-dependent manner (Ali and Salter 
2001; Lu et al. 1999; Xiong et al. 1998), suggesting that muscarinic receptors may 
regulate NMDAR function. Furthermore, Markam and Segal (1992) have also shown that 
the potentiation of NMDAR currents by mAChR agonists requires activation of 
phosphoinositide hydrolysis. Additionally, results from an in-vitro studies  showed that in 
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hippocampal CA1 pyramidal cells NMDAR is potentiated by genetically defined M1 
receptors, and that M1 receptors colocalized with NMDARs at postsynaptic glutamatergic 
synapses (Marino et al. 1998). The results reveal a spatial relationship between M1 
receptors and NMDARs.  Taken together, these findings suggest that cholinergic deficits 
in AD are linked to glutamatergic deficits via breakdown of intracellular signaling. 
However,  until now it has been unclear whether the M1/G-protein uncoupling correlates 
with cognitive decline in AD. This question will be addressed in Chapter 7.  
Furthermore, it is also not clear whether M1/G-protein uncoupling is related to the PKC 
deficits seen in AD (Cole et al. 1988), or to the hypofunction of NMDARs. These issues 
will be investigated in detail in Chapter 8. 
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4.1  INTRODUCTION 
Besides progressive loss of cognitive functions, AD patients frequently exhibit 
behavioral and psychological symptoms of dementia (BPSD).  BPSD include both 
psychotic symptoms (e.g. hallucinations and paranoid/delusional ideation) as well as 
nonpsychotic symptoms (e.g. aggression and wandering, affective disturbances, and 
anxieties/phobias, Cummings et al. 1994), and cause tremendous distress to the 
caregivers, often lead to institutionalization of the patients. Based on extensive animal 
and preclinical research evidence, it is reasonable to hypothesize that both cognitive 
decline and BPSD arise as a result of altered neurochemistry in the AD brain, which is 
in turn a consequence of both the neurodegeneration processes as well as reactive 
synaptic plasticity to these processes. 
The serotonergic system is also one of the most consistently affected 
neurotransmitter systems in AD.  Animal studies have already shown that the 
serotonergic system is important for cognition as well as behavioral processes (Buhot 
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1997).  For example, members of the   5-HT1 class of receptors are involved in a wide 
range of behavioral and physiological effects including sensorimotor reactivity, 
feeding, aggression, sexual behavior and anxiety responses (Lucki 1992).  
Additionally, the serotonergic system has become a major target for many 
psychotropic medications such as selective serotonin reuptake inhibitor (SSRI) and 
neuroleptics. Preclinical and clinical data suggest the anxiolytic and antidepressant 
activity of 5-HT1A receptor agonists (Charney et al. 1990; Handley 1995). These 
findings suggest that the serotonergic system may be involved in cognition and 
behavioral symptoms in AD.  Table 4.1 summarizes alternations of serotonergic 
neurons, 5-HT metabolites and 5-HT receptor subtypes as well as clinical correlations 
in AD. This chapter will present the current state of knowledge on serotonergic 
system alternations in AD using results from postmortem brain tissues. 
          
 Table 4.1  Serotonergic system changes and clinical correlates in AD.  
 Second messenger Changes in AD Clinical correlates 
Serotonergic 
neurons & nerve 
terminals 
 ↓ neurons in RN (Aletrino et al. 1992; 
Chen et al. 2000; Wilcock et al. 1988; 
Zweig et al. 1988). 
No correlation with behavioural change or cognitive decline (Chen et al. 2000); delusions 
and hallucinations correlated with ↓ neurons in dorsal RN (Forstl et al. 1994). 
5-HT  
 
  ↓ TC, HP and ST (Cross, 1990; 
Middlemiss et al. 1986; Reinikainen et al. 
1990). 
 
Rate of cognitive decline correlated with ↓ in FC (Lai et al. 2002); ↓ levels of 5-HT in 
cortical and subcortical regions in AD patients with psychotic behaviours compared with 
nonpsychotic AD patients (Zubenko et al. 1991); ↔ TC in AD patients with psychosis 




 ↓ TC (Cross, 1990) 
 
Anxiety correlated with ↓ in cortex, thalamus and putamen (Reinikainen et al. 1990). 
5-HTT  ↓ neocortex (Chen et al. 1996; Cross, 
1990). 
 
Depression correlated with ↓ in FC and TC (Chen et al. 1996); ↓ in TC in non-anxious AD 
patients only, anxiety correlated with LL genotype of the 5-HTTLPR functional 
polymorphism (Tsang et al. 2003)1,6. 
5-HT1 receptors    
1A 
 
↑ basal cAMP 




↓ FC, TC, HP and AMG; (Bowen et al. 
1983; Cross et al. 1984; Crow et al. 1984; 
Middlemiss et al. 1986); ↔ FC (Sparks,  
1989)2. 
 
↓ TC with moderate / severe aggression (Lai et al. 2003); ↓ 5-HT to 5-HT1A ratio in FC 
with higher rate of cognitive decline (Lai et al. 2002). 
 
1B,1D 1Dα - ↑cAMP 
(via Gi) 
↓ FC and TC (Garcia-Alloza et al. 2004). Cognitive decline correlated with ↓ in FC only (Garcia-Alloza et al. 2004)3. 
1E, 1F  ↓ cAMP Not reported. Not reported. 
5-HT2  receptors 
2A 
5-HT2 receptors- 
↑ PI turnover 
↑ Ca2+ influx 
↓K+ conductance 
 
↓ neocortex (particularly TC), HP and 
AMG (Cross et al. 1984; Crow et al. 
1984;  Jansen et al. 1990);   ↔ in FC and 
HP(Dewar et al. 1990). 
 
Cognitive decline correlated with ↓ in TC (Lai et al. 2005); a functional polymorphism in 
5-HT2A receptor (102-T/C) correlated with the presence of visual and auditory 
hallucinations in AD patients (Holmes et al. 1998); ↔ in cerebral cortex in a group of 




 Table 4.1. (Cont’d) 
  Changes in AD Clinical correlates 
2B  Not reported. Not reported.  
2C  Not reported. 
 
A  functional polymorphism in 5-HT2C receptor (Cys23Ser) correlated with visual 
hallucinations in AD patients (Holmes et al. 1998). 
5-HT3  receptors Direct ↑ cation 
conductance 
↔ AMG and HP (Barnes et al. 1990). Not reported 5. 
 
5-HT4  receptors ↑ cAMP (via Gs) ↔ FC and TC (Lai et al. 2003). None (Lai et al. 2003). 
5-HT5  receptors Unknown Not reported. Not reported. 
5-HT6  receptors ↑ cAMP ↓ FC and TC (Garcia-Alloza et al. 2004).  Overactivity correlated with ↓ in TC; aggression correlated with 5-HT6 to ChAT ratio in 
both FC and TC (Garcia-Alloza et al. 2004)1. 
5-HT7  receptors Not reported Not reported. Not reported. 
 
Table 4.1.  Note: ↓ = decreased; ↑ = increased; ↔ = no change; 5-HIAA = 5-hydroxyindoleacetic acid; 5-HT = 5-hydroxytryptamine; 5-HTT = 5-HT transporter; 5-HTTLPR = 5-HTT 
gene promoter region; AMG = amygdala; FC = frontal cortex; HP = hippocampus; OC = occipital cortex; PC = parietal cortex; RN = raphe nucleus; ST = striatum; TC = temporal cortex; 
cAMP = cyclic adenosine 3’,5’-monophosphate; Gi = inhibitory G protein; Gs = stimulatory G protein; K+ = potassium ion; PI = phosphoinositide  
 
1Correlations with longitudinally assessed clinical data. 
2May be due to cross-reactivity of [3H]5-HT for other receptor subtypes (Sparks, 1989). 
3↓ 5-HT1B/D receptors could reflect serotonergic neuronal  loss in AD, or may be plasticity responses to a deteriorated cholinergic system, as 5-HT1B/D receptors act as inhibitors of ACh  
release (Garcia-Alloza et al. 2004). 
4Potential confounding by cross-reactivity to dopamine receptors (Blin et al. 1993). 
55-HT3 antagonist ondansetron also failed to improve cognition in AD in a controlled trial (Dysken et al. 2002). 
6This study will be discussed in Chapter 9 of this thesis. 
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 4.2  SEROTONERGIC SYSTEM IN THE MAMMALIAN BRAIN 
4.2.1  Distribution of Serotonergic Neurons in the Brain 
 
Figure 4.1  Serotonergic system in the central nervous system.  














Serotonergic neurons project to widespread areas of the brain, and most of the cell 
bodies of serotonergic neurons are found in the raphe nuclei of the midline brainstem 
(Figure 4.1) (Palacios et al. 1990). The bulk of raphe nuclei consist of nine groups of 
serotonergic cell bodies (B1 – B9), and the largest group of serotonergic cells is B7, which 
is continuous with a smaller group of serotonergic cells, B6.  Depending on the location 
of the cell bodies of 5-HT neurons and the areas that they innervate, the serotonergic cell 
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 bodies can be divided into two main groups:  dorsal and median raphe nuclei (Tork 
1990). The B6 and B7 serotonergic cells together are considered as the dorsal raphe 
nuclei, and the B8 serotonergic cells are considered as the median raphe nuclei.  While 
fibres from the median nuclei project to the hippocampus, septum, and hypothalamus, the 
dorsal raphe nuclei innervate predominately to striatum. Since both dorsal and median 
raphe nuclei are responsible for projecting extensively to higher brain structures, the 
serotonergic system is thought to play an important role in the regulation of behavioral 
state and the modulation of more specific behaviors.   
4.2.2  Biosynthesis and Metabolism of Serotonin 
 













 Serotonin (5-HT) is derived primarily from dietary tryptophan, and the process of 
5-HT biosynthesis is relatively straightforward.  Briefly, tryptophan is converted to 5-
hydroxytryptophan by the action of tryptophan hydroxylase (an enzyme confined to 5-
HT-producing cells). The 5-hydroxytryptophan is then decarboxylated to 5-HT, by 
amino-acid decarboxylase. Degradation of 5-HT occurs mainly through oxidative 
deamination, catalysed by mitochondrial monoamine oxidase (MAO), followed by 
oxidation to 5-hydroxyindoleacetic acid (5-HIAA).  Alternatively, the released 5-HT is 
removed from synaptic cleft via an active 5-HT transporter (5-HTT, or 5-HT reuptake 
sites).   
4.2.3  Serotonergic Receptors in the Brain 
5-HT receptors are diverse (Figure 4.3). At least 14 serotonin receptor subtypes are 
known to date. Among the seven 5-HT receptor families-5-HT1-7-5-HT1 (5-HT1A, 5-
HT1B, 5-HT1D, 5-HT1E, and 5-HT1F) and 5-HT2 (5-HT2A, 5-HT2B, 5-HT2C) are further 
classified into various subtypes according to similar pharmacology and structure (Barnes 
and Sharp 1999). All serotonin receptors are G-protein-coupled metabotropic receptors, 
except for 5-HT3 receptor which is an ion-gated channel receptor. All 5-HT2 receptor 
subtypes are coupled positively to phospholipase C (PLC) and trigger the release of 
intracellular Ca2+. 5-HT2A, 5-HT2C, 5-HT3, and 5-HT4 receptors are located 
postsynaptically where some are known to modulate ion flux to cause neuronal 
depolarization.  Other 5-HT receptor subtypes like the 5-HT1A, 5-HT1B and possibly 5-
HT1D receptors are located on the 5-HT autoreceptors at the somatodendritic or nerve 
terminals. The 5-HT1 receptors couple negatively to adenylate cyclase via Gi proteins.  In 
CNS, 5-HT are excitatory on some neurons and inhibitory on others, depending on the 5-
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 HT receptor subtypes involved. It is becoming clear that some 5-HT receptors such as 5-
HT1B/D, 5-HT2A/C, 5-HT3 and 5-HT4 receptors are also located on the nerve terminals of 
non-5-HT neurons where they appear to function as heteroreceptors, regulating 
neurotransmitter release.  So far, very little is known about the locations and functions of  
5-HT5-7 receptors in CNS. 
 
Figure 4.3  Dendrogram showing the evolutionary relationship between various  
        human 5-HT receptor protein sequences (except 5-HT5A and 5-HT5B  
        receptors which are murine in origin, Barnes and Sharp 1999). 















































 4.3  SEROTONERGIC SYSTEM ALTERNATIONS IN AD 
4.3.1  Serotonergic System Association with Cognitive and Non-cognitive Features 
The evidence for serotonergic dysfunction in AD is based on the post mortem 
measurements in brain tissue of 5-HT metabolites and 5-HT receptor changes. Losses of 
5-HT presynaptic markers such as 5-HTT (Chen et al. 1996; Cross 1990) and 
degeneration of raphe nuclei (Chen et al. 2000) are prominent in AD.  Similarly,  
concentrations of 5-HT and metabolite (5-HIAA) in regions including temporal cortex, 
hippocampus and striatum  were markedly reduced in AD (Cross 1990; Middlemiss et al. 
1986; Reinikainen et al. 1990). Furthermore, 5-HT receptors are selectively affected in 
AD.  Postmortem studies have demonstrated that the levels of 5-HT1A receptor are 
significantly reduced in the frontal and temporal cortex, hippocampus and amygdala  
(Bowen et al. 1983; Cross et al. 1984; Crow et al. 1984; Middlemiss et al. 1986). 
However, the loss of 5-HT2A receptors is greater than the loss of 5-HT1A receptors in AD 
neocortex (Cross 1990).  Furthermore, the levels of 5-HT1B/1D receptor are reduced in AD 
frontal and temporal cortex (Garcia-Alloza et al. 2004).  On the other hand, the levels of 
5-HT3 and 5-HT4 receptors do not seem to be affected in AD (Barnes et al. 1990; Lai et 
al. 2003). Currently, not much work has been done on other 5-HT receptors except for a 
recent study showing a reduction of 5-HT6 receptors in the frontal and temporal cortex of 
AD patients (Garcia-Alloza et al. 2004).   
Various studies have demonstrated that cognition and neuropsychological 
symptoms in AD are correlated with the levels of 5-HT and 5-HIAA.  The reduction of 5-
HT to 5-HT1A ratio is correlated in frontal cortex is correlated with higher rate of 
cognitive decline in AD (Lai et al. 2002).  A postmortem study also reported that 
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 cognitive decline is correlated with the reduction of 5-HT1B/1D levels in the frontal cortex 
(Garcia-Alloza et al. 2004). There is also some evidence that serotonergic function may 
be involved in BPSD. Zubenko et al. (1991) have shown a greater loss of 5-HT in cortical 
and subcortical areas in AD patients with psychotic behaviors compared with 
nonpsychotic AD patients. Another study also reported that the reduction of 5-HT levels 
in AD cortical region was correlated with aggression (Palmer et al. 1988). 5-HIAA levels 
also associated with neuropsychological symptoms, with Reinikainen et al (1990) 
reporting that anxiety is associated with reduced levels of 5-HIAA in AD cortex, 
thalamus and putamen. Other postmortem studies have demonstrated that the loss of 
neocortical 5-HT transporters (5-HTT), which affects the turn-over rate of the released 5-
HT in the synaptic cleft, was correlated with depression (Chen et al. 1996).  
There are specific patterns of serotonin receptors alternations that may underlie 
the presence of different behavioral symptoms in AD.  While the reduction of 5-HT1A 
receptors in the temporal cortex was correlated with moderate / severe aggression (Lai et 
al. 2003), a loss of 5-HT6 receptors in the temporal cortex was correlated negatively with 
overactivity (Garcia-Alloza et al. 2004). However, not all serotonin receptors are affected 
in AD. Lai et al (2003) reported that the levels of 5-HT4 receptor in the frontal and 
temporal cortex in AD were unchanged and that 5-HT4 receptor was not associated with 
any neuropsychological symptoms.  More studies are needed to elucidate the status of 
other 5-HT receptors in AD as well as their putative roles in the clinical features of the 
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5.1  SUBJECT RECRUITMENT, COGNITIVE AND BEHAVIORAL 
ASSESSMENTS  
 
The postmortem brain tissues used in this thesis were obtained from two cohorts: 
one from Oxfordshire, United Kingdom (in collaboration with Professors Tony Hope and 
Margaret Esiri), and the other from the University of California, Los Angeles 
Alzheimer’s Disease Research Center (UCLA-ADRC), Los Angeles, USA (in 
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collaboration with Professors Harry Vinters and Jeffrey Cummings). Both cohorts were 
recruited for longitudinal studies initiated in the UK and USA over several years, and all 
clinical, cognitive and behavioral assessments as well as collection of associated data 
were conducted by our overseas collaborators, who provided the clinical data as well as 
postmortem samples. In this section, an overview of the subject recruitment process, 
patient demographics as well as the range of instruments used in the clinical assessments 
will be given in order to facilitate better understanding and interpretation of our clinico-
neurochemical correlation.   
5.1.1 The Oxford AD Cohort 
Introduction. Postmortem tissues from the Oxford cohort were obtained from 97 
dementia patients recruited into a longitudinal study of behavior in dementia (Hope et al. 
1997a; Hope et al. 1997b; Hope et al. 1999), of which 40 had autopsy follow-up. Tissues 
from 20-25 patients only were shipped to Singapore in batches as they became available 
and were used in studies described in Chapters 6,7 and 9. All available tissues from 
subjects with neuropathological confirmation of AD diagnosis at the time of a study were 
used, and there were no selection of subjects based on sex or dementia severity. 
Recruitment. Community-based dementia subjects living at home in Oxfordshire, 
UK, with a caregiver (e.g., spouse or child) who was able to give detailed information 
about the patient were recruited into the study (Hope et al. 1997a; Hope et al. 1997b; 
Hope et al. 1999). The study had been approved by the Institutional Review Board (IRB) 
of the Greater Oxford Psychiatric Sector, and informed consent was obtained either the 
patients or the next-of-kin as appropriate, from the dementia patients. Initial assessments 
were carried out to confirm a diagnosis of dementia using the Diagnostic and Statistical 
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Manual of Mental Disorders, 4th Edition (DSM-IIIR, 1987) criteria using CAMDEX 
(Cambridge Mental Disorders of the Elderly Examination) (Roth et al. 1986), a cognitive 
examination designed to detect dementia in the elderly which includes the Mini-mental 
state examination (MMSE) (Folstein et al. 1975).  Cognition was assessed every four 
months from study entry till death with MMSE, scores ranging from 0-30 (Folstein et al. 
1975). Dementia severity was measured by using the mean of up to five MMSE scores 
before death so as to avoid floor effects, since some patients may live for extended 
periods of time after their MMSE scores had reached 0 (Lai et al. 2001). Patients were 
considered to have severe dementia (ADsevere) if the mean predeath MMSE was ≤ 9, while 
those with scores between 10 – 24 were deemed to have mild to moderate dementia 
(ADmild/mod.). None of the subjects had scores > 24. The rate of cognitive decline per year 
was measured by the linear regression of serial MMSE scores on the time interval 
between recruitment and death, or when the MMSE first reached 0.  Findings from 
clinical investigations, including physical examinations, drug histories, full blood counts 
and biochemical screening were then used to assess whether patients fulfill the NINCDS-
ADRDA criteria (McKhann et al. 1984) for the diagnosis of probable AD.  Subjects who 
(i) presented with a probable cause of dementia other than AD or vascular dementia (e.g., 
hypothyroidism, previous head injury); (ii) had drunk more than 30 units of alcohol per 
week for two years; and (iii) had caregivers who could not give an accurate account of 
the day-to-day behavior of the subject were excluded from the study. Brain tissues from 
up to 20 elderly controls who were not known to have dementia or any other neurological 
disease, and based in the same community as the AD patients were also obtained. Tissues 
were not available in all brain areas for all subjects.   
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Demographics. The 97 subjects (49 males, 48 females) were aged between 60-95 
years (mean = 78; interquartile range = 75-83), and had a MMSE score from 0-26 (mean 
= 14; interquartile range = 10-20). The distribution of social class of subjects based on 
occupation were similar to that found in the population as a whole (Hope et al. 1997b). 
Clinical Assessments. Behavioral changes in the subjects were assessed with 
Present Behavioural Examination (PBE) (Hope and Fairburn, 1992) every four months 
from study entry till death. The PBE is a caregiver directed, semi-structured interview 
with high inter- and intra-rater reliability carried out by one of two highly trained 
interviewers on home visits, and covers in detail the observable behavior and mental state 
of the subject over the previous four weeks. Assessment for a range of behaviors, 
including depression, anxiety, aggression and psychosis consists of a main question, and 
some have further ‘nested’ questions to elucidate the caregiver’s positive response The 
majority of items are rated on a seven-point scale (0-6) based on the frequency reported 
by the caregiver (from 0, not present in the last 28 days; to 3, present in approximately 14 
days of the last 28 days; to 6, present everyday). For behaviors such as anxiety, which I 
studied (see Chapter 9), changes were considered to be significant if there a minimum of 
two frequency ratings were >3, or there was at least one rating of >3 and two ratings or 1-
3 (Chen et al. 1996). At each PBE interview, cognitive tests were performed on the 
patients, including the MMSE, which has a maximum score of 30 (0, severely impaired; 
28-30, cognitively normal). Dementia severity was defined as the mean of a maximum of 
five MMSE scores before death, also to avoid floor effects. The mean follow-up for 
clinical assessments was 3.3 years (SD = 2.38, range 0.33-9.0).   
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Neuropathology and tissue collection. At death, informed consent was obtained 
from the family of both the patient and control subjects prior to the removal of brain. One 
hemisphere was processed for histological examination. The neuropathological diagnosis 
of AD was confirmed by the CERAD (Consortium to Establish a Registry for AD) 
criteria (Mirra et al. 1991). Ten-μm-thick paraffin embedded sections of the orbito-frontal 
gyrus (Brodmann area 11, BA11) and mid-temporal gyrus (BA21) were stained with 
methenamine silver and modified Palmgren stains, and semi-quantitatively scored for 
senile plaques (SP, 0-3 point scale) and neurofibrillary tangles (NFT, 0-4 point scale) by 
two neuropathologists (Prof. Margaret Esiri and Dr Brandon MacDonald, University of 
Oxford) blinded to the clinical information. Blocks of gray matter were removed from 
BA11 and BA21 of the other hemisphere and stored at -75°C. In addition, the pH of brain 
homogenates (as an indication of agonal state) was measured as previously described 
(Hardy et al. 1985). 
5.1.2 The UCLA AD Cohort 
Introduction.  22 prospectively assessed dementia patients who were recruited 
into the University of California, Los Angeles Alzheimer’s Disease Research Center 
(UCLA-ADRC) were used in the study described in Chapter 8.  Frozen brain chunks 
were shipped to Singapore on dry ice and stored at -70°C until use.  All 22 subjects 
fulfilled the DSM-IV (1994) clinical criteria for dementia as well as the CERAD criteria 
(Mirra et al. 1991) for neuropathological diagnosis of definite AD.  Selection of subjects 
for the study was based on tissue availability, and not on dementia severity or Braak stage 
(Braak and Braak 1991). 
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          Recruitment.  The clinical study was approved by the IRB of UCLA and informed 
consent was obtained from the subjects or their caregivers.  Subjects with other 
associated neurodegenerative diseases or extensive cerebrovascular disease were 
excluded from the study. Clinical information including the duration of dementia and the 
most recent MMSE scores were obtained from the UCLA-ADRC longitudinal study 
database and patient charts.  
          Demographics.  Demographic details for the 22 AD (12 males, 10 females), as well 
as 12 elderly controls (6 males, 6 females) are listed in Table 5.1.  The mean age at 
death, storage time, and postmortem interval (PMI) were well-matched between AD 
subjects and controls (Student t-test; p>0.05).  Among the AD subjects, the mean 
duration of dementia symptoms was 9.5 ± 1.1 years.  
 
 Table 5.1  Demographics of controls and AD subjects, UCLA cohort. 
 Control AD 
Demographics   
    Maximum Number of Cases 12 22 
    Age at Death (y) 73.2 ± 4 78.8 ± 2 
    Sex (M/F) 6 / 6 12 / 10 
    Storage (y) 4.5 ± 0.5 5.4 ± 0.7 
    PMI (h) 14.4 ± 3 14.2 ± 2 
  Table 5.1  Data are mean ± S.E.M. PMI, post-mortem interval.  
   
Neuropathology and tissue collection.  At death, informed consent was obtained 
from the family of both patients and control subjects prior to the removal of brain. The 
brains of patients were removed within 48 hours after death and fixed in 10% buffer 
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formalin for at least 4 weeks. One hemisphere was processed for histological 
examination. One-cm-thick coronal sections were made and blocks were taken bilaterally 
from eight brain regions commonly sampled in the CERAD protocol, including the left 
and right orbitofrontal gyrus (Brodmann area, BA, 11), superior and mid-temporal gyrus 
(BA 21/22), and CA1 region of the hippocampus, were evaluated for neuropathology. 
The orbital frontal cortex was used in my study of the neurochemical correlates of 
muscarinic signaling in AD (see Chapter 8), as this area is known to be an important 
regulator of learning and behavior (Van Hoesen et al. 2000). One subject showed 
evidence of Lewy bodies (LB), another had LB and superior frontal infarct, while two 
others had mutli-infarct or cingulated stroke. In addition, severity of disease as 
determined by Braak staging of the subjects showed that the majority (n=18) were in 
Braak V/VI, and only two were in stage IV/V, and another two in stage IV. 
     
5.2  RADIOLIGAND BINDING ASSAYS 
 
5.2.1  Overview 
 
Saturation radioligand binding assay is a well-established approach to measuring 
neurotransmitter receptors in the postmortem brain. The neurochemical variables of 
interest are the affinity of binding of radioligand to its specific receptor sites (KD, 
expressed in nM) and the density of binding (Bmax, expressed in fmol radioligand bound / 
mg protein). Total binding (TB) is measured by incubating aliquots of brain membrane 
homogenates in appropriate assay buffer with a range of radioligand concentrations. 
which gives total binding (TB). Non-specific binding (NSB) is measured by parallel 
  72 
series of incubation set up as above but in the presence of a saturating concentration of 
unlabeled ligand (“cold blocker”) which will displace radioligand binding to specific 
sites. The specific binding (SB) value can then be obtained by subtracting the NSB value 
from TB value. Figure 5-1 depicts a flow-chart of assay procedures with detailed 
description of each numbered step to follow. 
 
Figure 5.1  Protocol for radioligand saturation binding assay. 
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5.2.2  Detailed Protocol  
Most of the radioligand binding assays described in Chapters 6-9 are based on 
minor modifications of published protocols (see references for the Chapters). In this 
thesis, the assay conditions have been optimized for single site, equilibrium binding. This 
section describes the conditions used. Chemicals and reagents were purchased from 
Sigma Aldrich Co. (St Louis, MO, USA) unless otherwise specified. 
Brain tissue homogenization and washing. All studies involving human 
postmortem tissues described in this thesis were approved by the IRB of the Singapore 
General Hospital. Brain tissues obtained as described above (Section 5.1) were thawed 
on ice, dissected free of white matter and meninges, and homogenized with a Polytron 
Ultra-Turrax T8 homogenizer (IKA Labortechnik GmbH, 15 s at maximum setting) in 10 
volumes of ice-cold 50mM Tris-HCl buffer, pH 7.4 containing 120mM NaCl and 5mM 
KCl. The homogenate was then centrifuged at 15,000 g, 4˚C, and the resultant 
supernatant was discarded and fresh buffer added to the pellet. The cycle of 
homogenization and centrifugation was repeated once more before the pellet was 
suspended in fresh buffer at a concentration of 30 – 50mg wet weight / ml. The washed 
plasma membrane preparation for radioligand binding studies was stored at -75˚C until 
use. 
Radioligand binding. The washed plasma membrane preparations were thawed 
and diluted 1:3 vol./vol. with incubation buffer. If the incubation buffer was not identical 
to the buffer (50mM Tris-HCl, pH 7.4) already in the preparation, the thawed samples   
would be centrifuged and the pellet resuspended in incubation buffer (4x original 
volume). The choice of incubation buffer is based on previously published data on human 
or animal brains. For all radioligand binding assays the buffer pH was kept between 7.4–
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7.7 according to published protocols. The radioligand concentration ranges were usually 
from KD / 5 to around 5 times KD*, which would label > 80% of available binding sites. 
Cold blockers used to define non-specific binding were usually a different ligand from 
the radioligand (except for MK-801 binding to NMDA receptors) and they were used at a 
concentration that was 100 - 1000 times of KD. As shown in Figure 5-2(A) in the 
example of [3H]pirenzepine binding to muscarinic M1 receptors, both total and non-
specific binding are correlated with radioligand concentration, while specific binding 
assumes a hyperbola and approaches a plateau with increasing radioligand concentration, 
indicating that the specific binding sites are saturable. In contrast, NSB varied linearly 
with radioligand concentration including its nonsaturable characteristics.  The cold 
blockers used were usually non-selective ligands which recognize the class of receptors 
in which the receptor of interest belongs. This is preferable to using the unlabeled form of 
the radioligand in cases where the radioligand binding is not well characterized.  
Incubation. Incubation time was based on previous work which reported 
extensive characterization data, including association constants (Kon). This ensures that 
the incubation period is adequate for binding to reach equilibrium. All the radioligands 
used here had Kon values in the range of 108 M-1 based on published data and our own 
results, indicating that an incubation time of at least 60 minutes would ensure equilibrium 






*Initial KD values were estimated from published data or determined from a trial assays. 
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Figure 5.2  [3H]pirenzepine binding  in human postmortem neucortex. 
 
 
Figure 5.2 [3H]Pirenzepine (PZ) binding in postmortem control and AD neocortex. A, representative 
saturation isotherm of [3H]PZ binding in an AD frontal cortex. B, Scatchard plot of binding data presented 




Terminating the binding assay.  At the end of incubation period, the binding 
assays were terminated by rapid vacuum filtration through GF/B glassfibre filters 
(Whatman Ltd, UK) followed by a 8 second wash with ice-cold sodium phosphate buffer, 
pH 7.4 using a Skatron semi-automatic cell harvester (Molecular Devices Ltd. USA). The 
filters were pre-treated with 0.1 % polyethylenimine to reduce non-specific binding. The 
filters were then dried, and discs containing the filtered membrane were punched out into 
scintillation vials, and containing 2ml of scintillation fluid (Wallac HiSafe 2, Perkin 
Elmer Life Sciences, USA).  Bound radioactivity was measured by liquid scintillation 
spectrophotometry (LSS) as described below. Table 5.2 summarizes the binding 
conditions of the radioligands under study. 
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Table 5.2  Optimized conditions for saturation radioligand binding assays. 
 
M1  M2 NMDA 5-HTT 
Radioligand (specific 






























‘Cold’ Blocker Atropine, 1μM  Atropine, 1μM MK-801 maleate, 10μM  
 
Fluvoxamine, 
10μM   
(Tocris Ltd., UK) 
 
Incubation Time 
(in min) 60 60 60 60  
Incubation 
Temperature (in °C) 
 
25 25 25 25 
 
Liquid scintillation spectrophotometry. Measurements of bound radioactivity by 
LSS was performed with a Wallac 1414 beta counter at ~45 % efficiency. The data 
output in disintegrations per minute (dpm) were obtained from counts per minute (cpm) 
values for each vial after correction for radioactivity quenching.  
Scatchard Transformation. Raw dpm data were entered into a PC-based software 
(EBDA and LIGAND) (McPherson 1985) for the computation of KD and Bmax values. 
EBDA performed the Scatchard transformations (see Figure 5-2(B)) while LIGAND is 
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an iterative curve fitting program which compared best fit to one-site or two-site binding. 
The software also computed Hill coefficients (NH). For the calculation of receptor 
density, an aliquot of tissue preparation used in each binding assays was measured for 
protein content by the Coomassie Blue reagent (Pierce Biotech, Inc., USA) using bovine 
serum albumin as the standard.  
 
5.3  MUSCARINIC M1 RECEPTOR-G-PROTEIN UNCOUPLING  
5.3.1  Overview 
The status of the M1 receptor coupling to its G-protein was pharmacologically 
determined by [3H]pirenzepine/carbachol competition assay according to previously 
published methods by Flynn et al. (1991)  with minor modifications. The assay was 
performed by measuring the extent of inhibition of [3H]pirenzepine binding to M1 
receptor by increasing concentrations of cholinergic agonist, carbachol. A parallel series 
of experiments was carried out by adding guanylyl-imidodiphosphate (GppNHp).  
GppNHp is a non-hydrolysable analogue of guanosine triphosphate (GTP) which keeps 
the G-protein in an “uncoupled” state.  In principle, the M1 receptor forms a ternary 
complex with its G-protein in the presence of an agonist, such as carbachol.  When M1 
receptor is in a “coupled” state or in the presence of G-protein, M1 receptor binds to 
carbachol with high affinity (i.e. the high affinity binding constant, Ki, is low).  
Alternatively, in the “uncoupled” state or in the absence of G-protein, M1 receptors bind 
to carbachol with a lower affinity (i.e. the Ki value is high).  Thus, the change of high 
affinity binding constant in the presence (Ki) and absence (KiG) of G-protein will serve as 
an index of G-protein receptor coupling.  For data analysis, the percentage specific 
binding data were plotted against log-transformed values of carbachol concentrations 
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with a non-linear regression curve-fitting software (Prism 3.0, GraphPad Inc. USA), and 
fifty percent inhibitory concentrations (IC50) values were derived from the binding 
curves. The IC50 values were subsequently used to calculate inhibitory constants for 
carbachol binding in the absence (Ki) and presence (KiG) of GppNHp using the Cheng 
and Prusoff’s equation (Cheng and Prusoff 1973).  The presence of excess GppNHp 
uncouples G-proteins from M1 receptors, thus causes a ‘right shift’ of the carbachol 
displacement curve and the value for KiG is significantly greater than that for Ki  (Figure 
5.3A).  However, in samples where G-proteins are endogenously uncoupled to M1 
receptors (higher Ki), addition of GppNHp results will not result in a similar shift (Fig. 
5.3B) and the KiG /Ki ratio will be closely to 1. Therefore, the ratio between KiG  and Ki 
provide a measure of the state of M1/G-protein coupling in control and diseased brains. 
 


















Figure 5.3 Carbachol competition for the % specific binding of [3H]pirenzepine to M1 receptors in the 
temporal cortex of a randomly selected control (A) and Alzheimer’s disease (AD) patient (B). Best-fit 
curves were derived from non-linear aggression of data.  Each data point denotes specific binding in the 
absence () and presence () of 0.2mM of GppNHp across log transformed carbachol concentrations.   
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5.3.2 Detailed Protocol 
Aliquots of tissue preparation prepared as described in section 5.2.2 were 
incubated in duplicates with 3nM of [3H]pirenzepine (specific activity 70-80 Ci/mmol, 
Perkin-Elmer Life Sciences, USA) and increasing concentrations of carbachol (10-9 to 10 -
2M) in buffer (20mM Tris-HCl, 1mM MnCl2, pH 7.4) for 150 min at room temperature.  
Specific binding was defined by binding difference in the absence and presence of 10μM 
atropine sulphate.  A parallel series of competition assays were performed with and 
without addition of 0.2mM GppNHp.  At the end of incubation period, the bound 
radioactivity was obtained by vacuum filtration measured by LSS as in Section 5.2.2. 
   
5.4  DETERMINATION OF CHOLINE ACETYLTRANSFERASE  
       (ChAT) ACTIVITY 
 
5.4.1  Detailed Protocol 
The method of measuring ChAT activity was modified from previously published 
method by Fonnum et al. (1975).  In brief, after thawing the brain homogenates, the 
Triton-X detergent (1μl of 5% triton for every 50μl of tissue, i.e. the final concentration 
of Triton-X is 0.1%) was added to the sample and incubated for 10 minutes at room 
temperature.  Then 10μl of reaction mixture (refer to Table 5.3) was added either to the 
sample tubes with brain homogenate (in triplicates, 4μl of homogenate per tube) or to the 
background tubes (in triplicates, 4μl of 50mM phosphate buffer per tube) and incubated 
for 10 minutes at 37°C.  After incubation, 100μl of ice-cold phosphate buffer (10mM) 
was used to terminate the reaction and 1ml of Kalignost (0.5g sodium tetraphenylboron 
per 100ml acetonitrile) was immediately added to the sample or background tubes and 
vortexed for 10 second.  The sample or background tubes were then centrifuged for 2 
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min.  After centrifugation, 500μl of the acetonitrile layer was transferred to scintillant 
vial with 5ml of scintillation fluid (HiSafe2, Wallac) for measurement by LSS using a 
Beta counter.  Homogenized brain tissue samples were kept at -30°C for subsequent 
protein determination with the Coomassie Blue reagent (Pierce Biotech, Inc., USA).   
 
Table 5.3  Reagents for 300μl of reaction mixture for ChAT assay (dissolved in  
     50mM phosphate buffer, pH7.4). 
 






Choline chloride 140mM 10mM 30 
NaCl 2.1M 300mM 60 
Sodium EDTA 140mM 10mM 30 
Eserine  1.4mM 0.1mM 30 
Acetyl-CoA 2.5mM 0.54mM 90 
[3H]acetyl-CoA  - - 30 
 
 
5.5  DETERMINATION OF KINASE ACTIVITIES  
5.5.1  Overview 
 The assay kit is based on phosporylation of a specific substrate peptide by the 
kinase under study using the transfer of the γ-phosphate of adenosine-5’-[32P] 
triphosphate ([γ-32P]ATP).  The [32P]phosphorylated substrate is then separated from the 
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5.5.2  Protein Kinase C (PKC) Activity 
Protein kinase C enzymatic assays were carried out using components of a 
commercially available PKC enzymatic assay kit (Upstate Biotechnology Inc., Lake 
Placid, NY) based on following reaction:   
                            
QKRPSQRSKYL +  [γ-32P]ATP -------------------->  QKRP[32PS]QRSKYL +ADP 
PKC, Ca2+, PS, 
DAG, Mg2+  
The assay kit was based on [32P]γ-phosphorylation of a specific substrate peptide 
(QKRPSQRSKYL) by PKC. In brief, 10μl of brain tissue lysate, was added to 50μl of 
incubation buffer containing the following (in final concentrations): 83μM substrate 
peptide, 0.3μM PKI (PKC inhibitor peptide), 3.3μM R24571 (CAMK inhibitor),        
0.08mg/ml phosphatidyl serine, 0.008mg.ml DAG, 10μCi [γ-32P]ATP (spec. act. 3000 
Ci/mmol, Perkin Elmer Life Sciences), 12.5mM MgCl2, 83μM unlabeled ATP, 20mM 
MOPS, 25mM β-glycerol phosphate, 1mM sodium orthovanadate, 1mM DTT,          
1mM CaCl2, 0.83mM EGTA, and incubated for 10 min at 30°C.  A 25μl aliquot was then 
transferred onto the center of a numbered phosphor-cellulose paper square.  The assay 
squares were washed with 0.75% phosphoric acid three times for 5 min each and once 
with acetone.  These steps separated the phosphorylated substrate from the residual       
[γ-32P]ATP.  After washing, the assay squares were transferred to a scintillation vial, 5ml 
of scintillation mixture was added, and radioactivity was determined in a scintillation 
counter to calculate enzyme activity (in pmol [32P]-phosphate incorporated into substrate 
/ min / mg protein). In order to control for phosphorylation of endogenous proteins in the 
membrane lysate, parallel assays were carried out as above in the absence of substrate 
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peptide, and radioactivity (typically < 20%) is subtracted from total counts for the 
calculation of specific PKC activity.      
5.5.3  Src Kinase Activity 
 
 The assay kit is based on phosphorylation of a specific substrate peptide 
[KVEKIGEGTYGVVYK] using the transfer of the [γ-32-P]ATP by Src kinase as shown 
by  the following equation: 
 
KVEKIGEGTYGVVYK +[γ-32P]ATP --------------->KVEKIGEGT[32pY]GVVYK +ADP 
Src kinase, Mn2+
 
 Src kinase activity assays were performed as for 5.5.2 except the reaction buffer 
consists of the following: 150μM substrate peptide, 50mM Tris-HCL, pH 7.2,           
10μCi [γ-32P]ATP, 30mM MnCl2, 125μM ATP, 20mM MOPS, 25mM β-glycerol 
phosphate, 0.5mM sodium orthovanadate, 3mM DTT, 3mM EGTA, and incubated for 10 
minutes at 30°C. 10μl substrate peptide, 10μl of Src reaction buffer, and 10μl of            
[γ-32P]ATP stock were added to a microcentrifuge tube and incubated for 10 minutes at 
30°C with agitation.  20μl of 40% trichloroacetic acid was then added to precipitate 
peptide, and a 25μl aliquot was transferred onto the center of a numbered P81 paper 
square.  The assay squares were washed with 0.75% phosphoric acid five times for 5 
minutes each and once with acetone and radioactivity was measured by LSS. In order to 
control for phosphorylation of endogenous proteins in the membrane lysate, parallel 
assays were carried out as above in the absence of substrate peptide, and radioactivity 
(typically 50-60%) was subtracted from total counts for the calculation of specific Src 
activity. 
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5.6     IMMUNOBLOTING 
5.6.1  Detailed Protocol 
Boiled brain homogenates in Laemmli sample buffer were electrophoretically 
separated on 7% polyacrylamide gels, transferred to nitrocellulose membranes, and 
blocked in 10mM phosphate buffered saline, pH 7.4 with 0.1% Tween 20 (PBST) / 5% 
skim milk for 1 hour before immunoblotting with a rabbit polyclonal antibody directed 
against the protein of interest (NR1 subunit of NMDA receptor) at the recommended 
dilution in PBST / 1% milk overnight at 4°C. Following washings in PBST / 1% milk and 
a 1 hour incubation with horseradish peroxidase conjugated goat anti-rabbit antibody 
(1:10,000, Jackson ImmunoResearch Inc.), immunoreactive bands on the membranes 
were visualized by enhanced chemiluminescence using the ECL system (Amersham 
Pharmacia Biotech), and quantified by an image analyzer (UVItec Ltd.). To ensure 
comparable sample loading across lanes, membranes were then stripped with stripping 
buffer (Promega Corp.), washed and reblotted with a mouse monoclonal anti-β-actin 
(1:5000, Sigma Aldrich Ltd., expected molecular weight 42 kDa), and the protocol 
described above was repeated with horseradish peroxidase conjugated goat anti-mouse 
antibody (Jackson ImmunoResearch Inc., USA). One lane for external standard 
consisting of known amounts of protein from an individual homogenate was included in 
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6.1 INTRODUCTION 
The cardinal neuropathological features of AD include extracellular senile 
plaques (SP), intracellular neurofibrillary tangles (NFT) and neuronal degeneration. Of 
the several neurotransmitter systems known to be affected in AD, one of the earliest and 
most consistently reported are degeneration of basal forebrain cholinergic neurons 
(Davies and Maloney 1976; Whitehouse et al. 1982), accompanied by presynaptic 
neurochemical alterations including reduced choline acetyltransferase (ChAT) and 
acetylcholinesterase (AChE) activities, reduced acetylcholine release, as well as losses of 
muscarinic M2 in the neocortex and hippocampus (Francis et al.  1985; Mash et al. 1985; 
Perry et al. 1977; Sims et al. 1983; Wilcock et al. 1982). Postsynaptic M1 receptors 
appeared to be preserved in AD (Mash et al. 1985) but was subsequently shown to be 
defective in coupling to G-proteins (Flynn et al. 1991; Ladner et al. 1995). Other studies 
also reported deficits in postsynaptic signaling such as decreases in phosphoinositide 
hydrolysis and protein kinase C (PKC) activities (Cole et al. 1988; Ferrari-DiLeo and 
Flynn 1993; Jope et al. 1997) which are activated by M1 and M3 receptors (Caulfield 
1993). There are also reports of deficits in nicotinic receptors (Perry et al. 1987; 
Warpman and Nordberg 1995). Taken together, these studies suggest a state of profound 
presynaptic as well as postsynaptic cholinergic dysfunction in AD that may underlie both 
the cognitive and behavioral symptoms of AD (Cummings and Kaufer 1996; Lai et al. 
2001; Minger et al. 2000; Perry et al. 1978; Tsang et al. 2005; Wilcock et al. 1982). 
AD is divided into familial and sporadic forms of disease according to family 
history. Both early onset (before 65 years of age) and late-onset (65 years and over) 
familial cases constitute up to 40 % of all AD (van Duijn et al. 1991). Several gene 
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mutations have been linked to familial forms of AD, such as those encoding amyloid 
precursor protein (APP), presenilin 1 and presenilin 2, which result in altered APP 
processing and increased production of amyloidogenic (plaque-forming) Aβ species 
(Selkoe 2001). For sporadic AD which constitutes the majority of cases, the major 
identified genetic risk factor is APOE, which encodes apolipoprotein E (apoE), a 34 kDa 
lipid carrier protein. The APOE gene is located on the long arm of chromosome 19 and 
exist as three polymorphic variants (Emi et al. 1988) (see Table 6.1).   
 
Table 6.1  Polymorphisms in apoE. 





Of the three APOE alleles (ε2, ε3 and ε4 encoding apoE2, apoE3 and apoE4 
isoforms respectively), the ε4 is dose-dependently associated with increased risk of 
developing AD compared with ε3 and ε2 (Corder et al. 1993; Poirier et al. 1993; 
Saunders et al. 1993). Clinical studies also indicate that the age of AD onset is inversely 
proportional to the number of ε4 alleles. On the other hand, ε3 and ε2 seem to provide 
some protection against AD. ApoE4 is different from apoE3 by a single amino acid 
change from cysteine to arginine at position 112, resulting in the formation of a salt 
bridge between Arg-61 in the amino terminus and Glu-255 in the carboxyl terminus, 
leading to a more compact structure than ApoE3 and resulting in ApoE4’s preference for 
binding VLDL (very low density lipoproteins) to HDL (high density lipoproteins, Dong 
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and Weisgraber 1996). The most common combination of APOE alleles is ε3/ε3 
(Hallman, et al. 1991).  ApoE is expressed in various types of tissues such as atrocytes, 
macrophages and monocytes, but mainly in the liver and brain (Siest et al. 1995). The 
apoE protein is the major apolipoprotein in the central nervous system which is a key 
regulator of lipid metabolism; therefore, apoE plays a role in many biological processes 
involving lipid metabolism, including myelination, synaptic plasticity and repair, with the 
E4 being less effective than the E3 isoform (Mahley and Huang 1999; White et al. 2001).  
E4 has also been shown to facilitate Aβ deposition and τ hyperphosphorylation more 
potently than E2 and E3 in vitro (Holtzman et al. 2000; Tesseur et al. 2000). 
Additionally, AD patients with one or two ε4 showed higher plaque and, to a lesser 
extent, higher tangle burden than non-ε4 carriers (Nagy et al. 1995; Olichney et al. 1996; 
Schmechel et al. 1993). Finally, apoE may affect cholinergic neurons and signaling in an 
isoform-specific manner. For example, some studies demonstrated that ε4 positive AD 
patients had more extensive deficits in ChAT activities compared with non-ε4 carriers     
( Beffert and Poirier 1996; Poirier et al. 1995; Soininen et al. 1995;) while others did not 
find a linear relationship between ChAT activities and number of ε4 allele copies  
(Corey-Bloom et al. 2000; Svensson et al. 1997; Tiraboschi et al. 2004). The effect of 
apoE genotype on other cholinergic markers are less clear. M1, M2 and nicotinic receptors 
do not seem to differ between patients with or without ε4 (Poirier et al. 1995; Reid et al. 
2001; Svensson et al. 1997). However, the radioligands used to label nicotinic sites in 
these studies are not subunit-specific, and it is not known whether apoE genotype is 
correlated with specific losses of nicotinic receptor subpopulations, such as those 
containing α4β2 subunits (Warpman and Nordberg 1995). Furthermore, although studies 
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have shown selective impairment of muscarinic receptor-mediated phosphoinositide 
hydrolysis by the E4 isoform (Cedazo-Minguez and Cowburn 2001), it is not known 
whether apoE affected the coupling of G-proteins to M1 receptors in AD. In this study, 
we correlated APOE genotype with a range of pre- and postsynaptic cholinergic 
neurochemical markers (M1 receptors, M2 receptors, α4β2 nicotinic receptors, M1/G-
protein coupling, ChAT activity and AChE activity) in the postmortem frontal and 
temporal cortex of a cohort of AD patients in order to test the hypothesis that deficits or 
alterations in cholinergic neurotransmission in the AD neocortex is influenced by APOE 
ε4 genotype.  
 
6.2 MATERIALS AND METHODS 
6.2.1   Patients and Neuropathological Assessments 
Up to 40 AD subjects and 20 elderly controls were included in this study. The AD 
subjects were derived from an autopsied subset of a cohort of community-based dementia 
patients from Oxfordshire, UK enrolled in a longitudinal study of behavior in dementia 
(Hope et al. 1999).  Subject recruitment, demographics and clinical assessment have been 
previously described in detail in Chapter 5 (Section 5.1.1).  Complete drug histories 
were recorded, and none of the subjects was on cholinomimetic medication.  At autopsy, 
brains were harvested after informed consent had been obtained from the patients’ 
relatives. One hemisphere was processed for neuropathological assessments, while the 
other was fresh-frozen for subsequent neurochemical assays. As mentioned in Chapter 5 
(Section 5.1.1) all subjects fulfilled CERAD criteria for the neuropathological diagnosis 
of AD (Mirra et al. 1991), and were neuropathologically staged at Braak V / VI (Braak 
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and Braak 1991). Two patients (both of ε3/ε3 genotype) had evidence of mixed vascular 
dementia and AD. Paraffin-embedded blocks of frontal as well as temporal cortex were 
then stained with methenamine silver and a modified Palmgren stain for a blinded, semi-
quantitative scoring of SP (0-3 points) and NFT (0-4 points), as previously described 
(Chapter 5, Section 5.1.1).  The selection of AD subjects as well as controls for the 
current study was based on postmortem-tissue availability; and not on APOE genotype. 
Not all neurochemical measures were performed in all participants due to shortage of 
tissue, and data for some of the neurochemical measurements were provided by our 
collaborators (AChE activities from Dr Maria Ramirez, University of Navarro, Spain; 
[3H]epibatidine binding and brain pH from  Dr Paul Francis, King’s College London, UK 
and APOE genotyping from Prof James Nicoll, University of Southampton, UK). All 
other assays described here were performed by us.    
6.2.2 Tissue Processing  
Tissue processing and neurochemical assays were performed blind to clinical 
information. All chemicals and reagents were from Sigma-Aldrich Ltd. (St Louis, MO) 
unless otherwise stated.  Brain tissue homogenate preparation has been described in 
Chapter 5 (Section 5.2.2).   
6.2.3 APOE Genotyping 
APOE genotyping were determined with DNA extracted from brain tissues 
according to previously described methods as performed in Prof James Nicoll’s 
laboratory (Nicoll et al. 1997). 
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6.2.4 Neurochemical Measurements  
Radiochemical determination of ChAT activity has been described in Chapter 5 
(Section 5.4).  AChE assay using a colorimetric method (Wang, et al. 1999) was 
modified as previously reported and performed in Dr Maria Ramirez’s laboratory 
(Garcia-Alloza et al. 2005).  Measurement of muscarinic M1 and M2 receptors was 
performed by saturation radioligand binding assays using [3H]pirenzepine (PZ) and 
[3H]AF-DX 384 (both from Perkin Elmer Life Sciences, Boston, MA), respectively, as 
detailed in Chapter 5 (Section 5.2.2).  [3H]Epibatidine (Perkin Elmer Life Sciences, 
Boston, MA) for α4β2 subunit-containing nicotinic receptors have been previously 
described as performed in Dr Paul Francis’ laboratory, using  250 nM unlabelled cytosine 
used to define non-specific binding (Gnadisch et al. 1999). Neurochemical parameters KD 
(binding affinity, in nM) and Bmax (binding density, in fmol/mg protein) for M1, M2 and 
α4β2 nicotinic receptors  were derived from binding data by Scatchard analyses as 
described in Chapter 5 (Section 5.2.2).  Pharmacological determination of M1 receptor 
coupling to G-proteins using a [3H]PZ / carbachol competition assay was detailed in 
Chapter 5 (Section 5.3).  
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Table 6.2  Demographic, disease and neurochemical variables in control and AD. 
 
AD Control 
Maximum Number of Cases1 40 20 
Age at Death (y) 81.7 ± 1 77.3 ± 2 
Sex (M/F) 20 / 20 13 / 7 
Post-Mortem Interval (h) 37.7 ± 4 47.7 ± 7 
pH 6.35 ± 0.07* 6.62 ± 0.09 
ChAT (pmol/mg prot/h)                     Frontal 
Temporal 
3.5 ± 0.3 (36)** 
1.9 ± 0.3 (34)† 
6.3 ± 0.7 (16) 
6.4 ± 0.3 (19) 
AChE (% Control)                              Frontal 
Temporal 
72 ± 3 (17)† 
70 ± 3 (17)† 
103 ± 5 (9) 
105 ± 3 (9) 
[3H]PZ KD (nM)                                 Frontal 
Temporal 
4.4 ± 0.2 (27)* 
4.5 ± 0.2 (27) 
3.6 ± 0.2 (12) 
4.1 ± 0.4 (12) 
[3H]PZ BBmax (fmol/mg prot)               Frontal 
Temporal 
575 ± 13 (27) 
614 ± 22 (27) 
601 ± 30 (12) 
594 ± 31 (12) 
[3H]AF-DX 384 KD (nM)                   Frontal 
Temporal 
3.7 ± 0.2 (27) 
4.3 ± 0.2 (27) 
4.2 ± 0.6 (12) 
4.2 ± 0.3 (12) 
[3H]AF-DX 384 BBmax (fmol/mg prot) Frontal 
Temporal 
483 ± 21 (27)** 
558 ± 26 (27) 
583 ± 30 (12) 
566 ± 42 (12) 
[3H]Epibatidine KD (pM)                    Frontal 
Temporal 
45 ± 6 (31) 
91 ± 22 (30) 
57 ± 8 (12) 
60 ± 24 (14) 
[3H]Epibatidine BBmax (fmol/mg prot)  Frontal 
Temporal 
50 ± 3 (31)* 
60 ± 5 (30) 
65 ± 9 (12) 
80 ± 11 (14) 
KiG / Ki                                                                             Frontal 
Temporal 
2.4 ± 0.3 (21)* 
2.1 ± 0.2 (25)** 
3.6 ± 0.2 (8) 
6.1 ± 0.9 (6) 
SP                                                                                   Frontal 
Temporal 
1.97 ± 0.1 (35)† 
2.31 ± 0.1 (35)† 
0.08 ± 0.08 (12) 
0.15 ± 0.1 (13) 
NFT                                                                             Frontal 
Temporal 
1.74 ± 0.2 (35)† 
2.26 ± 0.2 (35)† 
0.08 ± 0.08 (13) 
0.14 ± 0.1 (14) 
 
Table 6.2  Data are mean ± S.E.M. ChAT, choline acetyltransferase; AChE, acetylcholinesterase; KD, 
binding affinity constant; BBmax, binding density; KiG / Ki ,   measure of M1 / G-protein coupling (see text); 
SP, senile plaque score; NFT neurofibrillary tangle score. 
1Not all neurochemical measures were available for all cases. The N values available for each 
neurochemical measure are listed in parentheses.  
*Different from control p < 0.05; **Different from control p < 0.01; †Different from control p < 0.001. 
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6.2.5 Statistical Analyses 
Data were tested for normality for the selection of parametric or non-parametric 
tests. Demographic, disease and neurochemical variables between controls and AD were 
compared with Student’s t-tests. The effect of potential confounders on neurochemical 
variables, as well as the inter-correlations among variables were studied by Pearson’s 
product moment or Spearman’s correlation. The distribution of genotype frequencies 
between AD and controls were analyzed by Chi-square tests, while demographic and 
disease variables among the APOE genotypes in AD were compared by one-way analysis 
of variance (ANOVA) followed by Dunnett’s post-hoc tests, as the number of subjects in 
the groups were not matched and equal variances could not be assumed. All statistical 
analyses were performed with the SPSS 10.0 for Windows software (SPSS Inc. USA), 
except for Chi-square tests, which were carried out with StatXact 3 for Windows (Cytel 
Software Corp. MA, USA).    
 
6.3 RESULTS 
6.3.1 Demographic, Disease and Neurochemical Variables in Control vs. AD 
Table 6.2 shows that demographic variables were well-matched between the AD 
subjects and controls except for lower pH in AD, possibly an indication of more severe 
acidosis due to prolonged agonal state (Hardy et al. 1985). However, pH, as well as other 
demographic variables listed in Table 6.2, did not correlate with neurochemical variables 
(Pearson p > 0.05).  As shown in Table 6.2, ChAT and AChE activities as well as M2 and 
α4β2 nicotinic receptor densities are reduced in one or both regions in AD, while M1 
densities remained unchanged. Except for higher KD in [3H]pirenzepine binding in the 
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AD frontal cortex (Lai et al. 2001), there were no differences in receptor binding 
affinities. There was minimal neuropathology in controls, contrasting with significantly 
higher SP and NFT scores in AD. The distribution of APOE alleles between controls and 
AD also appeared to be different (Table 6.3); in fact, none of the controls in this cohort 
had the ε4/ε4 genotype. There was also no ε2/ε2 genotype in either AD or controls. 
 




N = 40 
Control 
N = 20 
ε2/ε3 or ε3/ε3 15 (38 %) 16 (80 %) 
ε2/ε4 or ε3/ε4 21 (52 %) 4 (20 %) 
ε4/ε4 4 (10 %) 0 (0 %) 
*Significantly different from control, Pearson’s Chi-Square (χ2 = 10.04) with Fisher’s exact test, p < 0.01. 
 
6.3.2 Effect of APOE Genotype on Demographic, Disease and Neurochemical 
Variables in AD 
 
Demographic factors as well as postmortem conditions were not significantly 
different among AD patients with zero (ε3/ε3 or ε3/ε2), one (ε3/ε4 or ε2/ε4) or two ε4 
alleles (Table 6.4), although there is a trend towards lower estimated age of AD onset 
with increasing ε4 dose. In contrast, both dementia severity (estimated by the Mini-
Mental State Examination score before death, Folstein et al. 1975) as well as temporal 
cortical senile plaque (SP) loads were higher in patients with two ε4 alleles compared to 
those with zero or one ε4, with similar trends for frontal cortical SP as well as 
neurofibrillary tangle scores in both regions. Finally, Figure 6.1 illustrates the neocortical 
cholinergic variables across APOE genotypes in AD. Because the neurochemical 
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variables between controls with the ε4 allele and those without were not significantly 
different (Student’s t tests, p > 0.05, data not shown), the mean control values were used 
as a baseline for comparisons with AD APOE genotype groups in order to study the 
effect of ε4 on the neurochemical alterations in AD.  
 
Table 6.4  Effect of APOE ε4 allele on demographic and disease variables in AD. 
 
 0 ε4 1 ε4 2 ε4 
Age at Death (y) 83.7 ± 2 80.6 ± 1 80.5 ± 0.6 
Age at Onset (y) 75.2 ± 2 71.7 ± 1.5 69.2 ± 3.2 
Disease Duration (y) 8.5 ± 0.8 8.9 ± 1 11.3 ± 3 
Sex (M/F) 7 / 9 12 / 9 2 / 2 
Post-Mortem Interval (h) 34.0 ± 3 39.1 ± 7 44.7 ± 16 
pH 6.38 ± 0.1 6.33 ± 0.1 6.34 ± 0.2 
Predeath MMSE 4.5 ± 2 5.3 ± 2 0.0 ± 0* 
SP                         Frontal
Temporal
2.23 ± 0.2 
2.31 ± 0.2 
1.68 ± 0.2 
2.21 ± 0.2 
2.67 ± 0.3 
3.00 ± 0.0* 
NFT                      Frontal
Temporal
1.92 ± 0.3 
2.23 ± 0.3 
1.53 ± 0.3 
2.21 ± 0.2 
2.33 ± 0.3 
2.67 ± 0.3 
 
Table 6.4  Data are mean ± S.E.M. for AD patients with no APOE ε4 allele (n = 13-15), 1 ε4 allele (n = 18-
21) or two ε4 alleles (n = 3-4). MMSE, Mini-Mental State Examination; SP, senile plaque score; NFT 
neurofibrillary tangle score. *Significant different from the 0 ε4 and from the 1 ε4 groups, one-way 
ANOVA with post-hoc Tamhane’s p < 0.05. 
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Figure 6.1  Effect of APOE ε4 allele on cholinergic neurochemical alterations  
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Figure 6.1  (Previous page)  For each neurochemical measure, data are expressed as mean % control 
values ± S.E.M. for controls (n = 6-19), AD patients with no APOE ε4 allele (n = 6-13), one ε4 allele (n = 
9-20) or two ε4 alleles (n = 2-4). ChAT, choline acetyltransferase; AChE, acetylcholinesterase; [3H]PZ 
BBmax, binding density of [ H]pirenzepine (labels M1 receptors); [ H]AFDX Bmax3 3 B , binding density of 
[3H]AF-DX 384 (labels M2 receptors); [3H]Epi BBmax, binding density of [ H]epibatidine (labels α4β2 
nicotinic receptors); K
3
iG / Ki ,   measure of M1 / G-protein coupling (see text). 
*Significantly different from controls, one-way ANOVA with post-hoc Dunnett’s p < 0.05. 




The ε4 allele of APOE is at present the only well-established susceptibility gene 
for sporadic AD, with risk of disease development at a particular age increasing with ε4 
allele dose. The widely replicable nature of these findings has led to intense research 
efforts toward uncovering the mechanisms by which ApoE4 affect the neurodegenerative 
process of AD. Here, using a well-characterized cohort of AD patients, we investigated 
whether inheritance of the ε4 allele was associated with cholinergic alterations using 
several pre- and postsynaptic neurochemical markers known to be affected in AD, 
including two markers (nicotinic α4β2 receptors and M1/G-protein uncoupling) which, to 
our knowledge, have not been previously correlated with APOE genotypes.  
6.4.1 Effects of APOE ε4 on ChAT Loss in AD  
Although ChAT and AChE activities, muscarinic M2 and nicotinic receptor 
densities as well as M1 receptor coupling to G-proteins were all found to be reduced in 
one or both cortical regions (see Table 6.2), only losses in ChAT activities were 
associated with ε4 (Figure 6.1). In the frontal cortex, ChAT activities were only 
significantly decreased in AD patients with at least one ε4. In the temporal cortex, 
although ChAT activities were reduced in all three genotype groups of AD patients when 
compared with controls, the ChAT values were most severely affected in patients with 
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two ε4 alleles, which were significantly lower than those with zero or one ε4. The 
particular vulnerability of the temporal cortex to neurodegeneration and cholinergic 
deficits in AD (Jobst et al. 1994; Wilcock et al. 1982) may explain the lower ChAT 
values we observed in this region. Importantly, our results suggest that presence of APOE 
ε4 does not directly lead to ChAT deficits, since temporal cortical ChAT was reduced 
even in AD patients without ε4; instead, ε4 may exacerbate the cholinergic denervation in 
both neocortical regions as indicated by loss of ChAT activities. These data are in 
agreement with some studies (Beffert and Poirier 1996; Poirier et al. 1995; Soininen et al. 
1995), while others (Corey-Bloom et al. 2000; Svensson et al. 1997; Tiraboschi et al. 
2004) failed to find significant effects of ε4 on ChAT. However, it is worth noting that in 
two of the negative studies (Corey-Bloom et al. 2000; Tiraboschi et al. 2004) 
cholinomimetic treatment status of the subjects was not reported. Given that 
cholinesterase inhibitor treatment in rodents are known to upregulate ChAT expression 
(Tayebati et al. 2004), the possibility that cholinomimetic treatment may confound the 
effect of ε4 on ChAT needs to be addressed. In the present study, all subjects were 
community-based patients who were never on cholinomimetic therapies, thus removing 
one potential confounder in the interpretations of ChAT data.  
6.4.2 Lack of APOE ε4 Effects on Peri- and Postsynaptic Cholinergic Markers  
In contrast to the ChAT results, neocortical AChE activity was reduced in AD but 
was not affected by APOE genotype (Figure 6.1). Unlike ChAT, which is expressed 
exclusively in cholinergic neurons in the brain, AChE is produced in cholinoceptive sites 
as well as non-cholinergic cells and released into the synaptic cleft (Grisaru et al.  1999; 
Taylor and Brown 1999). Thus, our data suggest that the reduced AChE in AD is an 
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indication of synapse loss rather than a consequence of APOE ε4-related cholinergic 
denervation. Similarly, the densities of M1 and α4β2 nicotinic receptors, which are 
predominantly postsynaptic; as well as M2 receptors, which could be localized to both 
pre- and postsynaptic compartments (Arroyo-Jiménez et al. 1999; Mash et al. 1985), were 
not significantly different among patients with different ε4 genotypes. Furthermore, 
although M1/G-protein coupling was reduced in the temporal cortex, the extent of 
coupling loss again did not differ among the ε4 genotypes. Taken together, our results 
indicate that APOE ε4 may selectively influence pre-, rather than postsynaptic, alterations 
of cholinergic neurotransmission in AD. 
In the frontal cortex, there was a nonsignificant trend towards recovery of KiG/Ki 
values with increasing ε4 dose. Possible mechanisms for this observation are unknown 
and need to be further studied. However, one limitation of the current study is the relative 
small numbers of ε4/ε4 AD patients in the cohort (Table 6.3), mainly due to the very low 
abundance of this genotype (1-3 % in the general population, reviewed in (Wilson et al.  
1996). At present, we have failed to uncover an effect of ε4 on M1/G-protein coupling. 
Taking into account the report by Cedazo-Minguez and Cowburn (2001) that apoE4 
disrupts muscarinic receptor-mediated phosphoinositide hydrolysis in neuroblastoma 
cells, our M1/G-protein coupling data suggest that either i) apoE4 targets signaling 
molecules downstream of G-protein (for e.g., phosphotidylinositol 3-kinase); or (ii) 
M1/G-protein uncoupling is a postsynaptic response to presynaptic ChAT loss (see Potter 
et al. 1999), and is not directly affected by APOE ε4. 
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6.4.3 Possible Mechanisms of APOE ε4 Effects  on ChAT Loss in AD 
It is worthwhile to further study the mechanisms whereby apoE4 may affect 
cholinergic neuronal function. One possibility is that cholinergic neurons, with their 
reliance on cholesterol transport as well as phospholipid metabolism for synaptic 
plasticity and synthesis of acetylcholine in the brain, may be particularly vulnerable to the 
diminished affinity of apoE4 for receptor-mediated uptake (Poirier 1994; Poirier et al., 
1995). Compared to the other isoforms, apoE4 also demonstrated lower activation of 
signaling molecules such as extracellular signal regulated kinase 1 / 2 (ERK1/2) which 
are involved in neurite outgrowth and synaptic plasticity (Qiu et al. 2004). Interestingly, 
Dubelaar et al. (2004) have shown that  APOE ε4 is related to reduced metabolic activity 
in the nucleus basalis of Meynert (nbM) in both cognitively normal controls as well as 
prodromal early AD, suggesting that ε4 contribute to AD risk via a state of 
hypometabolism and reduced adaptive capacity in the nbM, perhaps years before the 
appearance of cognitive decline. It is possible that reduced ChAT activity would be one 
marker of nbM hypometabolism or cell loss, leading to cholinergic dysfunction which 
may further contribute to AD progression or by increasing amyloidogenic processing of 
precursor protein and Aβ in plaques (Hellstrom-Lindahl 2000). This postulate is 
supported by present findings that frontal and temporal ChAT activities were correlated 
with SP from the same regions in AD (Pearson’s r = -0.376 [frontal], -0.408 [temporal], p 
< 0.05). In addition, SP scores were also higher in patients with two copies of ε4 
compared to those with zero or one ε4 in the temporal cortex, with similar trends in the 
frontal cortex (Table 6.4). However, as this is a postmortem neurochemical study where 
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the majority of the subjects had severe disease at death, and further work using subjects 
with a wider range of disease severity is needed to corroborate the present findings. 
  In conclusion, using a cohort of well characterized, community-based AD 
patients, we show that the APOE ε4 allele does not lead to reduced ChAT per se, but is 
related to higher losses of  ChAT activities in the neocortex compared to non APOE ε4 
patients. Furthermore, APOE ε4 has limited or no effect on other neurochemical 
cholinergic markers such as AChE, M1, M2, α4β2 nicotinic receptors, and M1/G-protein 
uncoupling. These findings suggest that presynaptic cholinergic function is selectively 
vulnerable to the effects of ε4, and the resultant exacerbation of cholinergic deficit may 
be related to AD risk via its effect on cognitive processes as well as Aβ deposition and 
plaque formation. 
6.4.4 Further Studies 
It is well established that the presynaptic components of the cholinergic 
neurotransmission including ChAT and muscarinic receptors are severely impaired in 
AD.  Additionally, findings from this study have shown that APOE ε4 selectively affects 
presynaptic cholinergic function which may contribute to both the clinical and 
neuropathological features of AD and that APOE ε4 exacerbates the cholinergic 
neurotransmission dysfunction in AD by indirectly influencing the ChAT activity.  
However, the current view that only the presynaptic cholinergic neurotransmission is 
impaired has been challenged by findings from other postmortem studies. Clinical trials 
using cholinergic replacement or cholinomimetic therapies to treat AD patients have 
shown relatively modest or no improvements (Greenlee et al. 2001). One possible 
explanation may be that the postsynaptic signal transduction of cholinergic 
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neurotransmission is disrupted in AD and thus severely limit the ability of cholinergic 
agonist to activate downstream signaling.  Flynn et al. (1991) have also shown that the 
postsynaptic muscarinic M1 receptor is “uncoupled” from its G-protein in AD.  In 
addition, other scientists have demonstrated that PKC activity is significantly reduced in 
AD (Cole et al. 1988; Masliah et al. 1991) But, whether M1/G-protein uncoupling 
correlates with cognitive decline in AD is still not fully understood and will be addressed 
in the next chapter.                       
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7.1  INTRODUCTION 
 
As previously mentioned, AD is characterized neuropathologically by senile 
plaques, neurofibrillary tangles, and losses of various neurotransmitter-producing 
neurons. Of the transmitter pathologies seen in AD, cholinergic dysfunction occurs early 
in the disease process (Mesulam 2004) and is thought to underlie much of the 
characteristic cognitive and neuropsychiatric symptoms (Francis et al. 1999; Lai et al. 
2001; Minger et al.  2000; Perry et al. 1981; Wilcock et al. 1982). Losses of basal 
                                                          
*Data presented in this chapter has been published: Tsang SW, Lai MK, Kirvell S, Francis PT, Esiri MM et 
al.  Neurobiology of Aging (2006) 27:1216-1223. 
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forebrain cholinergic neurons, along with reduced neocortical choline acetyltransferase 
(ChAT) activity, acetylcholine (ACh) release and muscarinic M2 receptor binding, 
constitute a state of presynaptic cholinergic deficit in AD (Francis et al. 1985; Mash et al. 
1985; Perry et al. 1977; Whitehouse et al. 1982). In contrast, the predominantly 
postsynaptic M1 receptors were originally thought to be unaltered (Mash et al. 1985), but 
subsequent studies showed that normal levels of radioligand binding to M1 receptors 
contrasted with reduced M1 immunoreactivity (Flynn et al. 1995). In addition, the ability 
of M1 receptors to form high affinity agonist-binding complexes with guanine nucleotide-
binding (G-) proteins was found to be impaired in AD (Flynn et al. 1991), along with 
reductions in phosphoinositide hydrolysis, phospholipase C (PLC) and protein kinase C 
(PKC) activities (Ferrari-DiLeo and Flynn 1993; Jope 1999; Masliah et al. 1991).  Taken 
together, these findings suggest that M1 or M1-like receptors are altered in the AD cortex, 
resulting in defective coupling to G-proteins and hypoactivation of second messengers. 
This breakdown in intracellular signal transduction associated with M1 receptors in the 
cortex is hypothesized to underlie the limited efficacy of cholinergic replacement 
therapies, since the ability of ACh or agonists to ameliorate deficits in cholinergic 
neurotransmission would have been severely limited (Flynn et al. 1991).  However, it is 
presently unclear whether M1/G-protein uncoupling is related to cognitive decline in AD. 
In this study, I measured M1 receptor densities and coupling to G-proteins in the post-
mortem neocortex of a cohort of longitudinally assessed AD patients, as well as in a 
group of age-matched controls. I then correlated the M1 neurochemical parameters with 
clinical data. 
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7.2  MATERIALS AND METHODS 
7.2.1   Patients, Clinical and Neuropathological Data 
Up to 24 AD subjects were included in this study.  The AD subjects were 
originally derived from an autopsied subset of a cohort of community-based dementia 
patients from Oxfordshire, UK, who were recruited for a prospective study of behaviour 
in dementia (Hope et al. 1999). The entry data, inclusion and exclusion criteria, natural 
history of these patients, and cognition assessment using Mini-Mental State Examination 
(MMSE) have previously been described in detail in Chapter 5 (Section 5.1.1).  
Dementia severity was measured by using the mean of up to five MMSE scores before 
death so as to avoid floor effects, since some patients may live for extended periods of 
time after their MMSE scores had reached 0 (Lai et al 2001). Patients were considered to 
have severe dementia (ADsevere) if the mean predeath MMSE was ≤ 9, while those with 
scores between 10 and 24 were deemed to have mild to moderate dementia (ADmild/mod.). 
None of the subjects had scores >24. The rate of cognitive decline per year was measured 
by the linear regression of serial MMSE scores on the time interval between recruitment 
and death, or when the MMSE first reached 0. Complete drug histories were taken, and 
none of the subjects received cholinomimetics.  As mentioned in Chapter 5 (Section 
5.1.1), all AD patients fulfilled the CERAD criteria for neuropathological diagnosis of 
AD. Selection of subjects for the current study was based on tissue availability, and not 
on dementia severity or Braak stage, and controls were well matched to subjects with 
regards to age, sex, and post-mortem delay.  
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7.2.2 Brain Membrane Homogenates 
Tissue processing and neurochemical assays were performed blind to clinical 
information.  All chemicals were from Sigma Aldrich (St Louis, MI) unless otherwise 
stated. Brain tissue homogenate preparation has been described in Chapter 5       
(Section 5.2.2).   
7.2.3 Neurochemical Assays 
The methods of pharmacological determination of M1 receptor coupling to G-
proteins using [3H]pirenzepine (PZ) / carbachol competition assay (see Fig 7.2 A and B) 
as well as measurement of muscarinic M1 receptors using saturation radioligand binding 
assay were detailed in Chapter 5 (Section 5.2 and 5.3).  Radiochemical determination of 
ChAT activity has been described in Chapter 5 (Section 5.4).  Note that brain 
homogenates were not available from both regions in some subjects. 
7.2.4 Statistical Analyses 
Data were first tested for normality to determine the use of parametric or non-
parametric tests. Neurochemical and demographic variables among the groups were 
compared by one-way analysis of variance (ANOVA) with post-hoc Tamhane’s tests, 
since the number of subjects was not evenly matched and equal variances could not be 
assumed. Disease variables between the AD cognitive groups were compared by 
Student’s t tests. Correlations of neurochemical variables with cognitive data, as well as 
inter-correlations among the neurochemical variables were performed by Pearson’s 
product moment or Spearman’s correlation, as appropriate. Results were considered 
statistically significant if p < 0.05. 
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7.3 RESULTS 
7.3.1  Demographics 
Table 7.1 shows that demographic variables such as age, sex, and post-mortem 
interval were well matched among the control, AD with mild / moderate dementia 
(ADmild/mod.), and AD with severe dementia (ADsevere), except for brain pH, which was 
significantly lower in the ADsevere group.  This is likely due to the prolonged agonal state 
of severely demented patients, resulting in brain acidosis (Hardy et al. 1985). However, 
brain pH and the other demographic variables listed on the table did not correlate with 
KiG /Ki values in either controls or AD subjects (Spearman p > 0.10).  Among the AD 
patients, entry and predeath MMSE scores were expectedly lower in the ADsevere 
compared to the ADmild/mod. group. Additionally, the rates of MMSE decline were 
significantly higher in the ADsevere group, while both disease duration (estimated duration 
between first symptoms and death) and follow-up (duration between study entry and 
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Table 7.1  Demographic and disease variables in controls and cognitive subgroups of 




N = 12 
AD (Mild / Moderate) 
N = 7 
AD (Severe) 
N = 17 
Demographic Variables    
Age, y 77 ± 3 81 ± 2 81 ± 2 
Sex, M / F 5 / 7 5 / 2 9 / 8 
Postmortem interval, h 47 ± 9 45 ± 9 35 ± 6 
pH 6.48 ± 0.1 6.25 ± 0.09 6.02 ± 0.05* 
Disease Variables    
Disease duration, y -- 8.4 ± 0.8 9.0 ± 1.2 
Follow up, y --  3.1 ± 0.2  3.4 ± 0.4  
MMSE at study entry -- 20.7 ± 1.1 11.3 ± 1.4** 
MMSE at predeath -- 13.1 ± 3.0 1.2 ± 0.7** 
MMSE decline / year -- 2.9 ± 0.7 6.1 ± 0.8** 
Table 7.1  Data are mean ± s.e.m. MMSE = Mini-Mental State Examination.  
*Significantly different from control, ANOVA with post-hoc Tamhame’s, p < 0.01. 
**Significantly different from AD (mild/moderate), Student’s t tests, p < 0.01. 
 
7.3.2  M1 Receptor Binding in AD: Correlation with Dementia 
For the neurochemical variables, [3H]pirenzepine binding affinity (KD) and 
density (Bmax) were unchanged in both frontal and temporal regions (Figure 7.1C and 
D). This contrasted with significantly reduced temporal cortical KiG /Ki in both ADsevere 
and ADmild/mod. (Figure 7.2C). In the frontal cortex, KiG /Ki was significantly reduced only 
in ADsevere, with intermediate values in ADmild/mod which were not significantly different 
from either control or ADsevere (Figure 7.2C). 
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Figure 7.1  [3H]Pirenzepine (PZ) binding in postmortem control and AD neocortex. 
 
 
Figure 7.1  (A) representative saturation isotherm of [3H]PZ binding in an AD frontal cortex.                  
(B) Scatchard plot of binding data presented in A with derived neurochemical parameters.                         
(C) and (D) mean ± s.e.m values of neocortical [3H]PZ binding affinity (KD, in nM) and M1 receptor 
density (Bmax, in fmol/mg protein), respectively, in control and AD cognitive groups.  
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Figure 7.2  Carbachol competition for the specific binding of [3H]pirenzepine to M1    
         receptors in the neocortex of a randomly selected control (A) and AD     
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Figure 7.2  (Previous page) Best-fit curves were derived from non-linear regression of data. Each data 
point denotes specific binding in the absence (■) and presence (□) of 0.2 mM GppNHp across log 
transformed carbachol concentrations. C, mean ± s.e.m. values of KiG /Ki in controls and cognitive groups 
of AD. *Significantly different from control, p ≤ 0.01 one-way ANOVA post-hoc tests. 
 
When the AD subjects were analyzed as a group, KiG /Ki was significantly correlated with 
rate of MMSE decline in the frontal, but not temporal cortex (Figure 7.3). 
[3H]Pirenzepine KD and Bmax did not correlate with MMSE decline in either region. 
Lastly, Figure 7.4A shows that ChAT activities were altered in AD cognitive groups in a 
pattern similar to KiG /Ki (see Figure 7.2C), while Figure 7.4B demonstrates that  KiG /Ki 
values of all subjects correlated with ChAT activities in both brain regions.   
 
 
Figure 7.3  Correlations of KiG /Ki values with the rate of MMSE decline in AD  




















Figure7.3  Data are available for 18 patients in the frontal cortex and 22 patients in the temporal cortex. 
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Figure 7.4  ChAT activities in control and AD cognitive groups and correlations  


































Figure 7.4  (A) ChAT data were available for 8 controls, 5 ADmild/mod. and 11 ADsevere patients in the frontal 
cortex, and for 6 controls, 6 ADmild/mod. and 14 ADsevere patients in the temporal cortex. *Significantly 
different from control, p < 0.01 one-way ANOVA post-hoc tests. (B) Spearman correlations of ChAT 




Muscarinic M1 receptors, together with M3 and M5 subtypes, belong to the family 
of Gαq/11-coupled seven-transmembrane domained receptors which are known to activate 
PLC and PKC mediated signaling pathways (Caulfield 1993). Postsynaptic M1 receptors 
are found in high densities in the neocortex and hippocampus, where they mediate 
cholinergic neurotransmission in a range of CNS functions including learning and 
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memory (Anagnostaras et al. 2003; Hagan et al.  1987; Roldan et al. 1997). Furthermore, 
in-vitro study by Lu et al. (1999), has demonstrated that by activating signaling cascades 
involving PKC and Src kinases, muscarinic receptors can potentiate glutamatergic 
NMDA receptor function, whose regulation of long-lasting forms of synaptic plasticity is 
thought to be the major physiological substrate of memory consolidation (McBain and 
Mayer 1994).    
Although cholinergic dysfunction is a well-known neurochemical feature in AD, 
investigations of its role in the cognitive features of AD have focused on presynaptic 
components (e.g., loss of ChAT activities, Minger et al. 2000; Perry et al. 1981; Wilcock 
et al. 1982). While previous studies had reported losses of postsynaptic M1/G-protein 
coupling as well as impairment of associated downstream signal transduction (Ferrari-
DiLeo and Flynn 1993; Flynn et al. 1991; Jope et al. 1997; Masliah et al. 1991), it was 
unclear whether the findings were related to cognitive decline in AD. Using post-mortem 
material from a cohort of longitudinally assessed AD patients, I now show that the extent 
of reduction in M1/G-protein coupling is related to the severity of cognitive symptoms in 
AD. Specifically, I found that compared with controls, temporal cortical coupling was 
lower in AD patients with mild/moderate, as well as severe dementia, while frontal 
cortical coupling was significantly reduced only in the subgroup of AD patients with 
severe dementia. Furthermore, reductions of M1/G-protein coupling in the frontal cortex 
(but not the temporal cortex) correlated with rate of cognitive decline. The basis of the 
observed regional difference is unclear. However, previous studies have demonstrated 
that cholinergic deficits selectively affect temporal and associated cortices in early stages 
of the disease (Jobst et al. 1994; Wilcock et al. 1982). It is thus possible that loss of 
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M1/G-protein coupling in the temporal region occurs early in AD, and is extensive even 
in patients with mild to moderate symptoms. Therefore, the lack of correlation with 
cognitive symptoms in this region may simply reflect a dampened effect as the 
neurochemical deficits reached a stable, low level (a ‘floor effect’). This postulate is 
supported by my finding that ChAT activities, a marker for cholinergic innervation, was 
also reduced in both cognitive groups in the temporal cortex; while in the frontal cortex, 
ChAT reduction was significant only in the severely demented group. However, because 
the majority of subjects in this longitudinal study were severely demented at the time of 
death, further studies on patients with a wider range of dementia severity are needed to 
confirm this postulate. In this regard, it may be of particular interest to investigate the 
state of M1/G-protein coupling in subjects who have minimal cognitive impairment 
(MCI), since a significant proportion of such patients will eventually progress to AD 
(DeCarli et al. 2004; Morris et al. 2001).  
My findings suggest that impairment of M1 receptor-mediated signaling in the 
neocortex via uncoupling with its G-protein may be a novel neurochemical substrate of 
cognitive decline in AD. Compared to presynaptic cholinergic deficits, a signaling 
dysfunction in the postsynaptic M1 receptors may be temporally more closely related to 
processes leading to cognitive impairment, and has implications in rational therapeutic 
strategies. For example, compounds which primarily act at the synaptic (e.g., 
cholinesterase inhibitors) or receptor (e.g., M1 agonists) levels will be predicted in light 
of my findings to be of limited efficacy in ameliorating dementia in AD. Instead, 
therapeutic compounds acting at the level of M -activated signaling molecules such as 
PKC may show more benefit (Etcheberrigaray et al. 2004).
1
 However, the current results 
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have also raised important questions which need to be further studied. Firstly, the 
antecedent or causal events leading to M1/G-protein uncoupling in AD are at present 
unclear. One hypothesis is that presynaptic cholinergic deficits precede M1/G-protein 
uncoupling. Potter et al. (1999) reported that cholinergic deafferentation of the 
hippocampus by immunolesioning resulted in reductions of M1-mediated norepinephrine 
release as well as M1/G-protein coupling without affecting [3H]-pirenzepine binding 
parameters. Using ChAT activity as a marker of cholinergic innervation, I show that 
neurologically normal controls with relatively intact cholinergic systems also had higher 
M1/G-protein coupling compared with cholinergically denervated AD subjects       
(Figure 7.4B).  I further showed that alterations of ChAT in cognitive groups of AD 
mirrored those seen in M1/G-protein coupling. Therefore, my data suggest that like the 
cholinergic lesions, the uncoupling of M1 receptors to their G-proteins may be an early 
event in the AD process. However, the molecular mechanisms relating ChAT alterations 
to M1/G-protein coupling are unknown. Furthermore, since none of the patients in the 
current study were on cholinergic replacement therapies, it is not clear whether the use of 
cholinomimetics would also lead to restoration of M1/G-protein coupling, and further 
studies are needed. 
 Another question arising from the present observations is the elucidation of 
molecular mechanisms underlying the uncoupling of M1 receptors to G-proteins in AD. 
Studies showing preserved radioligand binding to M1 receptors contrasting with reduced 
M1 immunoreactivity (Flynn et al. 1995) suggest structural changes which do not 
interfere with ligand binding, but which may affect antibody recognition. Such structural 
changes may possibly include covalent modifications such as phosphorylation. Further 
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studies are needed to investigate whether aberrant phosphorylation or dephosphorylation 
of key residues on the M1 receptor may alter its association with G-proteins. Another 
potential mechanism for the loss of M1/G-protein coupling may be a reduction of Gαq/11 
proteins, although this has been refuted by studies which show that G-proteins, including 
the Gαq subtype, are generally preserved in the AD brain (García-Jiménez et al. 2003). A 
third possibility may be that G-protein function is altered in AD (for e.g., loss of GTPase 
activity), which may again involve covalent modifications (García-Jiménez et al.  2002). 
 In conclusion, the present study points to loss of M1/G-protein coupling in the 
neocortex as a neurochemical substrate of cognitive decline in AD, and provides one 
explanation for the limited efficacy of cholinergic replacement therapies in ameliorating 
cognitive symptoms. Since M1/G-protein uncoupling may occur early in AD, and 
represents an initial point of disruption in a signaling cascades which are involved in 
cognitive functions, therapies which aim to correct or circumvent deficits in M1 mediated 
signaling may show improved efficacy in ameliorating clinical symptoms. However, 
more work is needed to elucidate both the causes and the mechanisms of G-protein 
uncoupling to M1 receptors in the AD brain. 
 
7.5  FURTHER STUDY 
 The findings from this study have demonstrated that M1 uncoupling is correlated 
with cognitive decline in AD.  One hypothesis is that the impairment of muscarinic M1 
receptor to its G-protein may affect NMDA receptor function. Indeed, Marino et al. 
(1998) has shown that activation of M1 receptors potentiates NMDA receptor current and 
that M1 receptors colocalize with NR1 subunit of NMDA receptors on the dendrites and 
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soma of hippocampal pyramidal neurons.  Additionally, NMDA receptors are regulated 
by PKC (MacDonald et al. 2001) and Src kinase (Ali and Salter 2001).  Taken together, 
results from these in-vitro studies suggest that there may be a functional link between M1 
and NMDA receptor.  However, it is currently not clear whether M1/G-protein 
uncoupling is associated with PKC deficits in AD and, more importantly, whether 
NMDA receptor hypofunction is correlated with both PKC and M1/G-protein uncoupling.  
I will discuss my work on this question in the next chapter. 
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8.1  INTRODUCTION 
 
Several neurotransmitter systems involved in cognitive processes are now known 
to be affected in Alzheimer’s disease (AD), among which losses of cholinergic neurons in 
                                                          
*Data presented in this chapter has been published: Tsang SW, Pomakian J, Marshall GA, Vinters HV, 
Cummings JL et al.  Neurobiology of Aging (2007) In Press. 
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the basal forebrain are one of the earliest and most consistent findings (Davies and 
Maloney 1976; Whitehouse et al. 1982). Cholinergic neuronal loss was thought to 
underlie the clinical symptoms of AD and provided the rationale for cholinergic 
replacement or cholinomimetic pharmacotherapies (Bartus et al. 1982). To date, 
treatment with available acetylcholinesterase inhibitors (AChEIs) has yielded modest 
improvements in clinical rating scales, while clinical trials on agonists of G-protein 
coupled muscarinic receptors have not shown much promise (Greenlee et al. 2001; 
Mouradian et al. 1988). Limiting factors for these compounds include stage-dependent 
efficacy, unfavorable side effects (Greenlee et al. 2001) and the involvement of other 
acetylcholine receptors (AChRs, e.g., nicotinic, Paterson and Nordberg 2000) or 
transmitter systems (e.g., serotonergic, Buhot et al. 2000). Another possible reason is a 
disruption of AChR-mediated signaling. For instance, muscarinic M1 receptors are the 
major cholinergic receptor subtype expressed in postsynaptic sites in the neocortex and 
are critically involved in the cholinergic regulation of cognitive processes. M1 receptors 
are coupled to the Gαq/11-family of guanine nucleotide-binding (G-) proteins and activate 
phospholipase C (PLC) and protein kinase C (PKC) mediated signaling cascades, which 
also involve Src family kinases (Caulfield 1993;  Lu et al. 1999). Previous studies have 
shown that while M1 receptor densities are preserved in the AD neocortex, the coupling 
of these receptors to their G-proteins is impaired (Flynn et al. 1991; Flynn et al. 1995; 
Warpman et al. 1993), suggesting a postsynaptic cholinergic dysfunction which may limit 
the efficacy of cholinomimetic therapies in ameliorating the cognitive deficits of AD. 
Prominent neuronal loss occurs in areas other than the basal forebrain, especially 
affecting the glutamatergic pyramidal neurons of the neocortex and hippocampus 
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(Greenamyre et al. 1988). Glutamate is the primary excitatory neurotransmitter and is 
involved in most aspects of cognition and higher mental functions. In particular, the 
phenomenon of long term potentiation (LTP), a form of use-dependent synaptic plasticity 
mediated by the ionotropic N-methyl-D-aspartate (NMDA) subtype of glutamate 
receptors, is the leading cellular model of memory consolidation (Milner et al. 1998). 
NMDA receptors are Ca2+ channels with a voltage-dependent Mg2+ block, and are 
thought to be tetrameric complexes of NR1 and NR2A - 2D subunits in a 1:1 ratio (Ishii 
et al. 1993; Kutsuwada et al. 1992; Monyer et al. 1992). In AD, abnormalities in the 
expression and ligand binding properties of NMDA receptor subunits (Hynd et al. 2001; 
Hynd et al. 2004; Procter et al. 1989) may underlie the cognitive symptoms of AD. 
Interestingly, M1 receptors colocalize with NR1 on the dendrites and soma of 
hippocampal pyramidal neurons, and activation of M1 receptors potentiates NMDA 
receptor currents (Marino et al. 1998). Additionally, work done by Lan et al. (2001) has 
provided evidence that PKC activity may enhance the rate of membrane insertion of 
NMDARs.  Currently it is not known whether M1 uncoupling is associated with loss of 
PKC in AD and whether PKC loss accounts for reduction of NMDAR density in AD.  
NMDA receptors are regulated by PKC (Lan et al. 2001; MacDonald et al. 2001) as well 
as Src kinase (Ali and Salter 2001). However, there is much in-vitro evidence of 
muscarinic receptors regulating the NMDA receptor function (Francis et al. 1999), but 
the relevance in AD is not known. Here I report the first post-mortem evidence that M1 
uncoupling is actually associated with losses of both PKC activity as well as NMDA 
receptor density. Given the important roles played by PKC in a variety of neuronal 
function, and the importance of NMDA receptor in learning and memory, these results 
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provide a mechanism whereby M1 uncoupling may contribute to the clinical and 
neuropathological features of AD, and provide the therapeutic rationale for PKC ligands 
in AD treatment.   
 
8.2  MATERIALS AND METHODS 
8.2.1  Patient Characteristics 
The 22 subjects with AD and 12 controls were obtained from our collaborators 
from UCLA (Professors Harry Vinters and Jeffrey Cummings). Subject recruitment, 
demographical data have been described in detail in Chapter 5 (Section 5.1.2).  
Selection of subjects for the current study was based on tissue availability, and not on 
dementia severity or Braak stage, and controls were well matched to subjects with 
regards to age, sex, and post-mortem delay (see Table 5.1).   
8.2.2  Postmortem Tissue Processing 
Tissue processing and neurochemical assays were performed blind to clinical 
information.  Brain tissue homogenate preparation has been described in Chapter 5 
(Section 5.2.2).   
8.2.3  Saturation Radioligand Binding Assays 
All chemicals were of analytical grade and were purchased from Sigma Aldrich 
(St Louis, MI) unless otherwise stated. Measurement of muscarinic M1 and NMDA 
receptors was performed by saturation radioligand binding assays using [3H]pirenzepine 
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8.2.4  M1/G-protein Coupling 
Pharmacological determination of M1/G-protein interactions was carried out by 
[3H]PZ / carbachol competition binding as previously described in Chapter 5 (Section 
5.3.2).  
8.2.5  PKC and Src Kinase Activities 
PKC and Src kinase enzymatic assays were carried out using components of a 
commercially available PKC and Src kinase enzymatic assay kits (Upstate Biotechnology 
Inc., Lake Placid, NY).  Detailed protocols were described in Chapter 5 (Section 5.5).   
8.2.6  Immunoblotting 
Immunoblotting of the NR1 subunit of NMDA receptor with a rabbit polyclonal 
antibody (1:1000, Chemicon, Inc., expected molecular weight of around 114 kDa) 
followed by stripping and normalization with β-actin densities have been described in 
Chapter 5 (Section 5.6).   
8.2.7  Statistical analyses 
All statistical analyses were performed using the SPSS 11.0 for Windows 
software (SPSS Inc.). Data were first checked for normality for the selection of 
parametric or non-parametric tests. Demographic and neurochemical variables were 
compared between AD and controls by Student’s t-tests, and correlations among these 
variables were performed using Pearson’s product moment. Within the AD group, the 
effects of potentially confounding demographic or disease variables on neurochemical 
measures were investigated with Pearson’s product moment or Student’s t-tests as 
appropriate. Lastly, multiple regression using the ‘stepwise’ method was used to 
investigate possible relationships between the dependent variables (PKC activity, Src 
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activity and NMDA receptor density), other neurochemical variables and demographic 
factors. This allowed for the fact that M1/G-protein coupling (KiG /Ki) may be related to 
multiple variables and indicated the strongest correlate. For all analyses, the null 
hypothesis was rejected at p < 0.05. 
 
8.3  RESULTS 
8.3.1  Effects of Demographic and Disease Factors on Neurochemical Variables  
Demographic factors including age, sex, post-mortem interval and storage interval 
in AD and controls were well matched (Table 8.1). Furthermore, binding affinity (KD) 
and density (BBmax) of [ H]PZ (M3 1 receptors) and [ H]MK-801 (NMDA receptors), NR1 
immunoblot density  as well as M
3
1/G-protein coupling status (KiG /Ki) did not correlate 
with the demographic factors listed above (Pearson’s p > 0.05, data not shown). Within 
the AD cohort, the presence of additional neuropathological findings i.e., LB and stroke 
(n = 4, see above), and duration of dementia symptoms (9.5 ± 1.1 y, range 3 -17 y) did 
not affect the neurochemical variables (Student’s p and Pearson’s p > 0.05,  respectively, 
data not shown). However, Braak stage was negatively correlated with NR1 density 
(Pearson r = -0.55, p = 0.03), but positively correlated with Src activity (Pearson r = 0.47, 
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Table 8.1  Demographic and neurochemical variables in AD subjects and controls.  
 
 Control AD 
Demographics   
    Maximum Number of Cases1 12 22 
    Age at Death (y) 73.2 ± 4 78.8 ± 2 
    Sex (M/F) 6 / 6 12 / 10 
    Storage (y) 4.5 ± 0.5 5.4 ± 0.7 
    PMI (h) 14.4 ± 3 14.2 ± 2 
Muscarinic M1 Receptors   
    KiG /Ki 7.1 ± 0.9 (12) 4.8 ± 0.4 (22)* 
    [3H]Pirenzepine KD 5.3 ± 0.5 (11) 6.9 ± 0.5 (18) 
    [3H]Pirenzepine BBmax 601 ± 39 (11) 590 ± 39 (18) 
NMDA Receptors   
    [3H]MK-801 KD  9.9 ± 1.7 (11) 8.2 ± 0.9 (22) 
    [3H]MK-801 BBmax  300 ± 46 (11) 200 ± 23 (22)* 
Protein Kinase Activities   
    PKC  776 ± 107 (11) 354 ± 57 (22)** 
    Src  6.8 ± 1.4 (11) 7.0 ± 1.2 (21) 
 
Table 8.1  Data are mean ± S.E.M. PMI, post-mortem interval; KiG/Ki , measure of M1/G-protein coupling 
(see text); KD, binding affinity constant (in nM); BBmax, binding density (in fmol/mg protein). Specific PKC 
(protein kinase C) and Src kinase activities are in pmol phosphate/min/mg protein. 
1Not all neurochemical measures were available for all cases. The N values available for each 
neurochemical measure are listed in parentheses.  *Different from control p < 0.05.  **Different from 
control p < 0.01. 
 
 
8.3.2  Neurochemical Variables of Controls vs. AD 
Table 8.1 shows that while M1 receptor KD and BBmax are unchanged in AD, 
receptor coupling to G-proteins is impaired (reduced KiG /Ki). Furthermore, PKC activity, 
NMDA receptor BmaxB  as well as NR1 immunoblotting density are reduced in the AD 
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frontal cortex (Table 8.1 and Figure 8.1B). In contrast, Src activity and NMDA receptor 
KD are unchanged. 
 
Figure 8.1  NMDA receptor NR1 levels in AD subjects and controls.  
Figure 8.1  (A) representative immunoblot of NR1 (top lane) from brain membrane homogenates was 
stripped and reblotted with antibody against β-actin (bottom lane) for controls (Cnt) and AD. Molecular 
weight markers in kilodaltons (kDa) are as indicated. (B) bar graph of mean normalized NR1 immunoblot 
optical densities (in arbitrary units) for available control (n = 12) and AD subjects (n = 18).  *Significantly 
different from control, p < 0.05 (Student’s t-test). 
 
 
8.3.3  Correlation of M1/G-protein Coupling with NMDA Receptor Status and 
 Kinase  Activities 
 
Figure 8.2 shows that KiG /Ki values of all subjects correlated with PKC, but not 
Src kinase, activities in the frontal cortex, while Figure 8.3 shows that KiG /Ki correlated 
with both NMDA receptor indices ([3H]MK-801 BBmax and NR1 immunoblot density). 
Finally, stepwise multiple regression analyses showed that of the list of demographic / 
neurochemical variables (excluding the dependent variable) in Table 8.1 plus Braak 
staging, KiG /Ki  was the strongest predictor for both PKC activity (adjusted R  = 0.30, β = 
0.59, p = 0.008) and NR1 density
2
 (adjusted R  = 0.26, β = 0.55, p = 0.015). 2
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Figure 8.2  Association of M1/G-protein coupling with protein kinase activities. 
 
Figure 8.2  Correlation of KiG/Ki, a measure of M1/G-protein coupling (see text) with (A) specific protein 




Figure 8.3  Association of M1/G-protein Coupling with NMDA Receptor  




Figure 8.3  Correlation of KiG/Ki with (A) [3H]MK-801 BBmax (binding density, in fmol/mg protein), and (B)  
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8.4  DISCUSSION 
Presynaptic cholinergic deficits are now well established findings in AD. 
Alterations of choline acetyltransferase (ChAT), acetylcholine levels and other 
presynaptic cholinergic markers are likely concomitant with basal forebrain neuronal loss 
as well as APOE ε4 allele as we have shown in Chapter 6 (see also Lai et al. 2006).  In 
turn, these presynaptic deficits may contribute to both the cognitive and behavioral 
symptoms of AD (Cummings and Kaufer  1996; Lai, et al. 2001; Minger et al., 2000; 
Perry et al. 1981; Wilcock et al. 1982). In contrast, although postsynaptic perturbations 
such as reduced muscarinic M1/G-protein coupling and loss of nicotinic receptor densities 
have been reported (Flynn, et al. 1991; Warpman et al. 1993), little is known about the 
clinical relevance and neurochemical correlates of these changes. I have recently shown 
that attenuation of M1/G-protein coupling is associated with dementia severity in AD (see 
Chapter 7 in this thesis, Tsang et al. 2005). Using postmortem material from a separate, 
well characterized cohort of patients, it is found that the extent of loss of M1/G-protein 
coupling is correlated with reductions of PKC activity as well as NMDA receptor density 
in AD frontal cortex. These correlations are not confounded by a number of demographic 
and disease factors under study. Therefore, the data link postsynaptic cholinergic 
dysfunction with two other substrates (PKC and NMDA receptor) known to play 
essential roles in cognitive processes (Milner et al. 1998; Sun and Alkon 2005) and 
provide further insight into the mechanisms by which impairment of M1 mediated 
signaling may underlie the cognitive decline of AD. 
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The PKC family of isozymes are serine / threonine kinases which are critical 
signaling molecules in most cell types, serving to integrate a multitude of extracellular 
signals with downstream signaling events concerned with gene transcription, protein 
processing, synaptic plasticity, cell survival and other physiological processes (Newton 
1995; Olariu et al. 2005; Tanaka and Nishizuka 1994). In neurons, these extracellular 
signals may be mediated by neurotransmitters like acetylcholine which acts on Gαq/11-
coupled receptors such as M1 (Caulfield 1993). Interestingly, Etheberrigaray et al. (2004) 
showed that treatment with bryostatin 1, a PKC activator devoid of tumour promoting 
activity, improved maze performance in AD transgenic mice. In postmortem AD cortex, 
reductions of PKC level and activity have been reported (Cole et al. 1988; Wang et al. 
1994), and the current data now suggest that this reduction may not simply reflect 
neuronal loss, but may be related to M1 receptor dysfunction. However, the molecular 
mechanisms underlying down-regulation or deactivation of PKC in AD is still unclear. 
Inactive PKC is normally localized in the cytosol. Upon activation by diacylglycerol, 
Ca2+ and other signals released by the action of PLC (which is in turn activated by 
Gαq/11), PKC translocates to the plasma or nuclear membrane via anchoring by RACK 
(receptor for activated C-kinase) proteins (MacDonald et al. 2001).  Interestingly, 
RACK1 has also been found to be decreased in AD (Battaini et al. 1999). Therefore, 
more work is needed to clarify whether M1 dysfunction is directly related to PKC 
hypoactivity by decreased activation, or by its effect on RACK and consequent 
perturbation of PKC translocation.      
The loss of frontal NMDA receptors is another salient marker of 
neurodegeneration in AD and of potential significance to the clinical features of the 
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disease (Francis et al. 1993; Francis 2003). In this study, we measured NMDA receptors 
by [3H]MK-801 binding as well as immunoblotting of the NR1 subunit. Because 
[3H]MK-801 binding density (BBmax) was expressed per unit weight of protein, the 
observed reduction in BmaxB  would likely reflect specific loss of NMDA receptors, rather 
than generalized cortical atrophy. MK-801 (dizocilpine), a non-competitive NMDA 
receptor channel blocker with anticonvulsant properties, is known to bind within the 
channel pore region formed by the NR1/NR2A complex (Lynch et al. 1994; MacDonald 
et al. 2001). Therefore, specific [3H]MK-801 binding can be considered to indicate 
functional NMDA receptor labeling. Nevertheless, since NMDA channel opening (hence, 
[3H]MK-801 BBmax) is also influenced by the concentrations of glutamate as well as 
regulators like glycine and polyamines (Mitchell and Anderson 1998),  saturating 
concentrations of these compounds were added in the binding assays to maximize 
channel opening, and further measured levels of the obligatory NR1 subunits of NMDA 
receptor by immunoblotting. The two NMDA receptor indices were strongly correlated  
(r = 0.58, Pearson’s p = 0.001) and showed a similar degree of reduction in AD           
(see Table 8.1 and Figure 8.1B), which suggest that overlapping pools of NMDA 
receptors were measured. However, although MK-801 binds with highest affinity to 
NR1/NR2A (Laurie and Seeburg 1994), which is the predominant NMDA receptor 
subtype in adult neocortex (Stephenson 2001), it is unclear whether reduced [ H]MK-801 
binding represents the loss of specific NMDA receptor populations in AD. Importantly, 
attenuation of M
3
1/G-protein coupling significantly correlated with both NMDA receptor 
indices, suggesting that impairment of M1 mediated signaling is related to reduced levels 
of functional NMDA receptors. 
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What is the putative molecular mechanism linking M1 signaling dysfunction with 
NMDA receptor alterations? The colocalization of M1 with NR1 indicate a spatial 
relationship allowing physiological interactions between the two receptors (Marino et al. 
1998), and preclinical studies have shown that activation of Gαq/11-coupled receptors 
such as M1 potentiates NMDA receptor currents, possibly via PKC dependent pathways 
(Lu et al. 1999; MacDonald et al. 2001; Marino et al. 1998). PKC is known to directly 
phosporylate regulatory regions of NR1 subunits and control trafficking and surface 
delivery of functional NMDA receptors (Lan et al. 2001; MacDonald et al. 2001;        
Scott et al. 2003; Tingley et al. 1997). Therefore, it is possible that impaired PKC activity 
associated with M1/G-protein uncoupling underlie NMDA receptor deficits in AD, either 
by decreased delivery of subunits to the surface, or increased rate of endocytosis and 
degradative sorting. Alternatively, the NR1 gene promoter is induced by transcription 
factors such as Sp1 (Krainc et al. 1998; Liu et al. 2001; Okamoto et al. 2002) which is in 
turn regulated by a variety of signaling molecules including PKC (Chu and Ferro 2005). 
Therefore, the potential effects of M1 mediated signaling on NMDA receptor gene 
expression should also be further studied.  In contrast to PKC, activity of Src kinase, a 
non-receptor tyrosine kinase and another regulator of NMDA receptor function (Lu et al. 
1999), was not altered in AD and did not correlate with M1/G-protein coupling or NMDA 
receptor levels. One other study on postmortem kinase activities in AD also reported no 
change in Src (Vener et al. 1993).  Therefore, Src activity may be resistant to AD 
changes, or compensatory mechanisms may exist. However, it should be noted that both 
PKC and Src kinase families include several closely-related enzymes with similar 
activities, and the enzymatic assays employed in this study may not be sensitive enough 
   140
to detect changes of specific kinase subtypes. Furthermore, although an effect of M1/G-
protein uncoupling on PKC and NMDA receptor alterations is biologically plausible, 
(Chu and Ferro 2005; Lu et al. 1999; MacDonald et al. 2001; Marino et al. 1998) the 
present correlational study is unable to verify a causal relationship between these 
neurochemical variables; other disease factors may also play a role. Indeed, the negative 
correlation of NR1 density with Braak stage (see Results) indicate that parenchymal 
neurodegenerative changes are at least partially responsible for NMDA receptor deficits, 
although stepwise regression analyses indicated a stronger correlation with M1/G-protein 
uncoupling. 
In conclusion, there is ample evidence from preclinical studies for physiological 
interactions among M1 receptors, NMDA receptors and signaling molecules such as PKC 
and Src kinase in the regulation of cognitive processes, but the significance of these 
findings to AD is unclear. We now show that the extent of postsynaptic M1 receptor 
uncoupling from G-proteins correlated with loss of PKC activity and NMDA receptor 
density in the postmortem frontal cortex of AD, suggesting that impaired M1-mediated 
signaling may underlie cognitive deficits via effects on PKC and NMDA receptor 
function. This study provides a neurochemical basis for the limited success of AD 
therapies which increase synaptic acetylcholine availability or target M1 receptors; 
instead, the data point to targets downstream of M1/G-protein activation, and predict 
improved efficacy for compounds which regulate PKC (Etcheberrigaray et al. 2004) or 
NMDA receptors (Frankiewicz and Parsons 1999). However, more work is needed to 
provide molecular delineation of the specific kinase and receptor subtypes involved in 
disease processes of AD.  
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9.1  INTRODUCTION  
Besides progressive cognitive impairment, Alzheimer’s disease (AD) is also 
characterized clinically by the presence of neuropsychiatric behaviors such as depression, 
anxiety, and psychosis.  Of these behavioral changes, anxiety is relatively prevalent, 
occurring in up to 50% of AD patients over the course of the disease (Hope et al. 1999; 
Mega et al. 1996). Neuropsychiatric behaviors like anxiety are clinically significant in 
AD in that they often lead to considerable caregiver distress and precipitate 
                                                 
* Data presented in this chapter has been published:  Tsang SW, Lai MK, Francis PT, Wong PT et al.  
Serotonin transporters are preserved in the neocortex of anxious Alzheimer’s disease patients.  
NeuroReport (2003) 14(10): 1297-1300. 
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 institutionalization of the patient (Chen et al. 1996; Kaufer et al. 1998; Steele et al. 1990)  
However, the neurochemical basis of these behavioral changes is not well-studied. 
Because the serotonergic system is affected in AD, with findings of losses of serotonergic 
raphe neurons, serotonin (5-HT) levels, and cortical 5-HT transporters (5-HTT, Aletrino 
et al. 1992; Chen et al. 1996; Chen et al. 2000) which facilitate the uptake of serotonin, 
and because selective 5-HT re-uptake inhibitors (SSRIs) are effective in the treatment of 
anxiety disorders, I queried whether alterations of neocortical 5-HTT binding may 
underlie anxiety in AD.  Furthermore, Heils et al.(1996) have discovered a 44-base pair 
insertion/deletion variant within the GC-rich repetitive sequence in the 5’ promoter 
region of the 5-HTT gene (5-HTTLPR) (Figure 9.1). Functional studies have 
demonstrated that the basal transcriptional activity of the deleted or ‘short’ (S) variant is 
about 2.5 to 3 times lower than that of the inserted, or ‘long’ (L) variant, and furthermore, 
is associated with anxiety traits (Heils et al. 1996; Lesch et al. 1996). Therefore, I 
examined whether the 5-HTTLPR whose long (L) and short (S) variants are known to 
result in increased and decreased expression of the 5-HTT protein, respectively, may be 
associated with anxiety symptoms in AD. 
 
Figure 9.1  Map of the 5-HTT gene promoter.  The 5-HTTLPR comprises of a 
repetitive sequence with a 44-bp insertion / deletion as indicated by the black box   








 9.2  MATERIALS AND METHODS 
9.2.1  Subjects Recruitment and Behavioral Assessment 
The 34 AD subjects which comprised this study has been described in detail in 
Chapter 5 (Section 5.1.1).  Briefly, behavioral changes of the subjects were assessed 
every four months from recruitment to death (for a mean of 2.6 years) with the Present 
Behavioural Examination (PBE) (Hope and Fairburn 1992).  Anxiety was assessed by 
behaviors and physical signs indicating inappropriate anxiety or fear. Rating for anxiety 
was on a 7-point score (0-6) based on frequency of occurrence reported by the caregiver.  
A subject was considered to have had significant anxiety if there were at least two ratings 
> 3, or one rating > 3 and two other ratings 1-3 over the course of the study (Chen et al. 
1996). At death, informed consent was obtained from the families of patients and control 
participants for the removal of brain.  Selection of AD subjects was based only on tissue 
availability and neuropathological confirmation of diagnosis by the CERAD criteria 
(Mirra et al. 1991). The 14 controls were neurologically normal, had no significant 
neuropathology and no history of psychiatric disease.  
9.2.2  Saturation Binding 
At postmortem, blocks of gray matter from orbito-frontal (BA11) and mid-
temporal (BA21) gyri were dissected and processed as previously described in       
Chapter 5 (Section 5.2.2).  In addition, semi-quantitative scores for senile plaques (SP, 
score 0-3) and neurofibrillary tangles (NFT, score 0-4) were obtained from methanamine 
silver / modified Palmgren stained sections of BA11 and BA21. Saturation binding with 
[3H]citalopram (Amersham Life Sciences, UK) has previously been described in 
Chapter 5 (Section 5.2.2).  Non-specific binding was determined in the presence of 
10μM unlabelled fluvoxamine maleate (Tocris Cookson Ltd, UK).  
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 9.2.3  5HTTLTR Genotyping 
For 5-HTTLPR genotyping, DNA was extracted from 20 mg aliquots of cortical 
tissue using commercially available kits, and analyzed by polymerase chain reaction 
(PCR) according to previously reported methods (Heils et al. 1996) to generate the L 
(528-bp) and S (484-bp) fragments. 
9.2.4  Statistical Analyses 
Statistical analyses were performed with SPSS 10.0 for Windows. Relationships 
between [3H]citalopram binding variables and potential confounders (demographic or 
disease factors) were studied with stepwise multiple regression. Binding parameters (KD 
and Bmax) of controls and AD behavioral groups were then compared by repeated 
measures analysis of variance (ANOVA, with brain area as the repeated measure), 
followed by post-hoc tests. Comparisons of binding parameters over 5-HTTLPR 
genotypes in the AD subjects were similarly studied. Analysis of genotype in controls 
was not attempted because of the small sample size, with only one individual having the 
LL genotype. Differences in binding parameters were considered significant if the p 
values for both the repeated measures ANOVA (effects of between-subject factor or 
interaction) and the post-hoc tests were < 0.05. Genotype frequencies in the behavioral 








 9.3 RESULTS 
9.3.1  Demographics 
The AD subjects and controls were well matched with regards to age, sex, 
postmortem delay and tissue storage interval, with the exception of lower brain pH in the 
AD behavioral groups (probably due to prolonged agonal state, Hardy et al. 1985)  
(Table 9.1).  
 
Table 9.1  Comparison of demographic and clinical features between controls and   
            AD behavioral groups. 
 
 Controls (n = 14) 
AD - anxiety 
(n = 22) 
AD + anxiety 
(n = 12) 
Age, y 75 (4) 81 (1) 81 (1) 
Sex, % male 50 50 58 
Postmortem interval, h  47 (7) 38 (6) 49 (8) 
Storage interval, mo 90 (3) 91 (3) 91 (3) 
pH 6.7 (0.08)a 6.3 (0.08) 6.2 (0.11) 
Disease duration, y - 9.6 (0.9) 8.9 (1.5) 
MMSEb - 4.2 (1) 7.8 (3) 
SP 
BA11























Table 9.1  Data are mean (S.E.M.). MMSE, Mini-Mental State Examination [24]; SP, senile plaque scores; 
NFT, neurofibrillary tangle scores. 
aSignificantly different (one-way ANOVA p = 0.003) from AD – anxiety (Scheffé multiple means 
comparison  p = 0.014) and AD + anxiety (Scheffé  p = 0.008). 
bMean of last five MMSE scores before death used as a measure of dementia severity to avoid floor   
effects [3].   
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 However, pH did not correlate with any of the binding parameters (stepwise multiple 
regression, p > 0.05) and thus was not entered as a covariate in subsequent analyses. 
Among the AD subjects, the binding parameters were not correlated with disease factors 
(disease duration, dementia severity, senile plaque and neurofibrillary tangle counts, 
stepwise multiple regression, p > 0.05), and there were no significant differences between 
the AD behavioral groups with regards to the disease factors (Student’s or Mann-Whitney 
p > 0.05, Table 9.1). Because chronic psychotropic medication may affect central 
serotonergic activity, I also compared the binding parameters between subjects who were 
taking sedative-hypnotics (n = 8), neuroleptics (n = 10) or tricyclic antidepressants (n = 
3) and those not on medication in the eight months before death. I found that of the 
medications, only sedative-hypnotic use was associated with increased [3H]citalopram 
BBmax in BA11 (adjusted R  = 0.09, β =  0.34, p = 0.044). Therefore, sedative-hypnotic use 
was entered as a covariate in subsequent analyses of AD subjects. 
2
9.3.2  Saturation Binding Assays 
There were no differences in affinity (KD) of [3H]citalopram binding among 
controls, non-anxious AD and anxious AD (respective mean values in nM [S.E.M.]: 2.72 
[0.4], 3.67 [0.5], 4.04 [0.7] in BA11; and 3.38 [0.4], 3.51 [0.5], 4.91 [1.0] in BA21). In 
contrast, [3H]citalopram binding density (Bmax) was reduced in non-anxious AD patients 
compared to controls, while the Bmax of anxious AD patients was preserved at around 
control values. However, this pattern of alteration reached post-hoc statistical 
significance only in BA21 (Figure 9.3A). When binding parameters in the AD patients 





Figure 9.2A  [3H]Citalopram binding to 5HTT in controls and anxiety subgroups  






















Figure 9.2B  The effect of 5HTTLPR genotype on [3H]Citalopram binding   













Figure 9.2  (Previous page)  (A) Data are mean ± S.E.M. for [3H]Citalopram binding to frontal cortex 
(BA11) and temporal cortex (BA21) in the controls and the AD behavioral groups with repeated measures 
ANOVA (2,43 df) for the effects of Group, F =  4.02, p = 0.025 and Interaction between Group and Brain 
area, F =  2.58, p = 0.088. Radioligand assays were not performed on two subjects due to shortage of tissue. 
*Significantly different (one-way ANOVA, p = 0.006) from Control (Scheffé  p = 0.033) and AD + anxiety 
(Scheffé p = 0.018) values in BA21.  (B) Data are mean ± S.E.M. for [3H]Citalopram binding to frontal 
cortex (BA11) and temporal cortex (BA21) across genotype in AD subjects with repeated measures 
ANOVA (2,28 df; with sedative-hypnotic use as covariate) for the effect of Genotype,  F =  13.4, p = 0.001 
and interaction between Genotype and Brain area, F =  2.04, p = 0.16. *Significantly different from SS/SL 
(Student’s t test, p < 0.01). 
 
 
in the “LL”, compared with “SS or SL”, genotypes (with sedative-hypnotic use as 
covariate, Figure 9.3B). KD was not significantly different between the genotypes (data 
not shown).  
9.3.3  5-HTTLPR Genotype Distribution in AD Group 
 Finally, I compared 5-HTTLPR genotype distribution between the AD behavioral 
groups, and found higher proportions of anxious patients with the “LL” genotype versus 
the “SS or SL” genotypes (Table 9.2), with an odds ratio of 6.25 (mid-p corrected 95% 
CI 1.14-37.04).  
         
Table 9.2  Anxiety by 5-HTTLPR genotype in AD.  Indicated are number of patients.    




SS/SL 6 19 





 9.4  DISCUSSION 
At present, at least 14 pre- and postsynaptic 5-HT receptor subtypes are known to 
function as effectors of 5-HT signaling (Barnes and Sharp 1999). In contrast, 5-HT re-
uptake from the synaptic junction is mediated by a single protein, the 5-HTT, which is 
critical in the regulation of the magnitude and duration of serotonergic activity (Lesch et 
al. 1996). Support for the involvement of 5-HTT in mood and emotional states comes in 
part from the efficacy of selective 5-HT reuptake inhibitors (SSRIs) in the treatment of 
depressive and anxiety disorders. This suggests that serotonergic deficits may form the 
neurochemical basis of some affective disorders, the symptoms of which can be 
ameliorated by blocking the reuptake of 5-HT and hence restoring serotonergic activity 
(Stahl 1998). In addition, a functional biallelic polymorphism of the gene promoter 
region of 5-HTT (5-HTTLPR) whose long (L) and short (S) variants determine increased 
or decreased 5-HTT expression, respectively, has been shown to be associated with 
anxiety-related personality traits (Greenberg et al. 2000; Lesch et al. 1996). These 
findings led me to examine whether the presence of anxiety in AD is related to 5-HTT 
levels in the postmortem neocortex; and if so, whether the 5-HTTLPR genotype may be a 
risk factor for the development of anxiety in AD via its influence on 5-HTT levels. 
In agreement with previous reports of presynaptic serotonergic deficits                  
(Aletrino et al. 1992; Chen et al. 1996; Chen et al. 2000), I found reduced densities of 5-
HTT in BA21 of non-anxious AD patients and a trend towards reduction in BA11, which 
may be due in part to the relatively severe neurodegeneration in temporal cortex (Jobst et 
al. 1994; Wilcock and Esiri 1982;). However, the novel finding in this study is the 
relative preservation of 5-HTT sites in anxious AD subjects, who were also more likely 
to have the high activity LL genotype of 5-HTTLPR. I then showed that 5-HTT binding 
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 is significantly higher in patients with the LL versus the SS/SL genotype. The SS and SL 
genotypes were analyzed as a group because of the phenomenon of “S dominance” 
(Lesch et al. 1996), whereby the heterozygous (SL) genotype displays 5-HTT activities 
which are similar to the homozygous (SS) genotype instead of intermediate values 
between SS and LL. Taken together, the data suggest that preservation of neocortical 5-
HTT sites in anxious AD patients may be mediated in part by 5-HTTLPR driven, 
enhanced expression of 5-HTT on remaining serotonergic neurons. We further postulate 
that this preservation of 5-HT re-uptake activity concomitant to presynaptic serotonergic 
deficits (Aletrino et al. 1992; Chen et al. 1996; Chen et al. 2000;) may exacerbate the 
depletion of 5-HT in the synaptic junction and predispose the patient to developing 
anxiety symptoms.   
This is, as far as I know, the first study which relates 5-HTTLPR with anxiety in 
AD, and the genetic data should be considered preliminary due to the relatively small 
sample size, perhaps inevitable in postmortem studies. Therefore, population 
stratification effects cannot be dismissed and may account for the atypically high odds 
ratio and a wide 95% CI. Furthermore, the present findings, although analogous to a 
recent study correlating the LL genotype with aggression in AD (Sukonick et al. 2001), is 
nevertheless at odds with data from the general population where the S allele has small 
but statistically significant contributions to anxiety-related personality traits (Greenberg 
et al 2000; Lesch et al. 1996). One possible reason for the discrepancy may be the 
presence of extensive cortical neurodegeneration and serotonergic deficits in AD which 
may lead to altered neurophysiological, neurochemical and behavioral manifestation of 5-
HTTLPR compared to non-AD brains. For example, a loss of serotonergic neurons in the 
raphe nuclei is an established neuropathological feature of AD (Chen et al. 2000), and it 
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 is possible that the presence of the L genotype would exacerbate this serotonergic deficit, 
leading to the occurrence of behavioral symptoms. Furthermore, a later study (Assal and 
Cummings 2004) did not find an association between 5-HTTLPR and neuropsychiatric 
symptoms in AD. One reason could be the different behavioral instrument used 
(Neuropsychiatric Inventory, NPI, Cummings et al. 1994) which uses different criteria 
and definitions for the behaviors. For example, the NPI does not have “anxiety” as a 
behavior but rather uses “agitation”, which may lead to differences in the measurement of 
observable behavior. Secondly, unlike my study, Assal et al. (2004) did not use 
longitudinal measurement of behavior, which may lead to lower sensitivity of measuring 
intermittent manifestation of psychiatric symptoms. 
 
9.5  CONCLUSION 
This study demonstrates that [3H]citalopram binding to 5-HTT is lost in the 
postmortem neocortex of non-anxious AD subjects, but preserved in subjects who 
manifested significant premortem anxiety. The preservation of neocortical 5-HTT sites, 
which may reflect synaptic plasticity mediated in part by genetic factors, is a putative 
neurochemical substrate of anxiety in AD by exacerbating the deficits in serotonergic 
neurotransmission. This study therefore provides the rationale for using SSRIs or 
serotonergic agonists as an alternative to benzodiazepines for the treatment of anxiety 
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10.1  SUMMARY OF MAJOR FINDINGS 
 In this thesis, three of the most severely affected neurotransmitter systems in AD, 
namely, the cholinergic, glutamatergic and serotonergic systems were investigated.  
Briefly, the muscarinic M1 receptors, glutamatergic NMDA receptors, and serotonergic 
5-HT transporters (5-HTT) were measured in the postmortem frontal and temporal 
cortices of two cohorts of well-characterized AD patients as well as controls (Chapter 5).  
Neurochemical findings were then correlated with the rate of cognitive decline as well as 
behavioral changes to test the hypothesis that neurochemical alternations may underlie 
both cognitive decline and behavioral changes in AD (Chapter 7 and 9).  Moreover, the 
status of M1 receptor coupling to G-protein in AD was measured and correlated with 
cognitive  decline as well as  with  measurements of ChAT, PKC and Src kinase activities 
in order to investigate the possible interactions between M1 receptor mediated signaling 
and  NMDA   receptor status  (Chapter 8).  Besides,   the effects of two  functional  gene  
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Table 10.1  Summary of major findings. 
 Status in AD2 Behavioral Correlates3
Receptors1   
1. M1 M1 receptors densities in frontal and 
temporal cortex were not altered. 
 
Reduction of frontal cortical M1/G-
protein coupling only in severely 
demented AD patients. 
 
Loss of M1/G-protein coupling was 
correlated with reductions in PKC 






Reduction of M1 receptor coupling to G-





2. NMDA Reduction of NMDA receptors in the 
frontal cortex measured with 




3. 5-HTT  Receptor density was reduced in 
temporal cortex of non-anxious AD but 
preserved in AD patients with anxiety. 
 
Genetics   
1.  ApoE ε4 allele  ε4 allele was dose-dependently 
correlated with higher losses of 
ChAT activities, but not with various 
other cholinergic markers.4 
 
Double dosage of ε4 alleles was 
associated with more Aβ containing. 
senile plaques in the temporal cortex 
compared with 0/1 ε4 allele. 
 
 
2.  5HTTLPR Significantly higher prevalence of LL 
genotype of the 5-HTTLPR 
functional polymorphism found in 
anxious AD patients. 
 
LL genotype of the 5-HTTLPR 
functional polymorphism correlated with 
higher 5-HTT densities as well as with 
anxiety. 
Enzyme activities   
1.  PKC PKC activity in neocortex was 
markedly reduced and correlated 
with extent of M1/G-protein 




2.  Src kinase Src kinase activity in neocortex was 
not altered  
 
 
1The 5-HT transporter (re-uptake site) is termed a receptor for the purpose of this discussion. 
2Receptor binding status of AD versus controls. 
3Receptor binding status between behavioral groups of AD subjects. 
4Includes neurochemical measurements performed by collaborators, see Chapter 6 for details. 
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 polymorphisms, i.e., APOE ε4 allele and LL genotype of the promoter region of 5-HTT, 
on the cholinergic and serotonergic systems, respectively, were examined in Chapter 6 
and 9 (refer to Table 10.1 for a detailed summary of major findings arising from this 
thesis). In the sections below, I will list some of the limitations of the study approach, 
followed by measures taken to address the shortcomings or measures taken for quality 
control of the data. Lastly, I will discuss the insights into the neurochemistry of AD 
obtained, as well as suggestions for further studies.  
   
10.2  LIMITATIONS 
Postmortem artefacts. By using postmortem tissues to study the neurochemical 
changes in AD, we are limited to studying a single time point at a late stage of the disease 
process.  Therefore, most, if not all, of the data are applicable only to severe AD. 
Interpretations in postmortem findings are also confounded by differences across studies 
in subject selection, postmortem delay, agonal state of the patients, tissue preparation, 
and exposure to psychotropic medications. To address these issues, I have tried to obtain 
tissues from comparable controls which closely match the AD subjects in demographic 
details, and also studied the effects of medication and other potential confounders on 
neurochemical variables statistically using correlational or comparative tests; and, where 
significant effects exist, I have included the confounders as covariants in subsequent 
regression analyses. 
Cohort effects.  All work from this thesis were based on either 20 – 25 patients 
from Oxford (Chapter 6, 7, and 9) or 22 patients from UCLA (Chapter 8).  Data was 
not available on all subjects for every receptor due to tissue shortage.  However, using 
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similar cohorts of subjects to perform various radioligand receptor binding assays may 
lead to cohort effects which limit the generalizability of the results for the population. On 
the other hand, performing a range of neurochemical measurements on the same patients 
reduces variability from study to study. 
 
10.3  QUALITY CONTROL 
Anatomical consistency.  Due to the established involvement of neocortex in 
behavior/cognition, we sampled two discrete regions from frontal cortex (BA11) and 
temporal cortex (BA21) to maintain anatomical consistence in sampling of patients. 
Neuropathological consistency.  Patients with evidence of neurodegenerative 
lesions suggestive of mixed diseases (e.g., Lewy bodies) or extensive neurovascular 
disease were excluded from the studies.    
Sample selection and blinding.  All available samples were used at the time of 
study, and there was no selection of subjects based on dementia severity, Braak stage, or 
presence of neuropsychiatric behaviors. Neurochemical measurements were performed 
blind to clinical information in order to minimize any potential bias. 
 
10.4  INSIGHTS 
Neurochemical alternations in AD are not a simple consequence of 
neurodegeneration but are summative expressions of complex, interacting processes 
involving neurodegeneration and synaptic plasticity. As can be seen from the preceding 
chapters, neurochemical changes are not universal, with subsets of AD patients 
displaying particular patterns of neurochemical changes which may in turn predispose 
them to increased risk of faster or more severe cognitive decline, or the development of 
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specific neuropsychiatric behaviors. Genetic variability adds another layer of complexity 
to these processes by interacting with neurochemical changes and further modifying 
synaptic plasticity.  
One example that illustrates the above is the finding that the well established link 
between APOE ε4 and AD may be mediated by the allele’s specific effects on 
presynaptic cholinergic markers such as ChAT activities, which may in turn exacerbate 
AD progression or cognitive impairment (Chapter 6). Furthermore, we showed the L* 
form of 5HTTLPR may predispose AD patients to manifest anxiety symptoms by 
upregulating 5-HTT levels (Chapter 9). Therefore, our studies provide putative 
mechanisms whereby genetic factors may modify AD progression and clinical features.  
This thesis has also advanced a deeper understanding of the pathogenic 
mechanism of well established features in AD. For example, the loss of cholinergic 
neurons and associated deficits in presynaptic cholinergic transmission (e.g. reduction of 
both ChAT activities and M2 receptor densities in the neocortex) are known since the 
1970s and provided a basis for the “cholinergic hypothesis” of AD and subsequent 
development of cholinergic replacement therapies. In addition, findings of relatively 
preserved postsynaptic cholinergic markers (e.g., unchanged M1 binding) led to 
therapeutic approaches which aimed to activate postsynaptic cholinergic signaling (e.g., 
M1 agonists). However, as detailed in Chapter 7, these approaches have met with limited 
success, and Flynn et al. (1991) provided the first potential explanation by finding that 
M1 receptors, although not lost, were in fact uncoupled from their G-proteins. This 
suggested that deficits in postsynaptic M1-mediated signaling may underlie the limited 
efficacy of cholinergic replacement therapies. Here, I have further studied M1/G-protein 
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uncoupling in AD, and have, for the first time, provided a clinical relevance to this 
finding by showing that the extent of uncoupling correlated with dementia severity 
(Chapter 7). I have further shown that  M1/G-protein uncoupling correlated with loss of 
PKC activities as well as reductions of NMDA receptors. These findings provided a 
potential mechanism whereby M1/G-protein uncoupling in AD interrupts its downstream 
signaling molecules such as PKC which in turn regulates NMDA receptor function 
(Chapter 8). In this regard, it is of interest to note that preclinical studies using AD 
rodent models have provided complementary data to my postmortem findings. For 
example, Potter et al. (1999) has shown that cholinergic immunolesioning, which models 
the presyanptic cholinergic deficit seen in AD, led to M1 receptor uncoupling to G-
proteins and reduces M1 receptor function, confirming the close association between pre- 
and postsynaptic cholinergic neurotransmission. The data also suggest that alternate 
therapeutic targets which ameliorate or bypass M1/G-protein uncoupling may show 
improved efficacy for AD, the proof of concept of which has been provided by 




10.5  FURTHER STUDIES 
 Due to the limitations of postmortem studies, our findings should be validated by 
in vivo neuroimaging studies e.g., positron emission tomography (PET) studies 
employing [11C] or [18F] radioligands. Much progress has been made in the development 
of radioligands of sufficient specificity for individual receptor subtypes, which would 
render such approaches increasingly feasible in the near future. Moreover, cell-based in 
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vitro and animal studies will be useful for elucidating the molecular mechanisms linking 
muscarinic receptor signaling to NMDA receptor function and cognition. For example,  
M1/G-protein uncoupling may be investigated by treating cultured neurons or cells 
expressing both muscarinic and NMDA receptors with uncouplers (e.g., GppNHp), and 
then investigating the effects of muscarinc agonists on NMDA-induced Ca2+ 
conductance. Furthermore, experimental cholinergic denervation could be performed on 
rodents (e.g., by intraventricular administration of 192-IgG conjugated with saporin 
neurotoxin) with subsequent measurements of neurochemical markers and learning 
(using water-mazes).   
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Introduction
Alzheimer’s disease (AD), the most common cause of dementia
in the elderly, is characterized neuropathologically by extracellular
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Available online on ScienceDirect (www.sciencedirect.com).forms of microtubule associated protein H , and neuronal degener-
ation. Although degeneration in the source nuclei of several
neurotransmitter systems has been found in AD, one of the earliest
and most consistently affected is the basal forebrain cholinergic
neuron (Davies and Maloney, 1976; Whitehouse et al., 1982).
Accompanying the loss of cholinergic neurons are neurochemical
alterations including reduced choline acetyltransferase (ChAT) and
acetylcholinesterase (AChE) activities, reduced acetylcholine
release, as well as losses of muscarinic M2 and nicotinic receptors
in the neocortex and hippocampus (Francis et al., 1985; Mash et
al., 1985; Perry et al., 1977; Perry et al., 1987; Sims et al., 1983;
Wilcock et al., 1982). Postsynaptic M1 receptors appeared to be
preserved in AD (Mash et al., 1985) but was subsequently shown
to be defective in coupling to G-proteins (Flynn et al., 1991;
Ladner et al., 1995). Other studies also reported deficits in
postsynaptic signaling such as decreases in phosphoinositide
hydrolysis and protein kinase C (PKC) activities (Cole et al.,
1988; Ferrari-DiLeo and Flynn, 1993; Jope et al., 1997) which are
activated by M1 and M3 receptors (Caulfield, 1993). Taken
together, these studies suggest a state of profound presynaptic as
well as postsynaptic cholinergic dysfunction in AD that may
underlie both the cognitive and behavioral symptoms of AD
(Cummings and Kaufer, 1996; Lai et al., 2001; Minger et al., 2000;
Perry et al., 1978; Tsang et al., in press; Wilcock et al., 1982).
Various gene mutations have been linked to familial forms of
AD, such as those encoding amyloid precursor protein (APP),
presenilin 1 and presenilin 2, which result in altered APP processing
and increased production of plaque-forming Ah species (Selkoe,
2001). For sporadic AD which constitutes the majority of cases, the
major genetic risk factor is APOE which encodes apolipoprotein E
(apoE), a 34 kDa lipid carrier protein. Of the three APOE alleles ((2,
M.K.P. Lai et al. / Neurobiology of Disease 22 (2006) 555–561556(3, and (4 encoding apoE2, apoE3, and apoE4 isoforms, respec-
tively), the (4 is dose-dependently associated with increased risk of
developing AD compared with (3 and (2 (Corder et al., 1993;
Poirier et al., 1993; Saunders et al., 1993). Much research effort has
been expanded into elucidating the pathogenic mechanisms of E4 in
AD. In addition to its role as a key regulator of plasma lipid levels,
apoE may be involved in neuronal repair and plasticity in the CNS,
with the E4 being less effective than the E3 isoform (Mahley and
Huang, 1999; White et al., 2001). E4 has also been shown to
facilitate Ah deposition and H hyperphosphorylation more potently
than E2 and E3 in vitro (Holtzman et al., 2000; Tesseur et al., 2000).
Additionally, AD patients with one or two (4 showed higher plaque
and, to a lesser extent, higher tangle burden than non-(4 carriers
(Nagy et al., 1995; Olichney et al., 1996; Schmechel et al., 1993).
Finally, apoE may affect cholinergic neurons and signaling in an
isoform-specific manner. For example, some studies demonstrated
that (4 positive AD patients had more extensive deficits in ChAT
activities compared with non-(4 carriers (Poirier et al., 1995;
Soininen et al., 1995; Beffert and Poirier, 1996) while others did not
(Corey-Bloom et al., 2000; Svensson et al., 1997; Tiraboschi et al.,
2004). The effect of APOE genotype on other cholinergic markers is
less clear. M1, M2, and nicotinic receptors do not seem to differ
between patients with or without (4 (Reid et al., 2001; Poirier et al.,
1995; Svensson et al., 1997). However, the radioligands used to
label nicotinic sites in these studies are not subunit-specific, and it is
not known whether APOE genotype is correlated with specific
losses of nicotinic receptor subpopulations, such as those containing
a4h2 subunits (Warpman and Nordberg, 1995). Furthermore,
although studies have shown selective impairment of muscarinic
receptor-mediated phosphoinositide hydrolysis by the apoE4 iso-
form (Cedazo-Minguez and Cowburn, 2001), it is not known
whether apoE4 affected the coupling of G-proteins to M1 receptors
in AD. In this study, we correlated APOE genotype in a cohort of
AD patients with a range of pre- and postsynaptic cholinergic
neurochemical markers in the postmortem frontal and temporal
cortex in order to test the hypothesis that deficits or alterations in
cholinergic neurotransmission in the AD neocortex are influenced
by APOE (4 genotype.Materials and methods
Patients and neuropathological assessments
A maximum of 40 AD subjects and 20 elderly controls were
included in this study. The AD subjects were derived from an
autopsied subset of a cohort of community-based dementia patients
from Oxfordshire, UK enrolled in a longitudinal study of behavior
in dementia (Hope et al., 1999). The inclusion/exclusion criteria as
well as point-of-entry characteristics have been previously de-
scribed in detail (Hope et al., 1997, 1999). Complete drug histories
were recorded, and none of the subjects was on cholinomimetic
medication. At autopsy, brains were harvested after informed
consent had been obtained from the patients’ relatives. One
hemisphere was processed for neuropathological assessments,
while the other was frozen for subsequent neurochemical assays.
All subjects fulfilled CERAD criteria for the neuropathological
diagnosis of AD (Mirra et al., 1991), and were neuropathologically
staged at Braak V/VI (Braak and Braak, 1991). Two patients (both
of (3/(3 genotype) also had evidence of vascular dementia.
Paraffin-embedded blocks of frontal as well as temporal cortexwere then stained with methenamine silver and a modified
Palmgren stain for a blinded, semi-quantitative scoring of SP
(0–3 points) and NFT (0–4 points), as previously described (Lai et
al., 2001). Controls did not have dementia or other neurological
diseases, did not meet CERAD criteria for AD diagnosis, and were
staged at Braak 0-II. The selection of AD subjects as well as
controls for the current study was based on postmortem-tissue
availability; and not on APOE genotype. Data were not available
for all neurochemical measures in all participants, and some
neurochemical data for a subset of subjects have been previously
reported (Garcia-Alloza et al., 2005; Lai et al., 2001; Minger et al.,
2000; Tsang et al., in press).
Tissue processing
Tissue processing and neurochemical assays were performed
blind to clinical information. All chemicals and reagents were from
Sigma-Aldrich Ltd. (St Louis, MO) unless otherwise stated. Frozen
brains were thawed on ice and blocks of gray matter (0.5–1.0 g)
from the frontal (Brodmann Area, BA 9–11) and temporal (BA 20,
21) cortices were dissected free of meninges before homogeniza-
tion in either of the following buffers for subsequent neurochem-
ical assays: 10 mM/75 mM phosphate buffer (pH 7.4, ChAT/AChE
assays) or 50 mM Tris–HCl buffer (pH 7.4, receptor binding
assays). Each neurochemical measure was measured only in one
frontal (BA 9, 10, or 11) and/or one temporal (BA 20 or 21) area.
Brain pH as an indication of agonal status was determined as
previously described (Hardy et al., 1985).
APOE genotyping
APOE genotyping was determined with DNA extracted from
brain tissues according to previously described methods (Nicoll et
al., 1997).
Choline acetyltransferase (ChAT) and acetylcholinesterase (AChE)
determinations
Radiochemical determination of ChAT activity was based on
minor modifications of the method by Fonnum (1975) as
previously reported (Minger et al., 2000). AChE assay using a
colorimetric method (Wang et al., 1999) was modified as
previously reported (Garcia-Alloza et al., 2005).
Receptor binding assays
Saturation binding assays with [3H]pirenzepine (PZ) for M1
sites, [3H]AF-DX 384 for M2 sites, and [3H]epibatidine for a4h2
subunit-containing nicotinic receptors have been previously
described (Gnadisch et al., 1999; Lai et al., 2001). Briefly, seven
or eight concentrations (0.5–15 nM) of [3H]PZ (sp. act. 70–80
Ci/mmol) or [3H]AF-DX 384 (sp. act. 120–133 Ci/mmol, both
from Perkin Elmer Life Sciences, Boston, MA) were added to
100 Al aliquots of washed brain membrane homogenates in
triplicates and incubated in a total volume of 0.5 ml sodium
phosphate buffer (pH 7.4) for 60 min at 25-C. Nonspecific
binding was measured by the addition of 1 AM atropine sulfate.
Incubation was terminated by vacuum filtration and washing onto
polyethylenimine-pretreated Whatman GF/B filters (Whatman
plc, UK) with a Skatron cell harvester (Molecular Devices Ltd.
USA) before transferring into vials for measurement of bound
Table 1
Demographic, disease, and cholinergic neurochemical variables in control
and AD
AD Control
Maximum number of casesa 40 20
Age at death (year) 81.7 T 1 77.3 T 2
Sex (M/F) 20/20 13/7
Postmortem interval (h) 37.7 T 4 47.7 T 7
pH 6.35 T 0.07* 6.62 T 0.09
ChAT (pmol/mg prot/h)
Frontal 3.5 T 0.3 (36)** 6.3 T 0.7 (16)
Temporal 1.9 T 0.3 (34)*** 6.4 T 0.3 (19)
AChE (% control)
Frontal 72 T 3 (17)*** 103 T 5 (9)
Temporal 70 T 3 (17)*** 105 T 3 (9)
[3H]PZ KD (nM)
Frontal 4.4 T 0.2 (27)* 3.6 T 0.2 (12)
Temporal 4.5 T 0.2 (27) 4.1 T 0.4 (12)
[3H]PZ Bmax (fmol/mg prot)
Frontal 575 T 13 (27) 601 T 30 (12)
Temporal 614 T 22 (27) 594 T 31 (12)
[3H]AF-DX 384 KD (nM)
Frontal 3.7 T 0.2 (27) 4.2 T 0.6 (12)
Temporal 4.3 T 0.2 (27) 4.2 T 0.3 (12)
[3H]AF-DX 384 Bmax (fmol/mg prot)
Frontal 483 T 21 (27)** 583 T 30 (12)
Temporal 558 T 26 (27) 566 T 42 (12)
[3H]Epibatidine KD (pM)
Frontal 45 T 6 (31) 57 T 8 (12)
Temporal 91 T 22 (30) 60 T 24 (14)
[3H]Epibatidine Bmax (fmol/mg prot)
Frontal 50 T 3 (31)* 65 T 9 (12)
Temporal 60 T 5 (30) 80 T 11 (14)
K iG/Ki
Frontal 2.4 T 0.3 (21)* 3.6 T 0.2 (8)
Temporal 2.1 T 0.2 (25)** 6.1 T 0.9 (6)
SP
Frontal 1.97 T 0.1 (35)*** 0.08 T 0.08 (12)
Temporal 2.31 T 0.1 (35)*** 0.15 T 0.1 (13)
NFT
Frontal 1.74 T 0.2 (35)*** 0.08 T 0.08 (13)
Temporal 2.26 T 0.2 (35)*** 0.14 T 0.1 (14)
Data are mean T SEM. ChAT, choline acetyltransferase; AChE, acetylcho-
linesterase; KD, binding affinity constant; Bmax, binding density; KiG/Ki,
measure of M1/G-protein coupling (see text); SP, senile plaque score; NFT,
neurofibrillary tangle score.
a Not all neurochemical measures were available for all cases. The n
values available for each neurochemical measure are listed in parentheses.
* Different from control P < 0.05.
** Different from control P < 0.01.
*** Different from control P < 0.001.
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beta counter. Assays for [3H]epibatidine (0.0125–2.5 nM, sp. act.
56 Ci/mmol, Perkin Elmer Life Sciences, Boston, MA) binding (4
h at 22-C) in 50 mM Tris–HCl buffer, 20 mM NaCl, 5 mM KCl,
2.5 mM CaCl2, and 1 mM MgCl2 (pH 7.4) were as above, with
250 nM cytosine used to define nonspecific binding. The
neurochemical parameters KD (binding affinity, in nM) and Bmax
(binding density, in fmol/mg protein) were derived from binding
data by Scatchard analyses followed by iterative curve-fitting
(McPherson, 1985). Binding data consistently fitted with one-site
binding with Hill constants around 1.0.
G-protein coupling to M1 receptors
Pharmacological determination of M1 receptor coupling to G-
proteins using a [3H]PZ/carbachol competition assay was based on
previously reported methods (Tsang et al., in press). Briefly,
aliquots of brain membrane homogenates were incubated in
duplicate with 3 nM of [3H]PZ and 12–15 concentrations of
unlabelled carbachol (109 to 102 M) in Tris–HCl buffer (pH
7.4) for 150 min at room temperature. Specific binding was defined
in the presence of 10 AM atropine sulfate. Parallel series of
competition assays were performed with or without the addition of
0.2 mM guanylyl imidodiphosphate (GppNHp) which uncouples
G-proteins from M1 receptors and reduces the affinity of M1
receptors for carbachol. Specific binding data from liquid
scintillation spectrometry were plotted against log-transformed
values of carbachol concentrations with a nonlinear regression
curve-fitting software (Prism 3.0, GraphPad Inc. USA) to derive
inhibitory constants for carbachol binding in the absence (K i) and
presence (K iG) of GppNHp using Cheng and Prusoff’s (1973)
equation. The ratio of KiG to Ki was then used as a measure of the
state of M1/G-protein coupling in control and diseased brains, with
lower K iG/Ki indicating less coupling.
Statistical analyses
Data were tested for normality for the selection of parametric or
nonparametric tests. Demographic, disease, and neurochemical
variables between controls and AD were compared with Student’s
t tests. The effect of potential confounders on neurochemical
variables, as well as the inter-correlations among variables, was
studied by Pearson’s product moment or Spearman’s correlation.
The distribution of genotype frequencies between AD and controls
was analyzed by Chi-square tests, while demographic and disease
variables among theAPOE genotypes in ADwere compared by one-
way analysis of variance (ANOVA) followed by Dunnett’s post hoc
tests, as the number of subjects in the groups was not matched and
equal variances could not be assumed. All statistical analyses were
performed with the SPSS 10.0 for Windows software (SPSS Inc.
USA), except for Chi-square tests, which were carried out with
StatXact 3 for Windows (Cytel Software Corp. MA).Results
Demographic, disease, and neurochemical variables in
control vs. AD
Table 1 shows that demographic variables were matched
between the AD subjects and controls (Student’s P > 0.05) exceptfor lower pH in AD, possibly an indication of more severe
acidosis due to prolonged agonal state (Hardy et al., 1985).
However, pH, as well as other demographic variables listed in
Table 1, did not correlate with neurochemical variables (Pearson
P > 0.05). As shown in Table 1, ChAT and AChE activities as
well as M2 and a4h2 nicotinic receptor densities are reduced in
one or both regions in AD, while M1 densities remained
unchanged. Except for higher KD in [
3H]pirenzepine binding in
the AD frontal cortex (Lai et al., 2001), there were no differences
in receptor binding affinities (Table 1). There was minimal
neuropathology in controls, contrasting with significantly higher
SP and NFT scores in AD (Table 1). The distribution of APOE
Table 2
Distribution of APOE genotypes in control and AD
Genotype AD n = 40* Control n = 20
(2/(3 or (3/(3 15 (38%) 16 (80%)
(2/(4 or (3/(4 21 (52%) 4 (20%)
(4/(4 4 (10%) 0 (0%)
* Significantly different from control, Pearson’s chi-square (v2 = 10.04)
with Fisher’s exact test, P < 0.01.
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(Table 2); in fact, none of the controls in this cohort had the (4/(4
genotype. There was also no (2/(2 genotype in either AD or
controls.
Association of APOE genotype with demographic, disease, and
neurochemical variables in AD
Demographic factors as well as postmortem conditions were
not significantly different among AD patients with zero ((3/(3 or
(3/(2), one ((3/(4 or (2/(4), or two (4 alleles (Table 3), although
there is a trend towards lower estimated age of AD onset with
increasing (4 dose. In contrast, both dementia severity (estimated
by the Mini-Mental State Examination score [Folstein et al.,
1975] before death) as well as temporal cortical senile plaque
(SP) loads were higher in patients with two (4 alleles compared
to those with zero or one (4, with similar trends for SP in the
frontal cortex, as well as NFT scores in both regions (Table 3).
Fig. 1 illustrates the neocortical cholinergic variables across
APOE genotypes in AD. In control subjects, because the
neurochemical variables between patients with the (4 allele and
those without were not significantly different (Student’s t tests,
P > 0.05, data not shown), the mean control values were used as
a baseline for comparisons with AD APOE genotype groups in
order to study the effects of (4 on the neurochemical alterations
in AD. Fig. 1 shows that of the neurochemical variables studied,
only losses of ChAT activities showed a dose-dependent
association with (4 in both cortices; while AChE activities as
well as temporal cortical KiG/Ki values are reduced in AD but are
not related to (4 dose.
Table 3
Association of APOE (4 allele with demographic and disease variables in
AD
0 (4 1 (4 2 (4
Age at death (year) 83.7 T 2 80.6 T 1 80.5 T 0.6
Age at onset (year) 75.2 T 2 71.7 T 1.5 69.2 T 3.2
Disease duration (year) 8.5 T 0.8 8.9 T 1 11.3 T 3
Sex (M/F) 7/9 12/9 2/2
Postmortem interval (h) 34.0 T 3 39.1 T 7 44.7 T 16
pH 6.38 T 0.1 6.33 T 0.1 6.34 T 0.2
Predeath MMSE 4.5 T 2 5.3 T 2 0.0 T 0*
SP
Frontal 2.23 T 0.2 1.68 T 0.2 2.67 T 0.3
Temporal 2.31 T 0.2 2.21 T 0.2 3.00 T 0.0*
NFT
Frontal 1.92 T 0.3 1.53 T 0.3 2.33 T 0.3
Temporal 2.23 T 0.3 2.21 T 0.2 2.67 T 0.3
Data are mean T SEM for AD patients with no APOE (4 allele (n = 13–15),
1 (4 allele (n = 18–21), or two (4 alleles (n = 3–4). MMSE, mini-mental
state examination; SP, senile plaque score; NFT, neurofibrillary tangle
score.
* Significant different from the 0 (4 and from the 1 (4 groups, one-way
ANOVA with post hoc Dunnett’s P < 0.05.Discussion
The (4 allele of APOE is at present the only well-established
susceptibility gene for sporadic AD, with risk of disease
development at a particular age increasing with (4 allele dose.
The widely replicable nature of these findings has led to intense
research efforts toward uncovering the mechanisms by which
ApoE4 affect the neurodegenerative process of AD. Here, using a
well-characterized cohort of AD patients, we investigated whether
inheritance of the (4 allele was associated with cholinergic
alterations using several pre- and postsynaptic neurochemical
markers known to be affected in AD, including two markers
(nicotinic a4h2 receptors and M1/G-protein uncoupling) which, to
our knowledge, have not been previously correlated with APOE
genotypes.
Association of APOE e4 with ChAT loss in AD
Although ChAT and AChE activities, muscarinic M2 and
nicotinic receptor densities as well as M1 receptor coupling to G-proteins were all found to be reduced in one or both cortical
regions (see Table 1), only losses in ChAT activities were
associated with (4 (Fig. 1). In the frontal cortex, ChAT activities
were only significantly decreased in AD patients with at least one
(4. In the temporal cortex, although ChAT activities were reduced
in all three genotype groups of AD patients when compared with
controls, the ChAT values were most severely affected in patients
with two (4 alleles, which were significantly lower than those with
zero or one (4. The particular vulnerability of the temporal cortex
to neurodegeneration and cholinergic deficits in AD (Jobst et al.,
1994; Wilcock et al., 1982) may explain the lower ChAT values
we observed in this region. Importantly, our results suggest that
presence of APOE (4 does not directly lead to ChAT deficits,
since temporal cortical ChAT was reduced even in AD patients
without (4; instead, (4 may exacerbate the cholinergic denervation
in both neocortical regions as indicated by loss of ChAT activities.
These data are in agreement with some studies (Poirier et al.,
1995; Soininen et al., 1995; Beffert and Poirier, 1996), while
others (Corey-Bloom et al., 2000; Svensson et al., 1997;
Tiraboschi et al., 2004) failed to find significant effects of (4 on
ChAT. However, it is worth noting that in two of the negative
studies (Corey-Bloom et al., 2000; Tiraboschi et al., 2004)
cholinomimetic treatment status of the subjects was not reported.
Given that cholinesterase inhibitor treatment in rodents is known
to upregulate ChAT expression (Tayebati et al., 2004), the
possibility that cholinomimetic treatment may confound the effect
of (4 on ChAT needs to be addressed. In the present study, all
subjects were community-based patients who were never on
cholinomimetic therapy, thus removing one potential confounder
in the interpretations of ChAT data.
Lack of APOE e4 effects on peri- and postsynaptic cholinergic
markers
In contrast to the ChAT results, neocortical AChE activity was
reduced in AD but was not affected by APOE genotype (Fig. 1).
Unlike ChAT, which is expressed exclusively in cholinergic
neurons in the brain, AChE is produced in cholinoceptive sites
Fig. 1. Effect of APOE (4 allele on cholinergic neurochemical alterations in
AD. For each neurochemical measure, data are expressed as mean %
control values T SEM for controls (n = 6–19), AD patients with no APOE
(4 allele (n = 6–13), one (4 allele (n = 9–20), or two (4 alleles (n = 2–4).
ChAT, choline acetyltransferase; AChE, acetylcholinesterase; [3H]PZ Bmax,
binding density of [3H]pirenzepine (labels M1 receptors); [3H]AFDX Bmax,
binding density of [3H]AF-DX 384 (labels M2 receptors); [3H]Epi Bmax,
binding density of [3H]epibatidine (labels a4h2 nicotinic receptors); KiG/
Ki, measure of M1/G-protein coupling (see text). *Significantly different
from controls, one-way ANOVA with post hoc Dunnett’s P < 0.05.
.Significantly different from 0 (4 and 1 (4 groups, one-way ANOVA with
post hoc Dunnett’s P < 0.05.
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(Grisaru et al., 1999; Taylor and Brown, 1999). Thus, our data
suggest that the reduced AChE in AD is an indication of synapse
loss rather than a consequence of APOE (4-related cholinergicdenervation. Similarly, the densities of M1 and a4h2 nicotinic
receptors, which are predominantly postsynaptic, as well as M2
receptors, which could be localized to both pre- and postsynaptic
compartments (Arroyo-Jime´nez et al., 1999; Mash et al., 1985),
were not significantly different among patients with different (4
genotypes. Furthermore, although M1/G-protein coupling was
reduced in the temporal cortex, the extent of coupling loss again
did not differ among the (4 genotypes. Taken together, our results
indicate that APOE (4 may selectively influence pre-, rather than
postsynaptic, alterations of cholinergic neurotransmission in AD.
In the frontal cortex, there was a nonsignificant trend towards
recovery of KiG/Ki values with increasing (4 dose. Possible
mechanisms for this observation are unknown and need to be
further studied. However, one limitation of the current study is the
relative small numbers of (4/(4 AD patients in the cohort (Table 2),
mainly due to the very low abundance of this genotype (1–3% in
the general population, Wilson et al., 1996). At present, we have
failed to uncover an effect of (4 on M1/G-protein coupling. Taking
into account the report by Cedazo-Minguez and Cowburn (2001)
that apoE4 disrupts muscarinic receptor-mediated phosphoinositide
hydrolysis in neuroblastoma cells, our M1/G-protein coupling data
suggest that either (i) apoE4 targets signaling molecules down-
stream of G-protein (for e.g., phosphotidylinositol 3-kinase) or (ii)
M1/G-protein uncoupling is a postsynaptic response to presynaptic
ChAT loss (see Potter et al., 1999), and is not directly affected by
APOE (4.
Possible mechanisms of APOE e4 effects on ChAT loss in AD
It is worthwhile to further study the mechanisms whereby apoE4
may affect cholinergic neuronal function. One possibility is that
cholinergic neurons, with their reliance on cholesterol transport as
well as phospholipid metabolism for synaptic plasticity and
synthesis of acetylcholine in the brain, may be particularly
vulnerable to the diminished affinity of apoE4 for receptor-mediated
uptake (Poirier, 1994; Poirier et al., 1995). Compared to the other
isoforms, apoE4 also demonstrated lower activation of signaling
molecules such as extracellular signal regulated kinase 1/2 (ERK1/
2) which are involved in neurite outgrowth and synaptic plasticity
(Qiu et al., 2004). Interestingly, Dubelaar et al. (2004) have shown
that APOE (4 is related to reduced metabolic activity in the nucleus
basalis ofMeynert (nbM) in both cognitively normal controls as well
as prodromal early AD, suggesting that (4 contribute to AD risk via a
state of hypometabolism and reduced adaptive capacity in the nbM,
perhaps years before the appearance of cognitive decline. It is
possible that reduced ChAT activity would be one marker of nbM
hypometabolism or cell loss, leading to cholinergic dysfunction
which may further contribute to AD progression or by increasing
amyloidogenic processing of precursor protein and Ah in plaques
(Hellstrom-Lindahl, 2000). This postulate is supported by present
findings that frontal and temporal ChAT activities were negatively
correlated with SP from the same regions in AD (Pearson’s r =
0.376 [frontal], 0.408 [temporal], P < 0.05). In addition, SP
scores were also higher in patients with two copies of (4 compared to
those with zero or one (4 in the temporal cortex, with similar trends
in the frontal cortex (Table 3). However, it is also possible that the
deleterious effects of APOE (4 on ChAT may be mediated by
increased deposition of neurotoxic Ah species and subsequent
neurodegeneration (Holtzman et al., 2000). As this is a postmortem
neurochemical study where the majority of the subjects had severe
disease at death, further work using animals as well as human
M.K.P. Lai et al. / Neurobiology of Disease 22 (2006) 555–561560subjects with a wider range of disease severity is needed to clarify
the pathogenic role of APOE (4 in AD.
In conclusion, using a cohort of well characterized, community-
based AD patients, we show that the APOE (4 allele does not lead
to reduced ChAT per se, but is related to higher losses of ChAT
activities in the neocortex compared to non-APOE (4 carriers.
Furthermore, APOE (4 has limited or no effect on other
neurochemical cholinergic markers such as AChE, M1, M2,
a4h2 nicotinic receptors, and M1/G-protein uncoupling. These
findings suggest that presynaptic cholinergic function is selectively
vulnerable to the effects of (4, and the resultant exacerbation of
cholinergic deficits may be related to AD risk via its effect on
cognitive processes as well as Ah deposition and plaque formation.Acknowledgments
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Impaired transmission of acetylcholine-mediated signaling by postsynaptic muscarinic M1 receptors has been postulated to underlie the
imited efficacy of cholinergic replacement therapies in Alzheimer’s disease (AD). However, a clear relationship between the functionality of
1 receptors and dementia severity has not been demonstrated. The present study aims to measure M1 coupling to its nucleotide binding (G-)
rotein in the AD neocortex, and to correlate neurochemical findings with clinical features. A cohort of dementia patients was longitudinally
ssessed for cognitive decline, with postmortem neuropathological confirmation of AD diagnosis. Measures of M1 receptor density, M1/G-
rotein coupling and choline acetyltransferase (ChAT) activities were performed in the frontal and temporal cortex of 24 AD patients as
ell as in 12 age-matched controls. We found that M1 receptor densities were unchanged in AD, which contrasted with significantly reduced
1 coupling to G-proteins in severely demented AD patients. Loss of M1/G-protein coupling in the frontal cortex, but not the temporal
ortex, also correlated with the rate of cognitive decline. Additionally, correlations between M1/G-protein coupling and ChAT activities were
emonstrated in both regions. These results suggest that defective coupling of neocortical M1 receptors to G-proteins is a neurochemical
ubstrate of cognitive decline in AD. Based on its associations with ChAT deficits and dementia severity, we propose that M1/G-protein
ncoupling may have a significant role in the disease mechanism of AD and thus may be considered to be a potential therapeutic target.
2005 Elsevier Inc. All rights reserved.
eywords: Muscarinic receptors; G-proteins; Alzheimer’s disease; Cognition
. Introduction
Alzheimer’s disease (AD) is currently the common-
st cause of dementia among those aged 65 years and
bove, and is characterized neuropathologically by senile
laques, neurofibrillary tangles, and losses of vari-
us neurotransmitter-producing neurons. Of the transmitter
∗ Corresponding author. Tel.: +65 6321 3731; fax: +65 6225 7796.
E-mail address: admin@dementia-research.org (M.K.P. Lai).
pathologies seen in AD, cholinergic dysfunction occurs early
in the disease process [28] and is thought to underlie much of
the characteristic cognitive and neuropsychiatric symptoms
[13,22,29,32,37]. Losses of basal forebrain cholinergic
neurons, along with reduced neocortical choline acetyl-
transferase (ChAT) activity, acetylcholine (ACh) release
and muscarinic M2 receptor binding, constitute a state of
presynaptic cholinergic deficit in AD [12,24,33,36]. In
contrast, the predominantly postsynaptic M1 receptors were
originally thought to be unaltered [24], but subsequent stud-
197-4580/$ – see front matter © 2005 Elsevier Inc. All rights reserved.
oi:10.1016/j.neurobiolaging.2005.07.010
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ies showed that normal levels of radioligand binding to M1
receptors contrasted with reduced M1 immunoreactivity [8].
In addition, the ability of M1 receptors to form high affinity
agonist-binding complexes with guanine nucleotide-binding
(G-) proteins was found to be impaired in AD [9], along with
reductions in phosphoinositide hydrolysis, phospholipase C
(PLC) and protein kinase C (PKC) activities [7,21,25]. Taken
together, these findings suggest that M1 or M1-like receptors
are altered in the AD cortex, resulting in defective coupling
to G-proteins and hypoactivation of second messengers. This
breakdown in M1 mediated intracortical signal transduction
is hypothesized to underlie the limited efficacy of cholinergic
replacement therapies, since the ability of ACh or agonists to
ameliorate deficits in cholinergic neurotransmission would
have been severely limited [9]. However, it is presently
unclear whether M1/G-protein uncoupling is related to cog-
nitive decline in AD. In this study, we measured M1 receptor
densities and coupling to G-proteins in the post-mortem
neocortex of a cohort of longitudinally assessed AD patients,
as well as in a group of age-matched controls. We then cor-
related the M1 neurochemical parameters with clinical data.
2. Materials and methods





























2.2. Brain membrane homogenates
At death, brains were removed from the AD subjects
as well as from 12 controls assessed to be free from
neurological diseases. One hemisphere was processed for
neuropathological assessment, while the other hemisphere
was fresh frozen and stored at −75 ◦C. To obtain brain mem-
brane homogenates, blocks of thawed tissue from frontal
(Brodmann Area 11) and temporal (BA 21) cortex were
dissected free of white matter and homogenized in Tris–HCl
buffer (pH 7.4) as previously described [22] and stored
at −75 ◦C.
2.3. Neurochemical assays
All chemicals were from Sigma Aldrich (St. Louis,
MI) unless otherwise stated. Neurochemical assays were
performed blind to clinical information. The state of M1
receptor coupling to G-proteins was measured according to
Flynn et al. [9] with modifications. Briefly, aliquots of brain
homogenates were incubated in duplicates with 3 nM of
[3H]pirenzepine (spec. act. 70–80 Ci/mmol, Perkin-Elmer
Life Sciences, USA) and increasing concentrations of car-
bachol (10−9 to 10−2 M) in buffer (20 mM Tris–HCl, 1 mM
MnCl2, pH 7.4) for 150 min at room temperature. Specific






























bThe present neurochemical study was approved by the
nstitutional Review Board (IRB) in Singapore. All subjects
escribed below were recruited under studies approved by
he IRB in Oxford. At post-mortem, informed consent was
btained from the subjects’ relatives prior to the removal of
rains. The 24 AD subjects were derived from a cohort of
ommunity-based dementia patients from Oxfordshire, UK,
ho were recruited for a prospective study of behavior in
ementia [18]. The entry data, inclusion and exclusion cri-
eria and natural history of these patients have previously
een described in detail [18,19,22]. Cognition was assessed
very 4 months from study entry till death with the Mini-
ental State Examination (MMSE, scores ranging from 0
o 30 [10]). Dementia severity was measured by using the
ean of up to five MMSE scores before death so as to avoid
oor effects, since some patients may live for extended peri-
ds of time after their MMSE scores had reached 0 [22].
atients were considered to have severe dementia (ADsevere)
f the mean predeath MMSE was ≤9, while those with scores
etween 10 and 24 were deemed to have mild to moderate
ementia (ADmild/mod.). None of the subjects had scores >24.
he rate of cognitive decline per year was measured by the
inear regression of serial MMSE scores on the time inter-
al between recruitment and death, or when the MMSE first
eached 0. Complete drug histories were taken, and none of
he subjects received cholinomimetics. At death, diagnosis
f AD was confirmed neuropathologically by the CERAD
riteria [30]. In addition, all AD patients in this study were
n Braak stages V/VI [2].resence of 10M atropine sulphate. Parallel series of com-
etition assays were performed with and without the addition
f 0.2 mM guanylyl imidodiphosphate (GppNHp), a non-
ydrolyzable analogue of guanosine triphosphate (GTP). At
he end of incubation, assays were terminated by vacuum
ltration using a Skatron cell harvester (Molecular Devices,
SA) onto Whatman GF-B glassfibre filters (Whatman
DS, UK), washed with ice-cold 50 mM sodium phosphate
uffer (pH 7.4), dried, punched into tubes with scintillant
Wallac HiSafe 2, Perkin-Elmer Life Sciences, USA) and
easured by scintillation spectrophotometry using a Wallac
eta-Counter. The percent specific binding data were plotted
gainst log-transformed values of carbachol concentrations
ith a non-linear regression curve-fitting software (Prism
.0, GraphPad Inc. USA), and fifty percent inhibitory
oncentrations (IC50) values were derived from the binding
urves. The IC50 values were subsequently used to calculate
nhibitory constants for carbachol binding in the absence (Ki)
nd presence (KiG) of GppNHp using Cheng and Prusoff’s
quation [4]. The presence of excess GppNHp uncouples
-proteins from M1 receptors, and the ability of M1 to form
igh affinity complexes with agonists like carbachol will be
iminished, resulting in a ‘right shift’ of the carbachol dis-
lacement curve (Fig. 2A) and KiG > Ki. However, in samples
here G-proteins are endogenously relatively uncoupled to
1 receptors (higher Ki), addition of GppNHp results in a
maller shift (Fig. 2B) and the KiG to Ki ratio (or KiG/Ki)
ill be relatively low. Therefore, KiG/Ki provide a measure
f the state of M1/G-protein coupling in control and diseased
rains.
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Measurements of M1 receptors were performed by
saturation radioligand binding (Scatchard) assays with
[3H]pirenzepine as previously described [22] to derive bind-
ing density (Bmax) and affinity (KD) values using an iterative
curve-fitting software [27]. Measurements of ChAT activ-
ity using a modification of the method of Fonnum [11] had
been reported previously [29]. Protein determinations were
performed with the Coomassie Blue reagent (Pierce Biotech
Inc., USA). Tissues were not available from both regions in
some subjects.
2.4. Statistical analyses
Data were first tested for normality to determine the use
of parametric or non-parametric tests. Neurochemical and
demographic variables among the groups were compared
by one-way analysis of variance (ANOVA) with post-hoc
Tamhane’s tests, since the number of subjects was not evenly
matched and equal variances could not be assumed. Disease
variables between the AD cognitive groups were compared
by Student’s t-tests. Correlations of neurochemical vari-
ables with cognitive data, as well as inter-correlations among
the neurochemical variables were performed by Pearson’s
product moment or Spearman’s correlation, as appropriate.











scores were expectedly lower in the ADsevere compared to the
ADmild/mod. group. Additionally, the rates of MMSE decline
were significantly higher in the ADsevere group, while both
disease duration (estimated duration between first symptoms
and death) and follow-up (duration between study entry and
death) were matched in the AD cognitive groups.
For the neurochemical variables, [3H]pirenzepine bind-
ing affinity (KD) and density (Bmax) were unchanged in both
frontal and temporal regions (Fig. 1C and D). This con-
trasted with significantly reduced temporal cortical KiG/Ki
in both ADsevere and ADmild/mod. (Fig. 2C). In the frontal cor-
tex, KiG/Ki was significantly reduced only in ADsevere, with
intermediate values in ADmild/mod. not significantly differ-
ent from either control or ADsevere (Fig. 2C). When the AD
subjects were analyzed as a group, KiG/Ki was significantly
correlated with rate of MMSE decline in the frontal, but not
temporal cortex (Fig. 3). [3H]Pirenzepine KD and Bmax did
not correlate with MMSE decline in either region. Lastly,
Fig. 4A shows that ChAT activities were altered in AD cog-
nitive groups in a pattern similar to KiG/Ki (see Fig. 2C),
while Fig. 4B demonstrates that KiG/Ki values of all subjects




















, p < 0.0
.0.. Results
Table 1 shows that demographic variables were matched
mong the control, AD with mild/moderate dementia
ADmild/mod.), and AD with severe dementia (ADsevere),
xcept for brain pH, which was significantly lower in the
Dsevere group (Table 1). This is likely due to the prolonged
gonal state of severely demented patients, resulting in brain
cidosis [17]. However, brain pH, as well as the other demo-
raphic variables listed on Table 1, did not correlate with
iG/Ki values in either controls or AD subjects (Spearman
> 0.10). Among the AD patients, entry and predeath MMSE
able 1
emographic and disease variables in controls and cognitive subgroups of A
Control (N = 12)
emographic variables
Age (year) 77 ± 3
Sex (M/F) 5/7
Postmortem interval (h) 47 ± 9
pH 6.48 ± 0.1
isease variables
Disease duration (year) –
Follow-up (year) –
MMSE at study entry –
MMSE at predeath –
MMSE decline (year) –
ata are mean ± S.E.M; MMSE = Mini-Mental State Examination.
* Significantly different from control, ANOVA with post-hoc Tamhame’s
** Significantly different from AD (mild/moderate), Student’s t-tests, p < 0Muscarinic M1 receptors, together with M3 and M5
ubtypes, belong to the family of Gq/11-coupled seven-
ransmembrane domained receptors which are known to
ctivate PLC and PKC mediated signaling pathways [3].
ostsynaptic M1 receptors are found in high densities in the
eocortex and hippocampus, where they mediate cholinergic
eurotransmission in a range of CNS functions including
earning and memory [1,16,35]. Furthermore, previous stud-
es [23] have shown that by activating signaling cascades
nvolving PKC and Src kinases, muscarinic receptors can
otentiate glutamatergic NMDA receptor function, whose
egulation of long-lasting forms of synaptic plasticity is
hought to be the major physiological substrate of memory
onsolidation [26].
ents
AD (mild/mod.) (N = 7) AD (severe) (N = 17)
81 ± 2 81 ± 2
5/2 9/8
45 ± 9 35 ± 6
6.25 ± 0.09 6.02 ± 0.05*
8.4 ± 0.8 9.0 ± 1.2
3.1 ± 0.2 3.4 ± 0.4
20.7 ± 1.1 11.3 ± 1.4**
13.1 ± 3.0 1.2 ± 0.7**
2.9 ± 0.7 6.1 ± 0.8**
1.
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Fig. 1. [3H]Pirenzepine (PZ) binding in postmortem control and AD neocortex. (A) Representative saturation isotherm of [3H]PZ binding in an AD frontal
cortex. (B) Scatchard plot of binding data presented in (A) with derived neurochemical parameters. (C and D) Mean ± S.E.M. values of neocortical [3H]PZ
binding affinity (KD, in nM) and M1 receptor density (Bmax, in fmol/mg protein) in control and AD cognitive groups.
Although cholinergic dysfunction is a well-known neu-
rochemical feature in AD, investigations of its role in the
cognitive features of AD have focused on presynaptic compo-
nents (e.g., loss of ChAT activities [29,32,37]). While previ-
ous studies had reported losses of postsynaptic M1/G-protein
coupling as well as impairment of associated downstream
signal transduction [7,9,21,25], it was unclear whether the
findings were related to cognitive decline in AD. Using post-
mortem material from a cohort of longitudinally assessed
AD patients, we now show that the extent of reduction in
M1/G-protein coupling is related to the severity of cognitive
symptoms in AD. Specifically, we found that compared with
controls, temporal cortical coupling was lower in AD patients
with mild/moderate, as well as severe dementia, while frontal
cortical coupling was significantly reduced only in the sub-
group of AD patients with severe dementia. Furthermore,
reductions of M1/G-protein coupling in the frontal cortex
(but not the temporal cortex) correlated with rate of cogni-
tive decline. The basis of the observed regional difference
is unclear. However, previous studies have demonstrated that
cholinergic deficits selectively affect temporal and associated
cortices in early stages of the disease [20,37]. It is thus possi-
ble that loss of M1/G-protein coupling in the temporal region
occurs early in AD, and is extensive even in patients with mild
to moderate symptoms. Therefore, the lack of correlation
with cognitive symptoms in this region may simply reflect
a dampened effect as the neurochemical deficits reached a
stable, low level (a ‘floor effect’). This postulate is supported
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Fig. 2. Carbachol competition for the specific binding of [3H]pirenzepine to M1 receptors in the neocortex of a randomly selected control (A) and AD patient
(B). Best-fit curves were derived from non-linear regression of data. Each data point denotes specific binding in the absence () and presence () of 0.2 mM
GppNHp across log transformed carbachol concentrations. (C) Mean ± S.E.M. values of KiG/Ki in controls and cognitive groups of AD. (*) Significantly
different from control, p≤ 0.01 one-way ANOVA post-hoc tests.
Fig. 3. Correlations of KiG/Ki values with the rate of MMSE decline in AD patients using Spearman’s test. Data are available for 18 patients in the frontal
cortex and 22 patients in the temporal cortex.
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Fig. 4. (A) Mean ± S.E.M. values of choline acetyltransferase (ChAT) activity in control and AD cognitive groups. (B) Correlations of KiG/Ki with ChAT
activity in control and AD patients using Spearman’s test. ChAT data were available for 8 controls, 5 ADmild/mod. and 11 ADsevere patients in the frontal cortex,
and for 6 controls, 6 ADmild/mod. and 14 ADsevere patients in the temporal cortex. (*) Significantly different from control, p < 0.01 one-way ANOVA post-hoc
tests.
by our finding that ChAT activities, a marker for cholinergic
innervation, was also reduced in both cognitive groups in the
temporal cortex; while in the frontal cortex, ChAT reduction
was significant only in the severely demented group. How-
ever, because the majority of subjects in this longitudinal
study were severely demented at the time of death, further
studies on patients with a wider range of dementia severity
are needed to confirm this postulate. In this regard, it may be
of particular interest to investigate the state of M1/G-protein
coupling in subjects who have minimal cognitive impairment
(MCI), since a significant proportion of such patients will
eventually progress to AD [5,31].
Our findings suggest that impairment of M1 receptor-
mediated signaling in the neocortex via uncoupling with its
G-protein may be a neurochemical substrate of cognitive
decline in AD. Compared to presynaptic cholinergic deficits,
a signaling dysfunction in the postsynaptic M1 receptors may
be temporally more closely related to processes leading to
cognitive impairment, and has implications in rational thera-
peutic strategies. For example, compounds which primarily
act at the synaptic (e.g., cholinesterase inhibitors) or recep-
tor (e.g., M1 agonists) levels will be predicted in light of our
findings to be of limited efficacy in ameliorating dementia
in AD. Instead, therapeutic compounds acting at the level of
M1-activated signaling molecules, such as PKC may show
more benefit [6]. However, an important limitation of the
current correlational study is the inability to demonstrate a
causal relationship between M1/G-protein uncoupling and
cognitive decline (Fig. 3). Since ChAT deficits correlated
with M1/G-protein uncoupling, and alterations of ChAT in
cognitive groups of AD mirrored those seen in M1/G-protein
coupling (Fig. 4), it is possible that M1 uncoupling is a sec-
ondary event preceded by presynaptic cholinergic deficits.
Indeed, Potter et al. [34] reported that cholinergic deafferenta-
tion of the rodent hippocampus by immunolesioning resulted
in reductions of M1-mediated norepinephrine release as well
as M1/G-protein coupling without affecting [3H]pirenzepine
binding parameters. Nevertheless, the antecedent or causal
events leading to M1/G-protein uncoupling in the AD neo-
cortex are at present unclear, and our data suggest that like the
cholinergic lesions, the uncoupling of M1 receptors to their
G-proteins may be an early event in the AD process. Addi-
tionally, the molecular mechanisms relating ChAT alterations
to M1/G-protein coupling are unknown. Furthermore, since
none of the patients in the current study were on cholinergic
replacement therapies, it is not clear whether the use of choli-
nomimetics would also lead to restoration of M1/G-protein
coupling, and further studies are needed.
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Another question arising from the present observations
is the elucidation of molecular mechanisms underlying the
uncoupling of M1 receptors to G-proteins in AD. Studies
showing preserved radioligand binding to M1 receptors con-
trasting with reduced M1 immunoreactivity [8] suggest struc-
tural changes which do not interfere with ligand binding,
but which may affect antibody recognition. Such structural
changes may possibly include covalent modifications, such
as phosphorylation. Further studies are needed to investigate
whether aberrant phosphorylation or dephosphorylation of
key residues on the M1 receptor may alter its association
with G-proteins. Another potential mechanism for the loss
of M1/G-protein coupling may be a reduction of Gq/11 pro-
teins, although this has been refuted by studies which show
that G-proteins, including the Gq subtype, are generally pre-
served in the AD brain [15]. A third possibility may be that
G-protein function is altered in AD (for e.g., loss of GTPase
activity), which may again involve covalent modifications
[14].
In conclusion, the present study points to loss of
M1/G-protein coupling in the neocortex as a neurochemical
substrate of cognitive decline in AD, and provides one
explanation for the limited efficacy of cholinergic replace-
ment therapies in ameliorating cognitive symptoms. Since
M1/G-protein uncoupling may occur early in AD, and
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dThere are few studies on the clinical and neurochemical correlates of postsynaptic cholinergic dysfunction in Alzheimer’s disease (AD).
e have previously found that attenuation of guanine nucleotide-binding (G-) protein coupling to muscarinic M1 receptors in the neocortex
as associated with dementia severity. The present study aims to study whether this loss of M1/G-protein coupling is related to alterations in
ignaling kinases and NMDA receptors. Postmortem frontal cortices of 22 AD subjects and 12 elderly controls were obtained to measure M1
eceptors, M1/G-protein coupling, NMDA receptors as well as protein kinase C (PKC) and Src kinase activities. We found that the extent of
1/G-protein coupling loss was correlated with reductions in PKC activity and NMDA receptor density. In contrast, Src kinase activity was
either altered nor associated with M1/G-protein coupling. Given the well established roles of neuronal PKC signaling and NMDA receptor
unction in cognitive processes, our results lend further insight into the mechanisms by which postsynaptic cholinergic dysfunction may
nderlie the cognitive features of AD, and suggest alternative therapeutic targets to cholinergic replacement.
2006 Elsevier Inc. All rights reserved.
eywords: Muscarinic receptors; Glutamate receptors; Protein kinase C; Src kinase; Neocortex
. Introduction
Several neurotransmitter systems involved in cognitive
rocesses are now known to be affected in Alzheimer’s
isease (AD), among which loss of basal forebrain cholin-
rgic neurons is one of the earliest and most consistent
ndings [46]. Cholinergic neuronal loss was thought to
nderlie the clinical symptoms of AD and provided the
ationale for cholinergic replacement or cholinomimetic
∗ Correspondence to: Dementia Research Laboratory, Department of Clin-
cal Research, Block 6, Level 6, Room B22, Singapore General Hospital,
utram Road, Singapore 169608, Singapore. Tel.: +65 6321 3731;
ax: +65 6225 7796.
E-mail address: mitchell.lai@dementia-research.org (M.K.P. Lai).
pharmacotherapies [3]. To date, treatment with available
acetylcholinesterase inhibitors (AChEIs) has yielded modest
improvements in clinical rating scales, while treatment trials
using muscarinic receptor agonists have not shown much
promise [17,33]. Limiting factors for these compounds
include stage-dependent efficacy, unfavorable side effects
[17] and the involvement of other acetylcholine receptors
(AChRs, e.g., nicotinic [36]) or transmitter systems (e.g.,
serotonergic [6]). Another possible reason is a disruption
of AChR-mediated signaling. For example, muscarinic
M1 receptors are the major cholinergic receptor subtype
expressed in postsynaptic sites in the neocortex and are
critically involved in the cholinergic regulation of cognitive
processes. M1 receptors are coupled to the Gq/11-family
of guanine nucleotide-binding (G-) proteins and activate
197-4580/$ – see front matter © 2006 Elsevier Inc. All rights reserved.
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protein kinase C (PKC) mediated signaling cascades, which
also involve Src family kinases [8,26]. Previous studies have
shown that while M1 receptor densities are preserved in
the AD neocortex, the coupling of these receptors to their
G-proteins is impaired [12,13], suggesting a postsynaptic
cholinergic dysfunction which may limit the efficacy of
cholinomimetic therapies in ameliorating the cognitive
deficits of AD.
In AD, prominent neuronal loss occurs in areas other than
the basal forebrain, especially affecting the glutamatergic
pyramidal neurons of the neocortex and hippocampus [16].
Glutamate is the primary excitatory neurotransmitter and is
involved in most aspects of cognition and higher mental func-
tions. In particular, the phenomenon of long term potentiation
(LTP) mediated by the N-methyl-d-aspartate (NMDA) sub-
type of glutamate receptors, is the leading cellular model
of memory consolidation [29]. NMDA receptors are Ca2+
channels formed from tetrameric complexes of NR1 and
one of NR2A/2B/2C/2D subunits [22]. In AD, abnormali-
ties in the expression and ligand binding properties of NMDA
receptors [20,21,37] may underlie the cognitive symptoms of
AD. Interestingly, M1 receptors colocalize with NR1 on the
dendrites and soma of hippocampal pyramidal neurons, and
activation of M1 receptors potentiates NMDA receptor cur-
rents [28]. Additionally, NMDA receptors are regulated by


























at postmortem to have minimal neurodegenerative changes
(All Braak 0 except for one at stage II and another at stage
IV). Selection of subjects for the current study was based
on tissue availability, and not on dementia severity or Braak
stage.
2.2. Postmortem tissue processing
Brains were collected at postmortem, and the orbitofrontal
gyrus of the right hemisphere was dissected and stored frozen
at −75 ◦C. Frozen brain chunks were later thawed on ice
and dissected free of meninges before homogenization with
an Ultra-Turrax homogenizer (IKA Labortechnik, 15 s maxi-
mum setting) in either (i) 10 mM sodium phosphate buffer, pH
7.4 containing 1.0 mM EDTA and protease inhibitors (Com-
plete Mini, Roche Diagnostics) followed by dilution 1:1 and
boiling in Laemmli sample buffer (Bio-Rad Laboratories) for
immunoblotting; or (ii) 50 mM Tris–HCl buffer, pH 7.7 for
radioligand binding/kinase assays, both in a final concentra-
tion of 50–100 mg tissue wet weight/ml.
2.3. Saturation radioligand binding assays
All chemicals were of analytical grade and were pur-
chased from Sigma–Aldrich Ltd., unless otherwise stated.






























bence of a functional link between M1 and NMDA receptors.
owever, it is not known whether the loss of M1/G-protein
oupling is associated with changes in signaling kinases or
MDA receptors in AD. In this study, we correlated the neu-
ochemical measurements of M1 and NMDA receptors, PKC
nd Src kinase in the postmortem frontal cortex of a well
haracterized cohort of AD subjects and elderly controls.
. Materials and methods
.1. Clinical and neuropathological assessments
A total of 22 subjects with AD, as well as 12 con-
rols, assessed at the University of California Los Angeles
lzheimer Disease Research Center (UCLA-ADRC) were
ncluded in this study, which was approved by the institutional
eview boards of UCLA and Singapore General Hospital.
elevant clinical information was obtained from the UCLA-
DRC longitudinal study database and patient charts. All 22
ubjects met the Diagnostic and Statistical Manual of Mental
isorders, 4th Edition (DSM-IV) clinical criteria for demen-
ia [1] as well as the CERAD criteria [31] for neuropathologi-
al diagnosis of definite AD. In addition, one subject showed
vidence of Lewy bodies (LB), another had LB and superior
rontal infarct, while two others had multi-infarct or cingu-
ate stroke. Braak staging [5] of the AD subjects revealed
hat the majority (n = 18) were in Braak V/VI, and only two
ere in stage IV/V, and another two in stage IV. The elderly
ontrols did not have neurological diseases and were foundation. M1 and NMDA receptors were measured by satura-
ion binding assays with [3H]pirenzepine ([3H]PZ, sp. act.
0–80 Ci/mmol) and [3H]MK-801 (sp. act. 28.9 Ci/mmol,
oth from Perkin-Elmer Life Sciences), respectively, based
n modifications of published methods [24,32] For [3H]PZ,
even concentrations of radioligand (ranging from 0.5 to
5 nM) were incubated in triplicates with 100l aliquots
f washed brain membrane homogenates in a total volume
f 0.5 ml sodium phosphate buffer, pH 7.4 for 60 min at
5 ◦C. 1M atropine sulphate was added to some aliquots
o define non-specific binding. At the end of incubation,
omogenates were vacuum filtered onto polyethylenimine-
retreated Whatman GF/B glassfibre filters (Whatman plc).
ried filters were then punched into vials, and 2 ml aliquots of
cintillant (Optiphase HiSafe 2, Perkin-Elmer Life Sciences)
ere added for measurement of bound radioactivity by liq-
id scintillation spectrophotometry. Assays for [3H]MK-801
inding (0.5–30 nM, 60 min at room temperature) in 50 mM
ris–HCl buffer, pH 7.7, containing final concentrations of
50M spermine, 25M glycine, and 20M l-glutamate
ere as above, except that brain homogenates were preincu-
ated for 60 min at 30 ◦C in 50 mM Tris–HCl buffer, pH 7.7 to
acilitate degradation of endogenous glutamate before incu-
ation with radioligand. Nonspecific [3H]MK-801 binding
as determined in the presence of 10M unlabelled MK-
01 maleate. The parameters KD (binding affinity, in nM)
nd Bmax (binding density, in fmol/mg protein) were derived
rom binding data by Scatchard analyses followed by iterative
urve-fitting. Binding data consistently fitted with one-site
inding with Hill constants around 1.0.
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2.4. M1/G-protein coupling
Pharmacological determination of M1/G-protein interac-
tions was carried out by [3H]PZ/carbachol competition bind-
ing as previously described [43]. Briefly, brain membrane
homogenates were incubated in duplicate with 3 nM [3H]PZ
and 15 concentrations of unlabelled cholinergic agonist car-
bachol (10−9 to 10−2 M) in 50 mM Tris–HCl buffer, pH 7.4
for 150 min at room temperature. Non-specific binding was
defined in the presence of 10M atropine sulphate, and par-
allel series of competition assays were performed with or
without the addition of excess guanylyl imidodiphosphate
(GppNHp, 0.2 mM), a non hydrolysable guanosine triphos-
phate (GTP) analogue which uncouples G-proteins from
M1 receptors and reduces the affinity of M1 receptors for
carbachol. Specific binding data were plotted against log-
transformed values of carbachol concentrations by non-linear
regression curve-fitting using Prism 3.0 software (GraphPad
Inc.) to derive inhibitory constants for carbachol binding in
the absence (Ki) and presence (KiG) of GppNHp. The ratio
of KiG to Ki was then used as a measure of the state of M1/G-
protein coupling in control and diseased brains, with lower
KiG/Ki indicating less coupling.



























incubation with horseradish peroxidase conjugated goat anti-
rabbit antibody (1:10,000, Jackson ImmunoResearch Inc.),
immunoreactive bands on the membranes were visualized by
enhanced chemiluminescence using the ECL system (Amer-
sham Pharmacia Biotech), and quantified by image analyzer
(UVItec Ltd.). To ensure comparable sample loading across
lanes, membranes were then stripped with stripping buffer
(Promega Corp.), washed and reblotted with a mouse mon-
oclonal anti--actin (1:5000, Sigma–Aldrich Ltd., expected
molecular weight 42 kDa), and the protocol described above
was repeated with horseradish peroxidase conjugated goat
anti-mouse antibody (Jackson ImmunoResearch Inc.). One
lane for external standard consisting of known amounts of
protein from an individual homogenate was included in each
membrane for normalization of data.
2.7. Statistical analyses
All statistical analyses were performed using the SPSS
11.0 for Windows software (SPSS Inc.). Data were first
checked for normality for the selection of parametric or non-
parametric tests. Demographic and neurochemical variables
were compared between AD and controls by Student’s t-
tests, and correlations among these variables were performed
using Pearson’s product moment. Within the AD group, the

























sThe phosphotransferase activities of PKC and Src in
rain membrane homogenates were measured with com-
ercial kits (Upstate Biotechnology) according to manufac-
urer’s instructions. Briefly, aliquots of brain homogenates
ere incubated with [-32P]adenosine triphosphate (spec.
ct. 3000 Ci/mmol, Perkin-Elmer Life Sciences) and kinase-
pecific substrate peptide (QKRPSQRSKYL for PKC or
VEKIGEGTYGVVYK for Src) in supplied buffer con-
aining the required activators, protease inhibitors and phos-
hatase inhibitors. Mixtures were then spotted onto phos-
hocellulose paper with washing and fixing, and transfer of
32P]-phosphate to specific residues on the substrate peptide
as quantified by scintillation spectrophotometry. Endoge-
ous phosphorylation of homogenate proteins, defined as
ounts from measurements in the absence of substrate pep-
ide, was subtracted from total counts to derive specific kinase
ctivities on substrate peptides, and expressed in pmol phos-
hate/min/mg protein.
.6. Immunoblotting
Boiled brain homogenates in Laemmli sample buffer
ere electrophoretically separated on 7% polyacrylamide
els, transferred to nitrocellulose membranes, and blocked
n 10 mM phosphate buffered saline, pH 7.4, 0.1% Tween 20
PBST)/5% skim milk for 1 h before immunoblotting with a
abbit polyclonal antibody directed against the NR1 subunit
f NMDA receptor (1:1000, Chemicon, Inc., expected molec-
lar weight of around 114 kDa) in PBST/1% milk overnight
t 4 ◦C. Following washings in PBST/1% milk and a 1 hariables on neurochemical measures were investigated with
earson’s product moment or Student’s t-tests as appropri-
te. Lastly, multiple regression using the ‘stepwise’ method
as used to investigate possible relationships between the
ependent variables (PKC activity, Src activity and NMDA
eceptor density), other neurochemical variables and demo-
raphic factors. This allowed for the fact that M1/G-protein
oupling (KiG/Ki) may be related to multiple variables and
ndicated the strongest correlate. For all analyses, the null
ypothesis was rejected at p < 0.05.
. Results
.1. Effects of demographic and disease factors on
eurochemical variables
Demographic factors including age, sex, postmortem
nterval and storage interval in AD and controls were well
atched (Table 1). Furthermore, binding affinity (KD) and
ensity (Bmax) of [3H]PZ (M1 receptors) and [3H]MK-
01 (NMDA receptors), NR1 immunoblot density as well
s M1/G-protein coupling status (KiG/Ki) did not corre-
ate with the demographic factors listed above (Pearson’s
> 0.05, data not shown). Within the AD cohort, the pres-
nce of additional neuropathological findings, i.e., LB and
nfarct (n = 4, see Section 2.1.), and duration of demen-
ia symptoms (9.5 ± 1.1 years, range 3–17 years) did not
ffect the neurochemical variables (Student’s p and Pear-
on’s p > 0.05, respectively, data not shown). However, Braak
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Table 1
Demographic and neurochemical variables in AD subjects and controls
Control AD
Demographics
Maximum number of casesa 12 22
Age at death (years) 73.2 ± 4 78.8 ± 2
Sex (M/F) 6/6 12/10
Storage (years) 4.5 ± 0.5 5.4 ± 0.7
PMI (h) 14.4 ± 3 14.2 ± 2
Muscarinic M1 receptors
KiG/Ki 7.1 ± 0.9 (12) 4.8 ± 0.4 (22)*
[3H]pirenzepine KD 5.3 ± 0.5 (11) 6.9 ± 0.5 (18)
[3H]pirenzepine Bmax 601 ± 39 (11) 590 ± 39 (18)
NMDA receptors
[3H]MK-801 KD 9.9 ± 1.7 (11) 8.2 ± 0.9 (22)
[3H]MK-801 Bmax 300 ± 46 (11) 200 ± 23 (22)*
Protein kinase activities
PKC 776 ± 107 (11) 354 ± 57 (22)**
Src 6.8 ± 1.4 (11) 7.0 ± 1.2 (21)
Data are mean ± S.E.M. PMI, postmortem interval; KiG/Ki, measure of
M1/G-protein coupling (see text); KD, binding affinity constant (in nM);
Bmax, binding density (in fmol/mg protein). Specific PKC (protein kinase C)
and Src kinase activities are in pmol phosphate/min/mg protein.
a Not all neurochemical measures were available for all cases. TheNvalues
available for each neurochemical measure are listed in parentheses.
* Different from control p < 0.05.
** Different from control p < 0.01.
stage was negatively correlated with NR1 density (Pearson
r = −0.55, p = 0.03), but positively correlated with Src activ-
ity (Pearson r = 0.47, p = 0.04). Therefore, Braak stage was
included as a covariate in subsequent regression analyses
(see below).
3.2. Neurochemical variables of controls versus AD
Table 1 shows that while M1 receptor KD and Bmax are
unchanged in AD, receptor coupling to G-proteins is impaired
(reduced KiG/Ki). Furthermore, PKC activity, NMDA recep-
tor Bmax as well as NR1 immunoblotting density are reduced
in the AD frontal cortex (Table 1 and Fig. 1B). In contrast,
Src activity and NMDA receptor KD are unchanged (Table 1).
3.3. Correlation of M1/G-protein coupling with NMDA
receptor status and kinase activities
Fig. 2 shows that KiG/Ki values of all subjects corre-
lated with PKC activities in the frontal cortex (A) as well
as with both NMDA receptor indices [3H]MK-801 Bmax
(C) and NR1 immunoblot density (D). KiG/Ki did not cor-
relate with Src kinase activities (B). Finally, stepwise mul-
tiple regression analyses showed that of the list of demo-
graphic/neurochemical variables (excluding the dependent
variable) in Table 1 plus Braak staging, KiG/Ki was the
strongest predictor for both PKC activity (adjusted R2 = 0.30,
β = 0.59, p = 0.008) and NR1 density (adjusted R2 = 0.26,
β = 0.55, p = 0.015).
4. Discussion
Presynaptic cholinergic deficits are now well established
findings in AD. Alterations of choline acetyltransferase
(ChAT), acetylcholine levels and other presynaptic cholin-
ergic markers are likely concomitant with basal forebrain
neuronal loss, and may contribute to both the cognitive
and behavioral symptoms of AD [10,24,30,47]. In contrast,
although postsynaptic perturbations such as reduced mus-


















dig. 1. NMDA receptor NR1 levels in AD subjects and controls. (A) Repre
tripped and reblotted with antibody against -actin (bottom lane) for contr
B) Bar graph of mean normalized NR1 immunoblot optical densities (in ar
ifferent from control, p < 0.05 (Student’s t-test).1
ave been reported [13,19], little is known about the clini-
al relevance and neurochemical correlates of these changes.
e have recently shown that attenuation of M1/G-protein
oupling is associated with dementia severity in AD [43].
sing postmortem material from a separate, well character-
zed cohort of patients, we now report that the extent of loss of
1/G-protein coupling is correlated with reductions of PKC
ctivity as well as NMDA receptor density in AD frontal
ortex. These correlations are not confounded by a number
f demographic and disease factors under study. Therefore,
ur data link postsynaptic cholinergic dysfunction with two
ther substrates (PKC and NMDA receptor) known to play
ssential roles in cognitive processes [29,40] and provide fur-
her insight into the mechanisms by which impairment of
e immunoblot of NR1 (top lane) from brain membrane homogenates was
) and AD. Molecular weight markers in kilodaltons (kDa) are as indicated.
nits) for available control (n = 12) and AD subjects (n = 18). *Significantly
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Fig. 2. Association of M1/G-protein coupling with protein kinase activities and NMDA receptors. Correlation of KiG/Ki, a measure of M1/G-protein coupling
(see text) with specific (A) PKC and (B) Src kinase activities (both in pmol phosphate/min/mg protein), (C) [3H]MK-801 Bmax (binding density, in fmol/mg
protein), and (D) normalized NR1 immunoblot optical densities (arbitrary units). *Significant Pearson correlation.
M1 mediated signaling may underlie the cognitive decline
of AD.
The PKC family of isoenzymes are serine/threonine
kinases which are critical signaling molecules in most cell
types, serving to integrate a multitude of extracellular sig-
nals with downstream signaling events concerned with gene
transcription, protein processing, synaptic plasticity, cell sur-
vival and other physiological processes [34,35,41]. In neu-
rons, these extracellular signals include neurotransmitters
like acetylcholine which are mediated by Gq/11-coupled
receptors such as M1 [8]. Interestingly, Etcheberrigaray et
al. [11] showed that treatment with bryostatin 1, a PKC acti-
vator devoid of tumor promoting activity, improved maze
performance in AD transgenic mice. In postmortem AD cor-
tex, reductions of PKC level and activity have been reported
[45], and our data now suggest that this reduction may not
simply reflect neuronal loss, but may be related to M1 receptor
dysfunction.
Currently, the molecular mechanisms underlying down-
regulation or deactivation of PKC in AD are still unclear.
Inactive PKC is normally localized in the cytosol. Upon acti-
vation by diacylglycerol, Ca2+ and other signals released
by the action of phospholipase C (which is in turn acti-
vated by Gq/11), PKC translocates to the plasma or nuclear
membrane via anchoring by RACK (receptor for activated





The loss of frontal NMDA receptors is another salient
marker of neurodegeneration in AD and of potential sig-
nificance to the clinical features of the disease [14]. In this
study, we measured NMDA receptors by [3H]MK-801 bind-
ing as well as immunoblotting of the NR1 subunit. Because
[3H]MK-801 binding density (Bmax) was expressed per unit
weight of protein, the observed reduction in Bmax would
likely reflect specific loss of NMDA receptors, rather than
generalized cortical atrophy. MK-801 (dizocilpine), a non-
competitive NMDA receptor channel blocker with anticon-
vulsant properties, is known to bind within the channel pore
region formed by the NR1/NR2A complex [27]. Therefore,
specific [3H]MK-801 binding can be considered to indi-
cate functional NMDA receptor labeling. Nevertheless, since
NMDA channel opening (hence [3H]MK-801 Bmax) is also
influenced by the concentrations of glutamate as well as reg-
ulators like glycine and polyamines [32], we added saturating
concentrations of these compounds in the binding assays to
maximize channel opening. We further measured levels of the
obligatory NR1 subunits of NMDA receptor by immunoblot-
ting. These two NMDA receptor indices were significantly
correlated (r = 0.58, Pearson’s p = 0.001) and showed a simi-
lar degree of reduction in AD (see Table 1 and Fig. 1B), sug-
gesting that similar pools of NMDA receptors were measured.
It should be noted, however, that although MK-801 binds with




aound to be decreased in AD [4]. Therefore, more work is
eeded to clarify whether M1 dysfunction is directly related
o PKC hypoactivity by decreased activation, or by its effect
n RACK and consequent perturbation of PKC translocation.MDA receptor subtype in adult neocortex [39], it is unclear
hether reduced [3H]MK-801 binding represents the loss
f specific NMDA receptor populations in AD. Importantly,
ttenuation of M1/G-protein coupling significantly correlated
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with both NMDA receptor indices, suggesting that impair-
ment of M1 mediated signaling is related to reduced levels of
functional NMDA receptors.
What are the putative molecular mechanisms linking M1
signaling dysfunction with NMDA receptor alterations? The
colocalization of M1 with NR1 indicate a spatial relationship
allowing physiological interactions between the two recep-
tors [28], and preclinical studies have shown that activation
of Gq/11-coupled receptors such as M1 potentiates NMDA
receptor currents, possibly via PKC dependent pathways
[27,28]. PKC is known to directly phosphorylate regulatory
regions of NR1 subunits and control trafficking and surface
delivery of functional NMDA receptors [27,38,42]. There-
fore, it is possible that impaired PKC activity associated with
M1/G-protein uncoupling underlie NMDA receptor deficits
in AD, either by decreased delivery of subunits to the sur-
face, or increased rate of endocytosis and degradative sorting.
Alternatively, the NR1 gene promoter is induced by transcrip-
tion factors such as Sp1 [23] which is in turn regulated by a
variety of signaling molecules including PKC [9]. Because
the present techniques are not able to differentiate membrane
surface expressed NMDA receptors from intracellular recep-
tor pools, which may far exceed the former [18], further
studies are needed to determine whether PKC deficits affect
NMDA receptors via changes in protein sorting or receptor






























the disruption of M1 signaling seen in AD. Importantly, these
results suggest that M1 agonists maybe efficacious in AD if
M1 receptors could be re-coupled to their G-proteins.
In conclusion, there is ample evidence from preclinical
studies for physiological interactions among M1 receptors,
NMDA receptors and signaling molecules such as PKC and
Src kinase in the regulation of cognitive processes, but the
significance of these findings to AD is unclear. We now show
that the extent of postsynaptic M1 receptor uncoupling from
G-proteins correlated with loss of PKC activity and NMDA
receptor density in the postmortem frontal cortex of AD, sug-
gesting that impaired M1 mediated signaling may underlie
cognitive deficits via effects on PKC and NMDA receptor
function. This study provides a neurochemical basis for the
limited efficacy of AD therapies which increase synaptic
acetylcholine availability or target M1 receptors; instead, our
data point to targets downstream of M1/G-protein activation,
or to strategies which restores the coupling of G-proteins to
M1 receptors, and predict improved efficacy for compounds
which regulate PKC [11] or NMDA receptors [15]. However,
more work is needed to provide molecular delineation of the








[In contrast to PKC, activity of Src kinase, a non-receptor
yrosine kinase and another regulator of NMDA receptor
unction [2], was not altered in AD and did not correlate with
1/G-protein coupling or NMDA receptor levels. One other
tudy on postmortem kinase activities in AD also reported no
hange in Src [44]. Therefore, Src activity may be resistant to
D changes, or compensatory mechanisms may exist. How-
ver, because Src is involved in multiple signaling events
n a number of physiological processes, the present tech-
iques may not be sensitive enough to detect specific changes
n interactions between Src and NMDA receptor in M1-
ediated signaling. It should also be noted that both PKC and
rc kinase families include several closely related enzymes
ith similar activities, and the enzymatic assays employed in
his study are unable to distinguish specific kinase subtypes.
urthermore, although an effect of M1/G-protein uncoupling
n PKC and NMDA receptor alterations is biologically plau-
ible [8,9,27,28], the present correlational study does not
erify a causal relationship between these neurochemical
ariables; other disease factors may also play a role. Indeed,
he negative correlation of NR1 density with Braak stage
see Section 3) indicate that parenchymal neurodegenerative
hanges are at least partially responsible for NMDA recep-
or deficits, although stepwise regression analyses indicated
stronger correlation with M1/G-protein uncoupling. Inter-
stingly, Caccamo et al. [7] showed that a novel M1 agonist
mproved both plaque and tangle burden as well as spatial
earning in a triple transgenic (3× Tg) AD mouse model.
owever, the M1/G-protein coupling status in these animals
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Densities of serotonin transporters (5-HTT) in the postmortem
neocortex of behaviorally assessed Alzheimer’s disease (AD) pa-
tients and aged controls were measured by radioligand binding
with [3H]citalopram. Itwas found that 5-HTTsites in the temporal
cortex of AD patients with prominent antemortem anxiety were
unaltered compared with controls, but were reduced in non-
anxious AD subjects. Furthermore, homozygosity for the high
activity allele of a functional polymorphism in the 5-HTT gene
promoter region (5-HTTLPR) was associatedwith both increased
[3H]citalopram binding and occurrence of anxiety in the AD sub-
jects. Since serotonin-synthesizing neurons are known to be lost in
theAD cortex, this study suggests that thepreservation of 5-HTT
may exacerbate serotonergic de¢cits and underlie anxiety symp-
toms in AD. NeuroReport 14:1297^1300 c 2003 Lippincott
Williams &Wilkins.
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INTRODUCTION
Late-onset Alzheimer’s disease (AD) is the most common
cause of dementia in the elderly, affecting 5–10% of those
aged 4 65 years. Besides cognitive impairment, AD is
characterized clinically by the presence of neuropsychiatric
behaviors. Of these behavioral changes, anxiety is relatively
prevalent, occurring in up to 50% of AD patients over the
course of the disease [1,2]. Neuropsychiatric behaviors like
anxiety are clinically significant in AD in that they often
lead to considerable caregiver distress and precipitate
institutionalization of the patient [3–5]. However, the
neurochemical basis of these behavioral changes is not
well-studied. Because the serotonergic system is affected in
AD, with findings of losses of serotonergic raphe neurons,
serotonin (5-HT) levels, and cortical 5-HT transporters (5-
HTT) [3,6,7], and because selective 5-HT reuptake inhibitors
(SSRIs) are effective in the treatment of anxiety disorders,
we queried whether alterations of neocortical 5-HTT
binding may underlie anxiety in AD. In addition, we
examined whether a functional polymorphism in the 5-
HTT gene promoter region (5-HTTLPR) [8,9] whose long (L)
and short (S) variants result in increased and decreased 5-
HTT expression and 5-HT reuptake, respectively, may be
associated with anxiety in AD.
MATERIALS AND METHODS
The 34 AD subjects in this study were part of 100
community-based dementia patients in Oxfordshire, UK
who were recruited for a longitudinal study of behavior in
dementia [1,10]. Behavioral changes of the subjects
were assessed every 4 months from recruitment to death
(for a mean of 2.6 years) with the Present Behavioural
Examination (PBE) [11], a standardized, caregiver-directed
interview covering in detail the observable behavior
and mental state of the patient over the previous 4 weeks.
Anxiety was assessed by behaviors and physical signs
indicating inappropriate anxiety or fear. Rating for anxiety
was on a 7-point score (0–6) based on frequency of
occurrence reported by the caregiver (from 0, absent
in the last 28 days; 3, present in 14 days of the last 28 days;
to 6, present every day). A subject was considered to
have had significant anxiety if there were at least two
ratings 4 3, or one rating 4 3 and two other ratings
of 1–3 over the course of the study [3]. At death, informed
consent was obtained from the families of patients and
control participants for the removal of brain. Selection of AD
subjects was based only on tissue availability and neuro-
pathological confirmation of diagnosis by the CERAD
criteria [12]. The 14 controls were neurologically normal,
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had no significant neuropathology and no history of
psychiatric disease.
At postmortem, blocks of gray matter from orbitofrontal
(BA11) and mid-temporal (BA21) gyri were dissected from
one hemisphere and processed for homogenization as
described previously [13], while the other hemisphere was
formalin fixed for neuropathological diagnosis. In addition,
semi-quantitative scores for senile plaques (SP, score 0–3)
and neurofibrillary tangles (NFT, score 0–4) were obtained
from methanamine silver/modified Palmgren stained sec-
tions of BA11 and BA21. Saturation binding with [3H]citalo-
pram (sp. act. 83.0Ci/mmol, Amersham Life Sciences, UK),
which has previously been reported to label 5-HTT with
high specificity and nanomolar affinity [14], was based on
modifications of published methods [15]. Briefly, brain
homogenates were thawed, diluted 1:1.5 vol/vol in incu-
bation buffer (50mM Tris–HCl, pH 7.4) and 100ml aliquots
were added to seven concentrations of [3H]citalopram (0.1–
12 nM) in triplicates and incubated for 60min at 251C in a
total volume of 0.5ml. Non-specific binding was deter-
mined in the presence of 10mM unlabelled fluvoxamine
maleate (Tocris Cookson Ltd, UK) and constituted around
30% of total binding. An aliquot of the homogenate was
used for protein determination. Incubation was terminated
by rapid filtration with a Skatron cell harvester (Skatron AS,
Norway) through 0.1% polyethylenimine-treated Whatman
GF/B filters (Whatman BDS, UK), and membrane-bound
radioactivity was measured by liquid scintillation spectrom-
etry. The EBDA and LIGAND software [16] were used to
calculate binding affinity (KD, nM) and density (Bmax, fmol/
mg protein). In all cases, the Scatchard plots were best fitted
to single binding sites with Hill coefficients ranging from
0.98 to 1.01.
For 5-HTTLPR genotyping, DNA was extracted from
20mg aliquots of cortical tissue using commercially avail-
able kits, and analyzed by polymerase chain reaction (PCR)
according to previously reported methods [9] to generate
the L (528 bp) and S (484 bp) fragments.
Statistical analyses were performed with SPSS 10.0 for
Windows. Relationships between [3H]citalopram binding
variables and potential confounders (demographic or
disease factors) were studied with stepwise multiple
regression. Binding parameters (KD and Bmax) of controls
and AD behavioral groups were then compared by repeated
measures ANOVA (with brain area as the repeated
measure), followed by post-hoc tests. Comparisons of
binding parameters over 5-HTTLPR genotypes in the AD
subjects were similarly studied. Analysis of genotype in
controls was not attempted because of the small sample size,
with only one individual having the LL genotype. Differ-
ences in binding parameters were considered significant if
the p values for both the repeated measures ANOVA (effects
of between-subject factor or interaction) and the post-hoc
tests were o 0.05. Genotype frequencies in the behavioral
groups of AD (anxious vs non-anxious patients) were
compared by Fisher’s exact test.
RESULTS
The AD subjects and controls were well matched with
regards to age, sex, postmortem delay and tissue storage
interval, with the exception of lower brain pH in the AD
behavioral groups (probably due to prolonged agonal state
[17], Table 1). However, pH did not correlate with any of the
binding parameters (stepwise multiple regression, p4 0.05)
and thus was not entered as a co-variate in subsequent
analyses. Among the AD subjects, the binding parameters
were not correlated with disease factors (disease duration,
dementia severity, senile plaque and neurofibrillary tangle
counts, stepwise multiple regression, p40.05), and there
were no significant differences between the AD behavioral
groups with regards to the disease factors (Student’s or
Mann–Whitney p4 0.05, Table 1). Because chronic psycho-
tropic medication may affect central serotonergic activity,
we also compared the binding parameters between subjects
who were taking sedative-hypnotics (n¼ 8), neuroleptics
(n¼ 10) or tricyclic antidepressants (n¼ 3) and those not on
medication in the 8 months before death. We found that of
the medications, only sedative-hypnotic use was associated
with increased [3H]citalopram Bmax in BA11 (adjusted R
2
¼ 0.09, b¼ 0.34, p¼ 0.044). Therefore, sedative-hypnotic use
was entered as a co-variate in subsequent analyses of AD
subjects.
There were no differences in affinity (KD) of [
3H]citalo-
pram binding among controls, non-anxious AD and anxious
AD (respective mean values7 s.e.m.: 2.727 0.4, 3.677 0.5,
4.047 0.7 nM in BA11 and 3.387 0.4, 3.517 0.5, 4.917
1.0 nM in BA21). In contrast, [3H]citalopram binding density
(Bmax) was reduced in non-anxious AD patients compared
to controls, while the Bmax of anxious AD patients was
preserved at around control values. However, this pattern of
alteration reached post-hoc statistical significance only in
BA21 (Fig. 1). When binding parameters in the AD patients
were compared over the 5-HTTLPR genotypes, the Bmax
values were significantly higher in those of LL genotype
than in SS or SL genotypes (with sedative-hypnotic use as
co-variate, Fig. 2). KD was not significantly different
between the genotypes (data not shown).
Table 1. Comparison of demographic and clinical features between con-








Age (years) 757 4 817 1 817 1
Sex (%male) 50 50 58
Postmortem interval (h) 477 7 387 6 497 8
Storage interval (months) 907 3 917 3 917 3
pH 6.77 0.08a 6.37 0.08 6.27 0.11
Disease duration (years)  9.67 0.9 8.97 1.5
Mini-Mental State
Examinationb [24]
 4.27 1 7.87 3
Senile plaques
BA11  2.87 0.1 3.07 0.01
BA21  2.87 0.1 3.07 0.01
Neuro¢brillary tangles
BA11  2.17 0.4 1.57 0.3
BA21  3.07 0.3 2.37 0.4
Data aremean7 s.e.m.
aSigni¢cantly di¡erent (one-way ANOVA, p¼ 0.003) from AD without
anxiety (Sche¡e¤ multiple means comparison p¼ 0.014) and AD + anxiety
(Sche¡e¤ p¼ 0.008).
bMeanof last ¢veMMSE scoresbefore deathused as ameasure of dementia
severity to avoid £oor e¡ects [3].
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Finally, we compared 5-HTTLPR genotype distribution
between the AD behavioral groups, and found higher
proportions of anxious patients with the LL genotype than
in those of SS or SL genotypes (Table 2), with an odds ratio
of 6.25 (mid-p corrected 95% CI 1.14–37.04).
DISCUSSION
At present, at least 14 pre- and postsynaptic 5-HT receptor
subtypes are known to function as effectors of 5-HT
signaling [18]. In contrast, 5-HT reuptake from the synaptic
junction is mediated by a single protein, the 5-HTT, which is
critical in the regulation of the magnitude and duration of
serotonergic activity [8]. Support for the involvement
of 5-HTT in mood and emotional states comes in part
from the efficacy of selective 5-HT reuptake inhibitors
(SSRIs) in the treatment of depressive and anxiety disorders.
This suggests that serotonergic deficits may form the
neurochemical basis of some affective disorders, the
symptoms of which can be ameliorated by blocking the
reuptake of 5-HT and hence restoring serotonergic activity
[19]. In addition, a functional biallelic polymorphism
of the gene promoter region of 5-HTT (5-HTTLPR) whose
long and short variants determine increased or decreased
5-HTT expression, respectively, has been shown to be
associated with anxiety-related personality traits [8,20].
These findings led us to examine whether the presence of
anxiety in AD is related to 5-HTT levels in the postmortem
neocortex and, if so, whether the 5-HTTLPR genotype may
be a risk factor for the development of anxiety in AD via its
influence on 5-HTT levels.
In agreement with previous reports of presynaptic
serotonergic deficits [3,6,7], we found reduced densities of
5-HTT in BA21 of non-anxious AD patients and a trend
towards reduction in BA11, which may be due in part to the
relatively severe neurodegeneration in temporal cortex
[21,22]. However, the novel finding in this study is the
relative preservation of 5-HTT sites in anxious AD subjects,
who were also more likely to have the high activity LL
genotype of 5-HTTLPR. We then showed that 5-HTT
binding is significantly higher in patients with the LL vs
the SS/SL genotype. The SS and SL genotypes were
analyzed as a group because of the similar levels of 5-HTT
activity in the SS and SL genotypes previously demon-
strated for 5-HTTLPR (S dominance [8]). Taken together, the
data suggest that preservation of neocortical 5-HTT sites in
anxious AD patients may be mediated in part by 5-HTTLPR
driven, enhanced expression of 5-HTT on remaining
serotonergic neurons. We further postulate that this pre-
servation of 5-HT reuptake activity concomitant to pre-
synaptic serotonergic deficits [3,6,7] may exacerbate the
depletion of 5-HT in the synaptic junction and predispose
the patient to developing anxiety symptoms.
This is the first study which relates 5-HTTLPR with

















200 controls (n = 14)
AD − anxiety (n = 20)
AD + anxiety (n = 12)
*
Fig. 1. Data are mean7 s.e.m. for [3H]citalopram binding to frontal
cortex (BA11) and temporal cortex (BA21) in the controls and the ADbe-
havioral groups with repeatedmeasures ANOVA (2,43 df) for the e¡ects
of group (F¼ 4.02, p¼ 0.025) and group brain area interaction
(F¼ 2.58, p¼ 0.088).Radioligand assays were not performed on two sub-
jects due to shortage of tissue. *Signi¢cantly di¡erent (one-way ANOVA,
p¼ 0.006) from control (Sche¡e¤ p¼ 0.033) and AD + anxiety (Sche¡e¤


















SS/SL (n = 23)
LL (n = 9)
*
*
Fig. 2. Data are mean s.e.m. for [3H]citalopram binding to frontal cor-
tex (BA11) and temporal cortex (BA21) across 5-HTTLPR genotype in AD
subjects with repeatedmeasures ANOVA (2,28 df; with sedative-hypno-
tic use as co-variate) for the e¡ect of genotype (F¼13.4, p¼ 0.001 and
genotype  brain area interaction (F¼ 2.04, p¼ 0.16). *Signi¢cantly dif-
ferent from SS/SL (Student’s t-test, po 0.01).




Data are number of patients.Fisher’s exact p¼ 0.031.
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preliminary due to the relatively small sample size, perhaps
inevitable in postmortem studies. Therefore, population
stratification effects cannot be dismissed and may account
for the atypically high odds ratio and a wide 95% CI (see
Results). Furthermore, the present findings, although
analogous to a recent study correlating the LL genotype
with aggression in AD [23], is nevertheless at odds with data
from the general population where the S allele has small but
statistically significant contributions to anxiety-related
personality traits [8,20]. One possible reason for the
discrepancy may be the presence of extensive cortical
neurodegeneration and serotonergic deficits in AD which
may lead to altered neurophysiological, neurochemical and
behavioral manifestation of 5-HTTLPR compared to non-
AD brains.
CONCLUSION
This study demonstrates that [3H]citalopram binding to 5-
HTT is lost in the postmortem neocortex of non-anxious AD
subjects, but preserved in subjects who manifested sig-
nificant premortem anxiety. The preservation of neocortical
5-HTT sites, which may reflect synaptic plasticity mediated
in part by genetic factors, is a putative neurochemical
substrate of anxiety in AD by exacerbating the deficits in
serotonergic neurotransmission. This study therefore pro-
vides the rationale for using SSRIs or serotonergic agonists
as an alternative to benzodiazepines for the treatment of
anxiety related symptoms in AD.
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